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Abstract 
Retroviruses can establish persistent infection despite induction of a multipartite 
antiviral immune response. Whether collective failure of all parts of the immune 
response or selective deficiency in one crucial part underlies the inability of the host 
to clear retroviral infections is currently uncertain. In this study, the contribution of 
virus-specific CD4
+
 T cells in resistance against Friend virus (FV) infection in the 
murine host is examined. The results show that the magnitude and duration of the FV-
specific CD4
+
 T cell response is directly proportional to resistance against acute FV 
infection and subsequent disease. Notably, significant protection against FV-induced 
disease is afforded by FV-specific CD4
+
 T cells in the absence of a virus-specific 
CD8
+
 T cell or B cell response. Enhanced spread of FV infection in hosts with 
increased genetic susceptibility causes a proportional increase in the number of FV-
specific CD4
+
 T cells required to control FV-induced disease. Thus, these results 
suggest that FV-specific CD4
+
 T cells provide significant direct protection against 
acute FV infection, the extent of which critically depends on the ratio of FV-infected 
cells to FV-specific CD4
+
 T cells. In addition to precursor frequency, the T cell 
receptor (TCR) affinity for antigen is also considered an important contributor to 
CD4
+
 T cell expansion and effector function. Study of polyclonal TCRβ-transgenic 
FV-specific CD4
+
 T cells has previously revealed a distinct pattern of clonal evolution 
during FV infection. In the current study, immunisation regimens, including 
adjuvanted peptide and replication-attenuated retrovirus vaccination, are assessed for 
the overall TCR affinity of the CD4
+
 T cell population they elicit. The implications 
for vaccine design and vaccine-induced CD4
+
 T cell-mediated protection are 
discussed. 
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Chapter One 
1 Introduction 
 21 
1.1 The Innate Immune System 
The mammalian immune system comprises the fast-acting, non-specific innate branch 
and the slower acting, pathogen-specific adaptive branch. When a pathogen infects a 
host, the innate and adaptive elements of the immune response work in synergy to 
control or, if successful, clear the infection, while simultaneously avoiding damage to 
the host. 
 
The innate immune system consists of physical and chemical barriers, innate immune 
lymphocytes, and the complement system. Physical barriers such as the epidermis and 
chemical barriers such as gastric acid provide the initial defence against invasion by a 
pathogen, while complement and innate immune cells are recruited if a pathogen is 
successful in evading these initial barriers. 
 
1.1.1 Mononuclear phagocytes 
Mononuclear phagocytes act by engulfing and destroying a pathogen or infected cell, 
and include macrophages and neutrophils. These cells are activated by cell damage or 
via interactions between pathogenic components and innate immune receptors called 
pattern recognition receptors (PRRs). Although their major role is phagocytosis, they 
also produce microbicidal reactive oxygen species (ROS) and nitric oxide (NO), and 
release chemokines and cytokines (Gordon, 2007).  
 
 22 
1.1.2 Natural killer cells 
Natural killer (NK) cells are large granular lymphocytes which comprise around 10-
15% of all peripheral blood lymphocytes. They do not have antigen-specific receptors 
but can recognize and kill abnormal cells such as virally-infected cells and tumour 
cells through a range of activating and inhibitory receptors, for example NKG2D and 
KIR respectively (Lanier, 2008). NK cell activity is induced by a range of cytokines, 
such as type I interferon (IFN) including IFN-α and IFN-β, to produce effector 
cytokines such as TNF-α and the type II IFN IFN-γ, mediate antibody-dependent 
cellular cytotoxicity (ADCC), and directly kill virus-infected cells via production of 
perforin and granzymes (Vivier et al., 2008). More recently, and somewhat out of 
character for cells of the innate immune system, NK cells have been shown to have 
memory capacity (Sun et al., 2010). 
 
1.1.3 Other innate immune cells 
Basophils, eosinophils and mast cells are immune mediators of type 2 immune 
responses against infection with parasites such as Schistosoma mansoni. Basophil 
differentiation is driven by IL-3, and they produce the type 2 cytokines IL-13, and IL-
4 which promotes Th2 CD4
+
 T cell responses, as well as lipid mediators in order to 
promote vascular permeability. Eosinophils are activated by IL-3 and IL-5, are 
predominantly localised to the mucosal tissues and produce a range of cytokines and 
other non-cytokine effector proteins. Mast cells produce histamine, among other 
chemical mediators, and cytokines including IFN-γ and TNF-α, and have major roles 
in both the immune response to pathogens and allergic hypersensitivity reactions 
(Stone et al., 2010). 
 23 
1.1.4 Toll-like receptors 
An important type of PRR involved in the induction of the immune response is the 
family of toll-like receptors (TLRs), which were initially described in Drosophila and 
later in humans (Medzhitov et al., 1997). TLRs are expressed on the surface of innate 
immune cells and are able to non-specifically recognise components of invading 
pathogens, known as pathogen-associated molecular patterns (PAMPs), including 
lipopolysaccharide (LPS) and double stranded ribonucleic acid (dsRNA), from 
bacteria and viruses respectively (Medzhitov and Janeway, Jr., 1997). TLR agonists 
can be used as adjuvants in vaccine preparations to facilitate uptake, processing and 
presentation of antigen which otherwise has low immunogenicity (van et al., 2006). 
 
1.1.5 The complement system 
The complement system comprises many proteins, some of which are enzymes, that 
make the components of the complement cascade which leads to inflammation, cell 
opsonisation and thus cell killing, and ultimately formation of the terminal 
complement complex (TCC), resulting in the lysis of a cell. As well as being initiated 
by innate immune receptors, complement can also be initiated by the adaptive 
immune system via antibody (Ricklin et al., 2010). 
 24 
1.1.6 Innate cytokines 
Cytokines produced during the innate immune response are required to activate and 
recruit other innate immune cells, as well as to have effects on the proliferation and 
function of adaptive immune cells. The major innate cytokines produced during the 
early inflammatory stages of the innate immune response are tumour necrosis factor-α 
(TNF-α), interleukin-1 (IL-1) and transforming growth factor-β (TGF-β), which 
together cause inflammation, coagulation and fever in the host. In addition, these 
cytokines lead to expression of adhesion molecules such as selectins, and the 
production of chemokines such as CXCL8 to enable recruitment of other phagocytic 
cells to the site of infection (Biron, 1998). 
 
Another important family of cytokines in the innate immune response are the type I 
IFNs IFN-α and IFN-β, which are produced mainly by plasmacytoid dendritic cells 
(DCs), and are induced during viral infections (Theofilopoulos et al., 2005). Type I 
IFNs have a range of functions which bridge the innate and adaptive immune 
responses, for example inducing production of innate inflammatory cytokines such as 
TGF-β and TNF-α, as well as inducing production of the type II interferon IFN-γ by 
the T cells of the adaptive immune response (Biron, 2001). Signals from IFN-α and 
IFN-β also lead to increased expression of major histocompatibility (MHC) class I 
molecules and co-stimulatory molecules on antigen presenting cells (APCs), 
enhancing antigen presentation to CD8
+
 T cells, and are able to enhance cytotoxic 
activity of NK cells, increasing clearance of a pathogen (Biron, 2001; Biron et al., 
1999). 
 
 25 
IL-12 is produced by innate cells including macrophages and dendritic cells and is 
induced in the host in response to infections with many pathogens including Listeria 
monocytogenes (Hsieh et al., 1993; Macatonia et al., 1995), Leishmaniasis (Scharton-
Kersten et al., 1995), as well as viral infections (Orange and Biron, 1996; Biron and 
Gazzinelli, 1995). The major functions of IL-12 are activation of macrophages and 
induction of IFN-γ production by NK cells, which mediates many downstream effects 
(Biron and Gazzinelli, 1995). Additionally, IL-12 drives the differentiation of CD4
+
 T 
helper cells to a specific phenotype (Hsieh et al., 1993). 
 
IFN-γ has diverse functions in both the innate and adaptive branches of the immune 
response and connects the two facets of the immune response. As a part of the innate 
immune response IFN-γ, produced primarily by NK cells, increases antigen 
presentation by upregulating MHC class I and II expression on APCs, activates 
macrophages, and induces anti-viral gene expression as well as driving the generation 
of an anti-viral state (Schroder et al., 2004). IFN-γ also has important roles during the 
adaptive immune response which will be discussed in the context of CD4
+
 T helper 
cell function in section 1.3.2. 
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1.2 The Adaptive Immune System 
The T cells and B cells of the adaptive immune system are derived from a common 
lymphoid progenitor in the bone marrow, and while B cells continue to develop in the 
bone marrow, T cells migrate to and develop in the thymus. Both T cells and B cells 
enter and circulate the peripheral blood and secondary lymphoid organs as naive cells 
until they encounter antigen presented to them by APCs, and become activated to 
proliferate and contribute towards the control of infection via a range of mechanisms. 
While T cells recognise antigen via their T cell receptor (TCR), B cells recognise 
antigen via their B cell receptor (BCR). 
 
1.2.1 T cells 
T cells initially develop in the thymus as CD4
+
CD8
+
 co-receptor double-positive 
precursors, but subsequently commit to the CD4 or CD8 lineage, becoming either T 
helper cells or cytotoxic T cells respectively (Hernandez-Hoyos et al., 2003). T cells 
further undergo clonal selection in the thymus, where cells possessing self-reactive 
TCRs experience high affinity interactions with self-antigen and are deleted, while 
those that experience low affinity interactions with self-antigen survive (Klein et al., 
2009). While CD8
+
 cytotoxic T cells act by directly killing infected cells, CD4
+
 T 
cells are helper cells which act by producing cytokines to promote CD8
+
 T cell and B 
cell function.  
 
CD8
+
 T cells are important for control and elimination of intracellular infections and 
cancerous tumours. CD8
+
 T cells are able to directly kill infected cells via several 
mechanisms. The major mechanism of CD8
+
 T cell-mediated cytotoxicity is release of 
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perforin to generate a pore in the target cell membrane, allowing administration of 
caspases known as granzymes which consequently break down intracellular proteins 
causing apoptosis of the cell. An alternative mechanism by which CD8
+
 T cells can 
kill infected cells or tumour cells is via ligation of Fas on target cells resulting in 
target cell death (Masopust et al., 2007). The major role of CD4
+
 T cells is to produce 
cytokines which activate this CD8
+
 T cell mediated killing, and to induce B cell 
activation and function. The effector mechanisms of CD4
+
 T cells will be discussed in 
more detail in section 1.3.2. 
 
1.2.2 Antigen presentation 
APCs present antigen after they are infected with a pathogen, or after ingesting 
pathogens or infected cells. Antigen is presented in complex with MHC molecules, 
and recognised by the TCR expressed on CD4
+
 or CD8
+
 T cells, which determine the 
antigen-specificity of a T cell. Co-stimulatory signals are also required for activation 
of T cells, and these are transmitted through ligation of CD28 on the T cell with co-
stimulatory molecules on the APC such as CD80 (B7-1) or CD86 (B7-2). 
 
While CD8
+
 T cells recognise antigen via their TCR in the context of MHC class I, 
CD4
+
 T cells recognise antigen in the context of MHC class II. The MHC class II 
molecule is heterodimeric, comprising an α and β chain, and the peptide binding cleft 
of this MHC molecule is created by a groove formed by arrangement of the three-
dimensional structure (Bjorkman et al., 1987). It is in this binding cleft that peptide 
binds and is presented to a T cell to induce antigen-specific proliferation. While 
 28 
dendritic cells (DCs) are the main professional APC, macrophages and B cells also 
express MHC class II and so are able to present antigen to CD4
+
 T cells. 
 
1.2.3 γδ T cells 
While conventional CD4
+
 and CD8
+
 T cells have a heterodimeric αβ TCR, another 
described subset of T cells have a heterodimeric γδ TCR, and are known as γδ T cells. 
These cells develop in both the thymus and periphery, and are known as innate-like 
lymphocytes due to their innate phenotype and function (Born et al., 2006). They are 
mainly found in the epithelium, and a major role of these cells is as a part of the initial 
defence against infection at mucosal surfaces, for example herpes simplex virus type 
2 (HSV-2) (Nishimura et al., 2004).  
 
γδ T cells have diverse roles, and have been shown to expand in animal models of 
viral, bacterial and parasitic infections, and are able to produce the required cytokines 
for control of these pathogens. They also have a role in tumour immune surveillance 
and autoimmune disease (Carding and Egan, 2002). As regards innate function, as 
well as their TCR, γδ T cells can express receptors typically found on innate cells, 
including TLRs and NK cells receptors, and unlike αβ T cells they can also act as 
APCs (Born et al., 2006; Moser and Brandes, 2006). However, γδ T cells also have a 
role in the adaptive immune response, and can produce type 1 and type 2 cytokines, as 
well as influencing the phenotype of responding CD4
+
 T cells. They have also been 
shown to produce IL-17, particularly during bacterial infections (Roark et al., 2008).  
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1.2.4 B cells 
Unlike T cells, which recognise antigen via their TCR in the form of peptide:MHC 
complexes on the surface of APCs, B cells recognise soluble antigen via their B cell 
receptor (BCR), leading to differentiation of B cells into Ab-secreting plasma cells 
and hence induction of the humoral immune response. Antibodies mediate many 
activities against pathogens including virus-neutralisation, mediation of Ab-dependent 
cellular cytotoxicity (ADCC), and activation of the complement system. Long-lived 
plasma cells circulate in the peripheral blood and constantly produce neutralising Ab 
(nAb) in case of a secondary infection (Slifka et al., 1998). B cells also play a role in 
controlling homeostasis of T cells, and in particular CD4
+
 T cells (LeBien and 
Tedder, 2008).  
 
B cells can produce inflammatory cytokines, while a subset of cells, known as Breg 
cells, are immunoregulatory and produce the immunosuppressive cytokine IL-10. 
Dysregulated B cells also contribute to autoimmunity, for example via production of 
autoantibodies, which contribute to pathogenesis of chronic inflammatory conditions 
including rheumatoid arthritis and systemic lupus erythematous (SLE) (Lund and 
Randall, 2010).  
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1.2.5  Immunological memory and vaccination 
After the primary immune response against a pathogen, the population of antigen-
specific adaptive immune cells undergoes contraction, with a small number (<10%) 
persisting as pathogen-specific memory cells. This occurs in both antigen-specific T 
cell and B cell pools, and in the case of reinfection, these pathogen-specific memory 
lymphocytes mount a secondary response which is more rapid and effective than that 
of the primary response, and works to prevent disease or accelerate pathogen 
clearance (Sallusto et al., 2010). This is defined as immunological memory, and is a 
remarkable outcome of mammalian evolution.  
 
This ability of the immune system to develop immunological memory has been 
exploited in the use of vaccination, where an immune response is artificially induced 
in the host leading to the development of memory, and thus priming the immune 
system for subsequent challenge so that in the event of exposure to the pathogen 
which the individual has been vaccinated against, a secondary immune response can 
be rapidly mounted to prevent establishment of infection. Types of vaccination in use 
or currently being developed include live-attenuated virus vaccines, subunit vaccines, 
inactivated virus particles, viral vectors and DNA vaccines. Often an adjuvant is 
utilised to enhance the immunogenicity of a vaccine, for example, MF59 which is 
used successfully in seasonal influenza vaccines (Black et al., 2010; Pellegrini et al., 
2009). Vaccine regimens also vary, with some vaccines requiring boosters while 
others provide life-long protection after one inoculation. 
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Vaccination programmes have been successful in completely eradicating some 
diseases, for example smallpox, where antibodies to the virus are still circulating in 
recipients of the vaccine up to 75 years later (Hammarlund et al., 2003). However, for 
some pathogens, a vaccine which induces a protective memory immune response is 
currently unavailable.  
 
Pathogen-specific nAb can immediately neutralise a pathogen in the case of 
reinfection, and subsequently memory B cells and T cells expand and mount their 
secondary response (Sallusto et al., 2010). Hence, vaccines which induce nAb provide 
a more protective memory response than those inducing T cell responses. 
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1.3 CD4+ T cells 
The primary function of CD4
+
 T cells is to produce cytokines to provide 
immunological help to other cells of the adaptive immune system, assisting CD8
+
 T 
cells to kill virally infected cells, and B cells to produce Ab via the release of 
cytokines. The importance of CD4
+
 T cells in the immune response is evident in 
primary and secondary immunodeficiencies. Patients suffering from bare lymphocyte 
syndrome, who have an MHC class II deficiency and hence a CD4
+
 T cell deficiency, 
have impaired humoral and cytotoxic T cell responses. As such, they are extremely 
susceptible to viral, bacterial, fungal and protozoal infections such as Pseudomonas, 
Salmonella and Escherichia species, cytomegalovirus (CMV) and Candida, generally 
leading to death during childhood (Klein et al., 1993).  
 
Infection of humans with human immunodeficiency virus (HIV) causes progressive 
depletion of CD4
+
 T cells, inevitably resulting in Acquired Immunodeficiency 
Syndrome (AIDS), where the host succumbs to fatal opportunistic infections such as 
Pneumocystis jiroveci and cancers such as Kaposi’s sarcoma. It is evident from these 
conditions that CD4
+
 T cells are a vital component of the mammalian immune 
response. 
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1.3.1 CD4+ T cell subsets 
In 1989, two T helper cell clones with different cytokine profiles were identified and 
designated Th1 and Th2. It was subsequently realised that CD4
+
 T cells differentiate 
into effector cells of different phenotypes upon encounter with antigen (Mosmann and 
Coffman, 1989). 
 
The fate of a CD4
+
 T cell is determined by the cytokines present during differentiation 
with IL-12 activating signal transducer and activator of transcription (STAT) 4 
directing cells towards a Th1 phenotype, and IL-4 activating STAT6 directing cells 
towards a Th2 phenotype. The Th1 and Th2 subsets can be defined by their 
production of IL-2 and IFN-γ, or IL-4, IL-5 and IL-13 respectively. In turn, 
production of IFN-γ by Th1 cells inhibits differentiation of Th2 cells, and production 
of IL-4 by Th2 cells inhibits the differentiation of Th1 cells (Fernandez-Botran et al., 
1988). Th1 and Th2 cells also produce the suppressive cytokine IL-10 as a self-
regulatory mechanism, resulting in a negative feedback effect on production of 
effector cytokines by the cell (Moore et al., 2001). Functionally, Th1 cells have been 
implicated in responses against intracellular infections such as Leishmania and 
Toxoplasma gondii, as well as autoimmune disease (Murphy and Reiner, 2002; Paul 
and Seder, 1994). Conversely, Th2 cells help to control extracellular parasitic 
infections, for example helminths, and are associated with control of the humoural 
immune system. They also play a role in allergic reactions when dysregulated 
(Faulkner et al., 1998; Soussi-Gounni et al., 2001). 
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The more recently described Th17 CD4
+
 T cells are polarised by IL-6. Th17 cells 
have been shown to help protect against bacterial extracellular infections such as 
Klebsiella pneumoniae and Salmonella enterica, fungal infections such as Candida 
albicans, and intracellular bacterial infections such as Mycobacterium tuberculosis via 
production of IL-17, IL-22 and IL-23 but also play a role in autoimmune disease 
(Curtis and Way, 2009). Mice deficient in Th17 cytokines or their receptors are 
resistant to Experimental Autoimmune Encephalomyelitis (EAE), a murine model of 
multiple sclerosis, while in the human autoimmune disease SLE, patients produce 
significantly elevated levels of IL-17 and IL-23 (Stockinger and Veldhoen, 2007; 
Wong et al., 2008).  
 
T follicular helper CD4
+
 T cells (Tfh) specifically provide help to B cells in an 
antigen-specific manner in the B cell follicle in the lymphoid nodes. IL-21 is the 
major effector cytokine of Tfh cells and plays a role in development of germinal 
centres and antibody isotype switching, for example from IgM to IgG. IL-21 also 
stimulates differentiation of Tfh cells in an autocrine manner. These cells 
predominantly differentiate from other Th cell subsets and can be defined by their 
expression of C-X-C chemokine receptor 5 (CXCR5), which directs them to the B cell 
follicle (Fazilleau et al., 2009). 
 
Regulatory T (Treg) cells comprise 5-10% of all CD4
+
 T cells and act to regulate 
immune responses, preventing immunopathology via production of 
immunosuppressive cytokines (Sakaguchi, 2004). The major effector cytokine of Treg 
cells is IL-10, but IL-35 has also been shown to be produced by Tregs and to be 
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inhibitory to other immune cells (Collison et al., 2007). The majority of Treg cells 
develop in the thymus but an inducible Treg (iTreg) cell population has recently been 
identified. Treg cells which develop in the thymus can be distinguished from iTreg, 
which undergo conversion from naive non-Treg CD4
+
 T cells in the presence of TGF- 
β in the periphery, as natural Treg (nTreg) cells (Quintana and Cohen, 2008).  
 
As well as different cytokine profiles, CD4
+
 T cell subsets can be defined by 
expression of unique subset-specific transcription factors, with Th1 cells expressing 
T-bet, Th2 cells expressing GATA3 and Th17 cells expressing RORγt (Ho and 
Glimcher, 2002; Ivanov et al., 2006). Treg cells can be defined by expression of 
CD25 and the Foxp3 transcription factor (Fontenot et al., 2003), while Tfh can be 
defined by expression of Bcl-6 (Fazilleau et al., 2009). 
 
Th cell subsets were initially identified in CD4
+
 T cell clones in vitro but these 
concepts have also been observed in vivo. In influenza infection, mice infected 
intravenously develop a response dominated by Th1 CD4
+
 T cells while mice infected 
intra-nasally develop a predominantly Th17 CD4
+
 T cell response. This is attributed 
to differentiation of naive CD4
+
 T cells in the presence of IL-12-producing splenic 
DCs after intravenous infection, while after intra-nasal infection responding CD4
+
 T 
cells differentiate in the presence of IL-6-producing mucosal DCs (Pepper et al., 
2010).  
 
Despite the ongoing description of new T helper cell subsets, more recently it has 
been accepted that there is a degree of plasticity between the different subsets, and 
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that once a naive cell has differentiated into a certain subset it is not necessarily 
committed for its whole lifespan and, under certain environmental conditions, can 
convert to an alternative subset. For example, Veldhoen et al. showed that the 
presence of TGF-β can cause Th2 cells to convert to an IL-9 producing subset in 
vitro. This IL-9 producing subset is distinct as it does not express any of the 
transcription factors found in other CD4
+
 T cell subsets, and was provisionally 
designated as the Th9 subset (Veldhoen et al., 2008). In vivo, Th17 cells specific for a 
pancreatic islet antigen were transferred into mice and seen to convert into cells with a 
Th1 effector function, inducing diabetes via IFN-γ production (Bending et al., 2009). 
Furthermore, in LCMV infection adoptively transferred Th2 cells were shown to 
reprogram to a subset with both Th1 and Th2 functions, as well as expressing both T-
bet and GATA-3 transcription factors. This subset was able to be maintained for 
several months in vivo and, in the presence of IL-12 amongst other factors, induction 
of type I and type II interferons by lymphocytic choriomeningitis virus (LCMV) 
infection was essential for this reprogramming (Hegazy et al., 2010). More recently it 
has been shown that the mechanism by which commitment to the Th2 lineage is 
reversed in humans involves suppression of the GATA3 transcription factor by type I 
IFNs (Huber et al., 2010). 
 
In summary, it is now acknowledged that CD4
+
 T cells possess a certain degree of 
plasticity and versatility, and are able to modify their function in order to mount the 
most appropriate response to a pathogen. 
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1.3.2 Effector functions of CD4+ T helper cells 
IL-2 and IL-4 are autocrine growth factors for Th1 and Th2 cells respectively. CD4
+
 
T cells are the main producers of IL-2 and, upon antigen stimulation, they upregulate 
the IL-2 receptor (IL-2R) and hence are able to receive more signals from IL-2 to 
promote clonal expansion of the antigen-specific population. In Th1 CD4
+
 T cells, IL-
2 promotes synthesis of IFN-γ and further IL-2. It is also able to stimulate B cell 
growth and promote antibody synthesis, and stimulate growth and cytolytic activity of 
NK cells (Waldmann, 2006). 
 
IFN-γ produced by Th1 cells has a broad range of anti-viral effects, including 
stimulating expression of MHC class I and II, activating APCs and increasing 
expression of co-stimulatory molecules on DCs, further augmenting antigen 
presentation. It also plays an important role in helping CD8
+
 T cells to kill virally 
infected cells via perforin and granzymes, and can enhance the microbicidal 
phagocytic activity of macrophages. In a more direct fashion IFN-γ can inhibit viral 
replication via induction of the anti-viral enzyme PKR (Schroder et al., 2004). This 
effect has been shown in vitro against hepatitis C virus (HCV) in concert with TNF-α, 
and in γ-herpesvirus infection in B cell-deficient mice (Christensen et al., 1999; Davis 
et al., 2008). 
 
The Th2 cytokines IL-4 and IL-5 mediate the response to extracellular infections such 
as parasites (Finkelman et al., 1997). IL-5 directly activates eosinophils and promotes 
their growth and differentiation, while IL-4 plays a major role in Ig heavy chain class 
switching of antibody from IgG to the IgE isotype. IgE binds to Fc receptors on cells 
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and has a range of effects, for example stimulating degranulation of mast cells (Stone 
et al., 2010). 
 
Several recent studies have highlighted a previously unappreciated role for Tfh cell-
derived IL-21 in chronic viral infection. Although absence of IL-21 during acute 
LCMV infection does not affect viral load or priming of LCMV-specific CD8
+
 T 
cells, lack of IL-21 signalling during chronic LCMV infection leads to a reduced 
number and polyfunctionality of CD8
+
 T cells, resulting in a higher viral titre 
(Elsaesser et al., 2009; Frohlich et al., 2009; Yi et al., 2009). Elevated numbers of IL-
21-producing CD4
+
 T cells were also seen during the chronic phase of LCMV 
infection, with more IL-21 produced per CD4
+
 T cell. Furthermore, treatment with IL-
21 was able to restore CD8
+
 T cell survival and function and reduce viral titre in 
chronically infected Il21r
-/-
 mice (Yi et al., 2009). 
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1.3.3 Cytotoxic activity of CD4+ T cells 
As well as providing immunological help via production of cytokines, CD4
+
 T cells 
have been shown to have direct anti-viral effects, with MHC class II-dependent 
killing identified in several infections, such as influenza (Maimone et al., 1986). 
These cytotoxic CD4
+
 T cells were initially only documented in vitro against 
pathogens such as EBV, but later studies showed that they are also active ex vivo in 
certain diseases (Appay et al., 2002). In the case of LCMV infection in mice, killing 
was shown to be MHC-class II dependent and antigen-specific (Jellison et al., 2005; 
Nikiforow et al., 2003). 
 
Cytotoxic CD4
+
 T cells may function through a variety of mechanisms, including 
ligation of the death receptor Fas on target cells with its ligand (FasL) on CD4
+
 T 
cells, and production of IFN-γ and TNF-α (Stalder et al., 1994). Alternatively they 
have been shown to act through production of perforin and granzymes, in a 
mechanism similar to that of cytotoxic CD8
+
 T cells (Williams and Engelhard, 1996).  
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1.3.4 Memory CD4+ T cells 
As described above, immunological memory is defined as the ability of a host to 
recognise a secondary challenge by a pathogen, and mount a more sensitive and 
effective response in order to prevent establishment of infection. After expansion of 
naive CD4
+
 T cells in response to antigen, a contraction of cell numbers takes place 
with ~90% of antigen-specific CD4
+
 T cells undergoing programmed cell death, and 
the remaining 10% enter the memory CD4
+
 T cell pool. Memory CD4
+
 T cells are 
constantly replenished by low level differentiation, at a higher rate than that of naive 
CD4
+
 T cells (Macallan et al., 2004). A combination of cytokines, T cell and APC 
interactions, and balanced expression of anti-apoptotic molecules is necessary for 
successful generation, and efficient maintenance of memory CD4
+
 T cells 
(Lanzavecchia and Sallusto, 2002).  
 
Memory CD4
+
 T cells can be further divided into effector memory (TEM) or central 
memory (TCM) cell subsets, depending on their level of expression of CCR7 and 
CD62L (L-selectin). CCR7 is a chemokine receptor which directs migration of cells 
to secondary lymphoid organs, while CD62L is an adhesion molecule which binds to 
ligands on epithelial cells, also controlling migration (Butcher and Picker, 1996; 
Sallusto et al., 1999). TEM CD4
+
 cells are CCR7
low
CD62L
low
 and are the first memory 
CD4
+
 T cells to respond to an assault by a pathogen, expressing tissue-homing β1 and 
β2 integrins and inflammatory chemokine receptors, which enable them to migrate to 
inflamed tissues and mount an effector CD4
+
 T cell response. TCM CD4
+
 cells are 
CCR7
high
CD62L
high
, and reside in the lymph nodes where they remain until they are 
prompted to differentiate into effector cells and migrate to the site of the secondary 
infection (Sallusto et al., 1999).  
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The life span of memory CD4
+
 T cells is not currently well defined. In murine studies 
LCMV-specific memory CD8
+
 T cells can be stably maintained throughout the 
lifetime of the host. However, LCMV-specific memory CD4
+
 T cell number, but not 
function, declines over time, albeit with a slower initial contraction phase than that of 
the LCMV-specific CD8
+
 T cell population (Homann et al., 2001). Memory CD4
+
 T 
cells have also been shown to decline in Listeria monocytogenes infection, while 
bacteria-specific CD8
+
 memory T cells were able to be maintained (Schiemann et al., 
2003). In contrast it was also shown that despite induction of memory CD8
+
 T cells 
during acute infection, memory CD8
+
 T cell effector function declined over time 
during LCMV infection (Fuller et al., 2004).  
 
In human studies on patients vaccinated against smallpox, vaccinia-specific memory 
CD4
+
 T cells were present more than 60 years after subjects had been immunised. 
Furthermore, these CD4
+
 T cells had retained effector function (Hammarlund et al., 
2003). Chimpanzees vaccinated with an HIV-1 vaccine candidate maintained antigen-
specific CD4
+
 T cells for five years post-immunisation while the population of 
antigen-specific CD8
+
 T cells declined. This was further observed in 1 of 4 human 
volunteers (Balla-Jhagjhoorsingh et al., 2004). 
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1.3.5 Homeostatic cytokines 
Newly developed memory CD4
+
 T cells must compete with original memory cells for 
access to homeostatic cytokines which are most often from the common γ chain (γc) 
cytokine family, and in order to receive signals from these cytokines cells must 
express the relevant receptor on their cell surface. 
 
IL-7 plays an important role in the generation of memory CD4
+
 T cells, as well as 
enhancing survival of effector CD4
+
 T cells. IL-7Rα is downregulated on activated T 
cells and re-expressed at high levels on memory T cells. IL-7 has been shown to be 
essential for the generation of memory CD4
+
 T cells from adoptively transferred 
effector CD4
+
 T cells in IL-7-deficient mice, and for generation of memory CD4
+
 T 
cells from effector CD4
+
 T cells in WT mice treated with an IL-7-blocking antibody 
(Li et al., 2003). Furthermore, IL-7 was shown to be necessary for survival of memory 
CD4
+
 T cells via the upregulation of the anti-apoptotic molecule Bcl-2, with memory 
cells unable to persist in IL-7-deficient mice, or in mice treated with an IL-7 blocking 
antibody (Kondrack et al., 2003). Concerted IL-7 and TCR signalling was shown to 
be necessary for optimum maintenance of memory CD4
+
 T cells. However, 
deficiency of IL-7 or abrogation of TCR signalling can be overcome by an increase of 
the other and hence display an element of redundancy (Seddon et al., 2003). 
 
As well as inducing T cell proliferation, IL-2 contributes towards blocking cell death 
via induction of anti-apoptotic molecules such as Bcl-2. However, it also inhibits 
cycling of CD4
+
 T memory cells, and although IL-2Rα is up-regulated on effector 
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CD4
+
 T cells, it is expressed at low levels on memory CD4
+
 T cells (Marrack et al., 
2000).  
 
IL-15 is produced by activated macrophages and DCs in response to infection and its 
role in the maintenance of memory T cells has mostly been studied in memory CD8
+
 
T cells. IL-15R deficient mice have normal numbers of memory CD4
+
 T cells but it is 
possible that compensatory mechanisms are in place, similar to those demonstrated in 
the absence of IL-7 (Seddon et al., 2003). These and other observations lead to the 
conclusion that IL-15 was required for CD8
+
 T cell homeostasis but not for CD4
+
 T 
cell homeostasis (Tan et al., 2002). However, more recently it has been shown that 
anti-viral memory CD4
+
 T cells require IL-15 for homeostatic survival, to the same 
extent as memory CD8
+
 T cells (Purton et al., 2007). 
 
Relative expression of homeostatic cytokine receptors on T cells is shown in Figure 
1.1. 
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Figure 1.1 Expression of homeostatic cytokine receptors at different stages of 
the CD4
+
 T cell life cycle  
CD4
+
 T cells express receptors in order to receive survival signals from the 
homeostatic γc cytokines IL-2, IL-15 and IL-7. Receptors for these cytokines are 
expressed at different levels at different stages of CD4
+
 T cell differentiation from a 
naive phenotype through to effector and memory cells. Adapted from (Schluns and 
Lefrancois, 2003). 
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1.3.6 Progressive differentiation and T cell exhaustion 
A model of progressive differentiation has been described whereby T cells 
differentiate to a certain level depending on the amount of antigen stimulation 
received. Each stage of differentiation is characterised by a different cytokine profile 
and cells can enter the memory pool at any of these stages (Lanzavecchia and 
Sallusto, 2000). This model of progressive differentiation can also be applied to the 
memory CD4
+
 T cell population (Seder et al., 2008). 
 
In the case of Th1 cells, in the early phases of differentiation from naive to effector 
CD4
+
 T cells they produce only IL-2. Increased antigen stimulation switches on 
production of IFN-γ, turning cells into double-producers, while higher levels of 
antigen stimulation leads to cessation of IL-2 production and hence a IFN-γ single-
producer population (Figure 1.2). Cells which receive only weak stimulation do not 
survive, while at very high levels of activation they ultimately become exhausted and 
succumb to deletion from the immune cell pool (Lanzavecchia and Sallusto, 2005).  
 
T cell exhaustion and deletion can occur during chronic viral infection when antigen 
persists at high levels, as demonstrated in CD8
+
 T cells in LCMV infection 
(Moskophidis et al., 1993). This exhaustion of virus-specific T cells has also been 
shown in chronic viral infections in humans, including EBV, CMV, hepatitis B and C, 
and HIV (Klenerman and Hill, 2005). As well as reduced frequency due to deletion 
after chronic activation, features of T cell exhaustion include reduced functionality of 
antigen-specific T cells, downregulation of co-stimulatory molecules such as CD127 
and CD62L, and increased expression of T cell inhibitory molecules such as PD-1 (Yi 
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et al., 2010). Notably, during T cell exhaustion during LCMV infection in mice, 
blocking interactions of PD-1 with its ligand (PD-1L) allowed recovery of antigen-
specific CD8
+
 T cell function and number (Barber et al., 2006).  
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Figure 1.2 Progressive differentiation of Th1 CD4
+
 T helper cells 
Naive T cells migrate from the thymus to the periphery where they encounter antigen 
and differentiate into effector T cells, producing different cytokines depending on the 
level of antigen stimulation received. In this example, Th1 CD4
+
 T cells produce IL-2 
at low levels of antigen stimulation, go on to become IL-2 and IFN-γ double-
producers at higher levels of antigen stimulation. They then cease producing IL-2 to 
become IFN-γ single-producers before undergoing activation-induced cell-deletion at 
the highest levels of antigen stimulation. Adapted from (Lanzavecchia and Sallusto, 
2005). 
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1.4 Retroviruses 
Retroviruses are enveloped, single stranded RNA viruses which can be divided into 
five groups of simple retroviruses, which are oncogenic, and two groups of complex 
retroviruses – lentiviruses and spumaviruses. Oncogenic retroviruses include human T 
cell leukaemia virus (HTLV) and murine leukaemia virus (MLV), while HIV is a 
member of the lentiviridiae family. 
 
1.4.1 Retroviral structure 
Retroviral virions have a lipid bilayer envelope studded with envelope glycoproteins. 
The retroviral genome, which contains single stranded RNA and viral enzymes, is 
encased in a protein capsid (Figure 1.3A). All retroviruses have three key protein 
coding genes: gag, env and pol. Gag encodes for virion proteins, env for viral 
envelope proteins and pol for reverse transcriptase, integrase and protease - the 
enzymes involved in viral replication (Figure 1.3B). Complex retroviruses have 
additional genes in their genome such as rev, tat, nef, vpu, vif and vpr, encoding for 
early proteins which have roles such as promoting immune evasion, and capsid 
uncoating (Nisole and Saib, 2004). 
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Figure 1.3 The generic structure and RNA genome of a simple retrovirus  
(A) The RNA genome of a retrovirus is contained within a protein capsid. This is 
surrounded by a lipid envelope which is studded with glycoproteins. These surface 
glycoproteins allow the virion to attach to its target cell membrane via receptors and 
gain entry into the cell.  
(B) The RNA genome of a simple retrovirus contains 3 major genes: gag which 
encodes for surface antigens, pol which encodes for enzymes required for retroviral 
replication, and env which encodes for envelope proteins in the virion. 
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1.4.2 The retroviral life cycle 
Retroviral envelope glycoproteins interact with receptors on the surface membrane of 
the host target cell in order to gain entry. In HIV for example, the glycoprotein gp120 
on the virus interacts with CD4 and CCR5 or CXCR4 molecules and a virological 
synapse forms. There are two ways in which a retrovirus can enter its target cell 
during infection: fusion of the viral envelope, as observed in HIV, or via endocytosis, 
as observed in murine leukaemia viruses (MLVs) (Katen et al., 2001). After cell 
entry, the viral protein capsid is released into the cell and reverse transcription of viral 
RNA to viral cDNA mediated by the viral reverse transcriptase enzyme occurs. Viral 
cDNA subsequently enters the host cell nucleus and integrates into the host cell 
genome. While lentiviruses such as HIV are able to integrate into the genome of non-
replicating cells, potentially by entering the nucleus via a nuclear pore, MLVs require 
cell division to take place in order for them to integrate (Nisole and Saib, 2004). 
Integration into the host genome is not random and favours active genes (Schroder et 
al., 2002; Wu et al., 2003). 
 
Viral DNA is then transcribed in viral RNA, viral genes are expressed and new virion 
components are produced in the cytoplasm. These components assemble to form a 
new virus particle which traffics to the cell membrane via interactions within the host 
cytoskeleton (Naghavi and Goff, 2007). The virion then uses the host cellular 
machinery to exit the cell, budding from the cell surface (Perez and Nolan, 2001). 
Once the retroviral virion has budded from the cell it matures and the cycle begins 
again (Naghavi and Goff, 2007). 
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1.5 Human Immunodeficiency Virus 
1.5.1 HIV/AIDS 
Despite only first being described several decades ago (Barre-Sinoussi et al., 1983), 
HIV/AIDS represents a major global health problem with more than 33 million people 
infected worldwide, and an estimated 2.5 million new infections occurring during 
2009 (www.who.int). Infection with HIV begins with an acute phase characterised by 
high viral load and flu-like symptoms, and a subsequent chronic phase where viral 
load persists at a lower level asymptomatically. Ultimately, profound loss of function 
and depletion of CD4
+
 T cells in the host leads to immunocompromisation and 
susceptibility to fatal opportunistic infections such as Pneumocystis jiroveci and 
cancers such as Kaposi’s sarcoma. This stage of disease is known as acquired immune 
deficiency syndrome (AIDS).  
 
During peak HIV viraemia, the major sites of CD4
+
 T cell depletion are mucosal 
tissues and associated lymphoid tissues, with up to 80% of CD4
+
 T cells depleted 
from the gut-associated lymphoid tissue during initial infection (McMichael et al., 
2010; Brenchley and Douek, 2008). There is evidence showing that although CD4
+
 T 
cell depletion occurs at a range of sites, the gastro-intestinal tract remains the 
principal site of this depletion throughout HIV infection (Brenchley et al., 2004). 
Several mechanisms underlying the loss of CD4
+
 T cells during HIV infection have 
been described. The major mechanism has not yet been determined, and it is likely 
that several mechanisms contribute to depletion of CD4
+
 T cells during HIV infection 
(McCune, 2001a).  
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As well as cytopathic infection of CD4
+
 T cells by the virus and killing of infected 
cells by cytotoxic CD8
+
 T cells, immune activation has been shown to play a key role 
in destruction of the CD4
+
 T cell pool during both the acute and chronic phases of 
infection (McMichael et al., 2010). Chronic activation of CD4
+
 T cells during HIV 
infection results in overactivation of these cells, resulting in them becoming 
hyperactivated and exhausted, and subsequently undergoing activation-induced cell 
death (McCune, 2001b). Activated CD4
+
 T cells are also more susceptible to infection 
by HIV, and increased numbers of these cells will therefore promote spread of the 
virus (McMichael et al., 2010). B cells and CD8
+
 T cells can also be damaged due to 
chronic immune activation during prolonged HIV infection, resulting in further 
reduction of overall immune function (McMichael et al., 2010).  
 
A small proportion of HIV-infected individuals are able to control progression to 
AIDS in the absence of antri-retroviral drugs. These include long-term non-
progressors (LTNPs) and elite controllers. LTNPs are able to retain a normal CD4
+
 T 
cell count despite infection with HIV and high viral load, while elite controllers are 
able to control viral load, maintaining it at a low level and hence controlling 
progression to AIDS (Blankson, 2010). These populations provide opportunities to 
investigate mechanisms which lead to control of HIV infection, prevention of CD4
+
 T 
cell loss and delay of AIDS onset, and may provide valuable clues for vaccine 
development. 
 
Despite the development and increased distribution of highly active anti-retroviral 
therapy (HAART) as a treatment for HIV infection, a vaccine is the only way in 
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which to effectively prevent the spread of HIV and control this global epidemic. 
However, development of a vaccine to protect against infection by HIV remains a 
seemingly unachievable task. Since its discovery in 1985, numerous candidate 
vaccines have been proposed and investigated to no avail. Some recent examples of 
clinical trials for prophylactic HIV vaccines are described below. 
 
1.5.2 Development of an HIV vaccine 
In the Merck Step Study a replication-incompetent adenovirus serotype 5 (Ad5) 
vector vaccine containing gag, pol and nef genes was trialled, but phase II trials 
showed that the vaccine was not able to provide protection against HIV infection. In 
fact, there was a trend towards an increased susceptibility to HIV infection in those 
participants which had previous adenoseropositivity upon commencing the trial. This 
observation resulted in premature termination of the trial (Buchbinder et al., 2008). 
Further analysis revealed that the vaccine induced functional HIV-specific CD4
+
 and 
CD8
+
 T cell responses regardless of initial Ad5 antibody titre, but was not able to 
reduce viral load in those who became infected after receiving the vaccine (McElrath 
et al., 2008). Further study showed that in vitro stimulation of T cells from healthy 
volunteers who were adenovirus seropositive resulted in expansion of adenovirus 
specific memory CD4
+
 T cells. These CD4
+
 T cells had a mucosal homing phenotype 
and were particularly susceptible to infection by HIV, potentially explaining why 
those volunteers who were adenoseropositive at the beginning of the trial were more 
susceptible to infection by HIV (Benlahrech et al., 2009).  
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A trial carried out in Thailand, where volunteers were vaccinated with a canarypox 
vector vaccine and subsequently boosted with a recombinant gp120 vaccine, showed a 
potentially promising outcome. Preliminary studies showed that CD8
+
 T cell 
responses and nAb responses were induced by the vaccine regimen (Nitayaphan et al., 
2004). The phase III clinical trial showed that the vaccine was adequate to protect 
against HIV infection with 30% efficacy. However, no reduction of viral load or 
preservation of CD4
+
 T cells was seen in those patients who did contract the virus 
after vaccination compared to the placebo group (Rerks-Ngarm et al., 2009). 
Although protection was low, this study provides a promising basis for further 
examination. These clinical trials show that much more study is required into the 
specific immune responses required to protect against HIV, as well as the vaccination 
approaches necessary to induce such an immune response. 
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1.5.3 Obstacles to vaccinating against HIV 
The major obstacle in the development of an effective vaccine to prevent HIV 
infection is the high level of antigenic variability of retroviruses, enabling HIV to 
successfully evade recognition by the immune response. As well as the antigen 
variability observed between strains, reverse transcriptase, the viral enzyme involved 
in reverse transcription, has a highly error-prone nature (Ji and Loeb, 1992; Roberts et 
al., 1988). This high error-rate of retroviral reverse transcriptase is due in part to its 
lack of exoribonuclease proof reading mechanism (Svarovskaia et al., 2003). Another 
factor contributing to the variability of HIV is the high rate of HIV replication. The 
virus has a relatively short half-life of approximately two days, while mathematical 
models have estimated that 10.3 × 10
9
 HIV virions are produced per day (Perelson et 
al., 1996; Wei et al., 1995). Together, this results in constantly altering epitopes, and 
hence makes selecting appropriate epitopes for target with vaccines a complex 
challenge. 
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1.5.4 Role of CD4+ T cells against HIV infection 
HIV-specific CD4
+
 T cells are present in HIV infected individuals, and a strong HIV-
specific CD4
+
 T cell response is generally associated with slow rate of disease 
progression (Lichterfeld et al., 2005). However, as HIV also preferentially infects 
HIV-specific CD4
+
 T cells (Douek et al., 2002), it is unclear whether a strong virus-
specific CD4
+
 T cell response is the cause or simply the consequence of low viral 
replication.  
 
Patients who are able to control viraemia without HAART show vigorous HIV-
specific CD4
+
 T cell responses, and the magnitude of these responses correlates 
inversely with viral load, while acutely infected individuals treated with HAART 
develop strong CD4
+
 T cell responses, again correlating with a reduced viral load 
(Rosenberg et al., 1997). However, it has also been shown that HAART-mediated 
prolonged suppression of HIV viraemia during infection can leads to loss of HIV-
specific CD4
+
 T cells (Pitcher et al., 1999). 
 
As mentioned with regards to other viral infections, cytotoxic CD4
+
 T cells have also 
been identified in HIV. HIV Gag-specific CD4
+
 T cell clones derived from infected 
individuals have been shown to have perforin-dependent cytolytic ability in vitro as 
well as producing IFN-γ (Norris et al., 2001). This cytotoxic function of HIV-specific 
CD4
+
 T cells against HIV-infected cells was further demonstrated ex vivo, and direct 
inhibition of replication in a cell contact-dependent but IFN-γ-independent manner 
was observed (Norris et al., 2004).  
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SIV Gag- and Nef-specific CD4
+
 T cells were shown to be able to directly inhibit 
replication of HIV in infected macrophages but not in other infected CD4
+
 T cells 
(Sacha et al., 2009), while HIV Nef-specific CD4
+
 T cells were also shown to inhibit 
viral replication in both macrophages and CD4
+
 T cells (Zheng et al., 2009).  
 
Although the correlation between control of viral load and a strong HIV-specific 
CD4
+
 T cell response has been demonstrated extensively, the cause and effect 
relationship between the CD4
+
 T cell response and its role in controlling HIV 
infection, as well as the major mechanisms by which CD4
+
 T cells control HIV 
infection, remain undetermined. 
 
1.5.5 Role of CD8+ T cells against HIV infection 
The resolution of the acute phase of HIV infection and control of viral load is 
primarily attributed to CD8
+
 T cells (McMichael et al., 2010). Using SIV infection as 
an animal model for HIV infection, it was shown that depleting CD8
+
 T cells during 
acute infection rendered animals unable to control viral replication, while depleting 
CD8
+
 T cells in chronically infected animals resulted in increased viremia, which was 
resolved upon restoration of the CD8
+
 T cell pool (Schmitz et al., 1999). 
 
CD8
+
 T cells are also shown to be at higher frequencies in LTNPs, possibly 
explaining the ability of this population of HIV-infected persons to delay the onset of 
AIDS. These CD8
+
 T cells were shown to be able to kill HIV-infected CD4
+
 T cells 
via administration of granzyme B, more efficiently than those CD8
+
 T cells from 
progressors (Migueles et al., 2008). These findings demonstrate the importance of 
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CD8
+
 T cells in HIV infection, and in particular the importance of their cytolytic 
capacity. 
 
Both avidity and polyfunctionality of CD8
+
 T cells have been shown to be correlative 
with effective control of HIV replication (Almeida et al., 2007). Furthermore, HIV-
specific CD8
+
 T cells of high avidity have been shown to have increased 
polyfunctional ability compared to those of low avidity (Almeida et al., 2009). CD8
+
 
T cells specific for HIV have also been shown to inhibit replication of the virus in 
macrophages more than they can in CD4
+
 T cells (Fujiwara and Takiguchi, 2007). 
This difference is due to downregulation of MHC class I by Nef on CD4
+
 T cells, 
occurrence of this on macrophages is negligible. 
 
A recently identified role for CD4
+
 T cell-derived IL-21 in viral infection was 
discussed above. In HIV, it was found that IL-21-producing CD4
+
 T cells were 
present during acute and chronic HIV infection, and that elevated levels of these cells 
were associated with control of viral load via maintenance of CD8
+
 T cells (Yue et al., 
2010). A further study confirmed the requirement for these IL-21 producing CD4
+
 T 
cells in control of HIV infection, showing IL-21 mediated enhancement of CD8
+
 T 
cell cytotoxic activity (Chevalier et al., 2010). 
 
A major problem limiting the effectiveness of CD8
+
 T cells in controlling HIV 
infection is immune escape by the virus (McMichael et al., 2010; Davenport et al., 
2008). During acute SIV infection, CD8
+
 T cell-resistant escape variants of SIV were 
shown to develop (O'Connor et al., 2002). Furthermore, during acute HIV infection 
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virus mutations developed in CD8
+
 T cell epitopes (Bernardin et al., 2005). This 
immune escape has hindered the development and limited efficacy of HIV vaccines 
designed to induce CD8
+
 T cells against the virus.  
 
1.5.6 Inducing CD4+ T cells against HIV 
Although the above studies show that CD4
+
 T cells clearly play a role in controlling 
HIV infection, inducing them can also have a detrimental effect. HIV has been shown 
to preferentially infect HIV-specific CD4
+
 T cells, suggesting that inducing HIV-
specific CD4
+
 T cells may not only be ineffective but could actually be harmful to the 
host (Douek et al., 2002). Furthermore, vaccinations that elicit a CD4
+
 T cell response 
have been shown to have a damaging effect in both animal and human subjects. In 
HIV-infected individuals, vaccination with influenza vaccine resulted in a boost in 
viral replication and increased HIV plasma viral load, correlating with induction of 
influenza-specific T cell responses (Staprans et al., 1995). Other studies vaccinating 
with the env gene, as a DNA vaccine in cats against Feline Immunodeficiency Virus 
(FIV) has shown, result in advancement of the acute phase of infection (Richardson et 
al., 1997). Furthermore vaccination of macaques against SIV induced CD4
+
 T cells 
but also resulted in increased viral replication and a more rapid onset of simian AIDS 
(Staprans et al., 2004). 
 
Other vaccinations where CD4
+
 T cells were induced have been shown to be 
protective against infection. Vaccination against SIV Gag using a lentiviral vector was 
also able to protect against SIV infection, again correlating with preservation of SIV-
specific memory CD4
+
 T cells during the acute phase of infection (Beignon et al., 
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2009). Additionally, transfer of activated CD4
+
 T cells resulted in expansion of 
endogenous T cells, immune reconstitution, increased CD4
+
 T cell count and reduced 
expression of CCR5 (Bernstein et al., 2004; Levine et al., 2002).  
 
In conclusion, these latter studies indicate that CD4
+
 T cells are an essential 
component in immune protection against HIV. Indeed, it has been shown that CD4
+
 T 
cell epitopes on HIV-1 may be subject to less variation than CD8
+
 T cell epitopes 
(Koeppe et al., 2006). This suggests that CD4
+
 T cells would provide a less variable 
target for vaccination, and that employing a vaccine strategy that induces CD4
+
 T 
cells could be more widely efficient and resist the variation seen in HIV epitopes. 
Hence, the contribution of CD4
+
 T cells to control of HIV infection is not clearly 
defined and requires further investigation. 
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1.6 Friend Virus 
1.6.1 The Friend virus complex 
Friend Virus (FV) provides a useful and adaptable murine model in which the 
immune response to retroviral infection can be investigated. FV was discovered after 
the observation that leukaemia could be transferred into adult mice by inoculating 
them with a cell-free filtrate from spleens of leukemic mice. Infection of susceptible 
mice with this virus results in two stages of Friend disease: splenic enlargement and 
subsequently, fatal erythroleukaemia (Friend, 1957).  
 
The FV retroviral complex is comprised of replication-competent Friend Murine 
Leukaemia helper virus (F-MuLV) and replication-defective spleen focus-forming 
virus (SFFV). The SFFV env gene encodes gp55 - an envelope fusion glycoprotein 
which mimics erythropoietin (Epo) and binds to and causes the constitutive activation 
of the erythropoietin receptor (EpoR). Ligation of gp55 with the EpoR on the cell-
surface and endoplasmic reticulum of FV-infected cells causes expansion of BFU-E 
(burst-forming units-erythroid) and CFU-E (colony-forming units-erythroid), and 
results in prolonged polyclonal proliferation of erythroid precursor cells, leading to 
splenic enlargement and erythroleukaemia (Li et al., 1990; Ney and D'Andrea, 2000). 
FV infection persists in the spleen of mice after recovery and its primary reservoir has 
been identified as a small population of B cells, rather than erythroid precursors which 
comprise the majority of the infected cell population during acute infection (Chesebro 
et al., 1979; Hasenkrug et al., 1998). 
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Although the FV complex does not contain an oncogene, mutations are acquired as 
mice progress into erythroleukaemia. Pro-viral integration of the SFFV component of 
the FV complex occurs at the host gene Spi-1 (SFFV proviral integration 1, also 
known as PU.1) locus, an oncogene which is only seen in murine erythroleukaemia 
and not myeloid or lymphoid leukaemia (Moreau-Gachelin et al., 1988). During FV 
infection, rearrangement of, and mutations in, the p53 gene lead to truncation of the 
protein or complete abrogation of protein expression. Both result in p53 inactivation, 
a process which is necessary for development of Friend erythroleukaemia (Munroe et 
al., 1990). Overall, FV-induced erythroleukaemia is characterised by activation of 
EpoR and Spi-1, and inactivation of p53.  
 
Entry of murine leukaemia viruses, including FV, into rodent cells occurs via a 
membrane receptor designated as the ecotropic MuLV receptor. This receptor is an 
amino acid transporter, specifically transporting cationic amino acids across the cell 
membrane (the cationic amino acid transporter, or CAT). This receptor is ubiquitously 
expressed in mice, but notably is not expressed in hepatocytes, commensurate with 
the observation that murine leukaemia viruses do not infect cells in the liver (Kim et 
al., 1991; Wang et al., 1991). Additionally, binding of the viral gp70 envelope 
glycoprotein to this receptor prevents further infection of the cell via this receptor, but 
not amino acid transportation (Kim et al., 1991; Overbaugh et al., 2001). It was 
thought that CAT-1, which is not expressed in the liver was the receptor for ecotropic 
MuLV, while CAT-2 which is expressed in the liver, was the receptor for 
amphotropic MuLV. However, while CAT-1 expression is essential for infection of 
hepatocytes by ecotropic virus, neither CAT-2A or CAT-2B isotypes are adequate to 
allow infection of hepatocytes by amphotropic virus (Closs et al., 1993). 
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1.6.2 Susceptibility to FV-induced pathology 
Susceptibility to, and recovery from, FV infection differs between mouse strains and 
can be determined by both immunological and non-immunological host genes 
(Chesebro et al., 1974). Differences in the MHC H-2 haplotype control susceptibility 
to splenomegaly, erythroleukaemia and immunosuppression, (Morrison et al., 1987; 
Morrison et al., 1986). These are summarised in Table 1.1. B6 mice are H-2
b/b
, while 
C mice are H-2
d/d
 and hence are fully susceptible (Hasenkrug and Chesebro, 1997).  
 
The high incidence recovery H-2
b/b
 haplotype is within the H-2D region and is 
thought to exert its effect via regulation of virus-specific cytotoxic CD8
+
 T cells. 
Other loci which contain genes affecting the immune response to FV include the H-
2A, E and Qa/Tia regions. Expression of H-2E has been shown to have both positive 
and negative effects on recovery from FV (Perry et al., 1994). 
 
The H-2D MHC haplotype can also affect the number of IFN-γ producing CD8+ and 
CD4
+
 T cells. Thus, H-2
b/b
 mice have high numbers of IFN-γ producing cells and H-
2
a/b
 and H-2
d/d
 mice have lower numbers, correlating with the differences in recovery 
seen in mice of this genotype (Peterson et al., 2000). It has also been shown that MHC 
class I is able to modify the CD4
+
 T cell response to FV. This requires the presence of 
CD8
+ 
T cells and so suggests an unconventional provision of help to CD4
+
 T cells 
from CD8
+
 T cells (Peterson et al., 2000; Peterson et al., 2002). 
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Table 1.1 Summary of susceptibility to FV infection 
 
MHC Genotype Effect of FV Infection 
H-2
a/a
 Splenomegaly and fatal erythroleukaemia 
H-2
b/b
 Initial splenomegaly followed by spontaneous recovery 
H-2
d/d
 Fully susceptible to splenomegaly and erythroleukaemia 
H-2
a/b
 
Low dose infection - splenomegaly then recovery 
No recovery from high dose infection 
H-2
b/d
 Can not recover from splenomegaly and die 
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The Rfv-1 and Rfv-2 genes are both MHC-linked and affect recovery from FV disease 
(Chesebro and Wehrly, 1978; Miyazawa et al., 1995). In contrast, Rfv3 is a non-MHC 
gene which controls induction of FV-specific antibodies and recovery in association 
with H-2 genes and has no effect on susceptibility to immunosuppression (Morrison et 
al., 1986).  
 
Compared to H-2
a/b
 or H-2
b/b
 Rfv-3
r/s
 mice, animals with an H-2
a/a
 Rfv-3
r/s
 genotype 
cannot mount an FV-specific T cell response. Although they can mount a virus-
neutralising IgM antibody response, they cannot class-switch to IgG and thus have a 
low recovery phenotype. However, induction of the nAb response in all three H-2 
genotype Rfv-3
r/s
 mice is dependent on the presence of CD4
+
 T cells, and viraemia is 
increased in their absence. Furthermore, in the absence of CD4
+
 T cells, H-2
a/a
 Rfv-3
r/s
 
mice do not recover from FV-induced splenomegaly, showing a requirement for CD4
+
 
T cell help in FV infection of Rfv-3
r/s
 mice independent of H-2 genotype. Proliferation 
of CD4
+
 T cells has been seen after FV infection in H-2
a/a
 Rfv-3
r/s
 mice but their 
specificity was not known (Super et al., 1998). 
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1.6.3 Friend virus susceptibility genes 
In addition to MHC variability, FV disease pathogenesis and susceptibility to disease 
in mice is controlled by a broad range of non-MHC host genes – Friend virus 
susceptibility genes 1-6 (Fv1-Fv6), which are able to confer their effects via both 
immunological and non-immunological mechanisms (Bieniasz, 2003).  
 
The Fv1 locus was the first restriction factor to be described. Restriction factors are 
also found in humans (e.g. Restriction factor 1 (Ref1) in HIV) and have developed 
throughout evolution to prevent integration of retroviruses into the host genome 
(Goff, 2004). The Fv1 gene encodes Fv1, which is derived from an endogenous 
retrovirus and restricts establishment of the viral RNA genome after it has entered the 
cell and reverse transcription has occurred (Best et al., 1996). Fv1 is related to an 
endogenous retrovirus Gag-related protein, and in laboratory mouse strains two major 
alleles exist: Fv1
n
 and Fv1
b
 (from NIH and BALB/c mice respectively). Depending on 
their ability to replicate in cells carrying either the Fv1
n
 or Fv1
b
 allele, different 
strains of MuLV are allocated as N-tropic, B-tropic or NB-tropic. The Fv1
n
 allele 
restricts B-tropic virus while the Fv1
b
 allele restricts N-tropic virus. NB-tropic virus 
strains can replicate in cells with either or both alleles, while cells that are 
heterozygous are resistant to both N- and B-tropic strains. Furthermore, Fv1 is 
saturable, and its restriction can be overridden by increased viral load (Bieniasz, 2003; 
Pryciak and Varmus, 1992; Bieniasz, 2004). 
 
The Fv2 gene controls susceptibility to FV-induced splenomegaly and 
erythroleukaemia by determining gp55-mediated proliferation of SFFV-infected 
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erythroblasts. In Fv2 susceptible (Fv2
s
) mice the Fv2 gene encodes for both a full 
length and truncated form of a receptor tyrosine kinase, known as Stk and sf-Stk 
respectively (Persons et al., 1999). However, in Fv2 resistant (Fv2
r
) mice the Fv2 
gene encodes only for Stk, and as sf-Stk is required for FV-mediated 
erythroproliferation, these mice are resistant to splenomegaly (Finkelstein et al., 
2002). Sf-Stk lacks the N-terminal ligand binding domain and confers susceptibility 
of erythroid cells to proliferation via covalent interactions between cysteine residues 
in its extracellular domain and in the gp55 molecule, resulting in constitutive 
activation of the EpoR (He et al., 2010). While most laboratory mouse strains are 
Fv2
s
, C57BL/6 (B6) mice and related strains are Fv2-resistant (Fv2
r
) (Persons et al., 
1999; Ney and D'Andrea, 2000). However, B6 mice with susceptibility at the Fv2 
allele (B6.A-Fv2
s
) are susceptible to FV-induced splenomegaly compared to wild-
type B6 mice, although they recover from this splenomegaly. In contrast, B6 mice 
with susceptibility at the Fv2 allele and a deficiency in adaptive immune cells (B6.A-
Fv2
s
Rag1
-/-
 mice) suffer acute splenomegaly which is fatal (Marques et al., 2008).  
 
The Fv4 gene blocks cell-surface receptors by expressing an endogenous retroviral 
envelope protein that competes with F-MuLV env for ligation of these receptors 
(Ikeda et al., 1985). Whilst Fv3 and Fv5 have not been clearly established as 
independent loci, Fv3 is known to regulate FV-induced immunosuppression, 
potentially by regulating the number or function of Tregs (Morrison et al., 1986), 
while Fv6 determines resistance to early onset erythroleukaemia (Shibuya and Mak, 
1982). 
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1.6.4 FV infection as a mouse model of HIV 
There are several problems associated with studying the immune response to HIV. 
Immune responses in ex vivo samples from HIV-infected patients can be studied but 
the exact duration and stage of infection are often difficult to determine, and so 
parameters of the immune response during different phases of infection cannot be 
examined. Additionally, human research trials require ethical approval. Non-human 
primates provide a laboratory animal model in which the homologous SIV is used, but 
these have time and cost limitations as well as ethical considerations. 
 
HIV host range does not extend to rodents and this is unfortunate because gene 
knockout mice and transgenic mouse models provide powerful tools for investigating 
the role of individual cell types and molecules such as cytokines and MHC, and to 
study pathogen-specific immune responses. Additionally, in mouse models the 
immune response can be monitored and studied in detail at defined points during 
infection.  
 
The major pathogens used in mouse models to study the immune response to viral 
infection include and vesicular stomatitis virus (VSV), and while these have provided 
valuable information regarding anti-viral T cell responses, the significance for 
understanding the immune response to HIV is limited as they are not retroviruses. A 
murine model which has been widely utilised to study the immune response to 
chronic viral infection is infection with lymphocytic choriomeningitis virus (LCMV). 
In particular, LCMV Clone 13 which results in chronic infection and T cell 
exhaustion has been useful, as opposed to LCMV Armstrong which causes an acute 
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and relatively rapidly cleared infection. Several observations concerning the immune 
response during LCMV Clone 13 infection are in line with those described in HIV 
infection with regards to CD4
+
, CD8
+
 and B cell responses, as well as data concerning 
T cell exhaustion. However, while parallels to HIV can be drawn from results from 
studies in LCMV, LCMV is not a retrovirus, and hence FV provides an alternative 
model for studying immune responses to chronic retroviral infection. 
 
In contrast to these models, the retroviral complex FV exhibits many analogous 
properties to HIV, including similar mechanisms of replication via the error prone 
enzyme reverse transcriptase, and integration into the host cell genome (Nisole and 
Saib, 2004). Furthermore, both viruses are able to replicate in macrophages and have 
many common targets of infection. Although the major target of FV is erythroid 
precursors which FV infects via CAT-1, while the major target of HIV is CD4
+
 T 
cells which HIV infects via CD4 and either CCR5 or CXCR4, these differences allow 
us to dissociate from the direct effect of viral infection on the CD4
+
 T cell response to 
HIV from those of antigen presentation to CD4
+
 T cells in FV. Additionally, FV and 
HIV both persist throughout the life span of the host, and remain latent in reservoirs 
(Chesebro et al., 1979; Trono et al., 2010).  
 
In conclusion, the FV mouse model represents a strong resource for the study of 
retroviral infection by providing an easily adaptable and versatile model in which all 
aspects of the immune response to retroviral infection can be investigated. 
Information gained from the study of the FV mouse model provides information that 
can further be applied to understanding other retroviral infections, such as HIV. 
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1.7 Lactate Dehydrogenase Elevating Virus 
1.7.1 Lactate dehydrogenase elevating virus 
Lactate dehydrogenase elevating virus (LDV) was first described in 1960, and was 
identified as a plasma enzyme-elevating virus (MAHY, 1964). LDV is a rapidly 
replicating RNA virus from the Nidovirales family, which cytopathically infects a 
subset of lactate dehydrogenase scavenging macrophages, causing an elevated level of 
lactate dehydrogenase in the host (Robertson et al., 2008). Infection with LDV occurs 
naturally in mice in the wild and although it does not have a harmful effect on the 
host, it has been shown to influence several aspects of the immune response, 
including reduction of antigen presentation by macrophages (Isakov et al., 1982), and 
activation of B cells leading to hypergammaglobulinaemia (Coutelier et al., 1990).  
 
1.7.2 History 
The possibility that previous studies and results regarding the immune response to FV 
may have been affected by contamination of the virus stock was largely ignored, 
despite a commentary on the subject several decades ago stating that LDV was a 
major contaminant in numerous transplantable murine tumours and suggesting that 
the absence of LDV should be confirmed for accuracy tumour studies (Riley, 1974). 
As well as transplantable tumour studies, LDV was also shown to increase the 
severity and duration of Plasmodium yoelii infection in a mouse model of malaria 
(Henderson et al., 1978).  
 
 71 
1.7.3 Contamination of FV stocks 
FV virus stock can be passaged in vivo or cloned in vitro, with in vivo passaging 
preferred due to its capacity to produce a virus complex containing more natural 
levels of SFFV due to positive selection of the virus (Robertson et al., 2008). 
However, in vivo passaging of FV resulted in contamination of virus stocks with LDV 
(Steeves et al., 1969). Despite this observation, researchers continued to use LDV-
contaminated FV stock for several more decades. Coinfection of LDV and FV has 
been shown to have major effects on the immune response to FV, delaying recovery 
and increasing severity of FV disease. The effects of FV/LDV coinfection are 
discussed in detail below. 
 
1.7.4 Effects of LDV coinfection on the immune response to FV 
When FV alone infects immunocompetent and genetically resistant mice, the peak of 
infection occurs at day 7 and is subsequently resolved. However, in FV/LDV co-
infection, infection does not peak by day 7 and continues to increase to a higher peak 
of infection at day 14, although again infection is resolved by day 28 (Marques et al., 
2008).  
 
As regards to effects on FV-specific immune responses, LDV has also been shown to 
have a suppressive effect on FV-specific CD8
+
 T cells, resulting in a delayed CD8
+
 T 
cell response in FV/LDV co-infected mice compared to FV alone, while no effect on 
the CD4
+
 T cell response was observed. Further analysis of the mechanism of CD8
+
 T 
cell-suppression showed that Treg cells induced by the virus are responsible for the 
delayed FV-specific CD8
+
 T cell response in FV/LDV co-infection. The delay in peak 
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viraemia and recovery was attributed to the reduced CD8
+
 T cell response during 
initial infection (Robertson et al., 2008).  
 
In a separate study, B6 mice infected with FV alone did not develop splenomegaly 
and only marginal splenomegaly was seen after FV/LDV co-infection. In contrast, 
B6.A-Fv2
s
 mice, which have been shown to suffer only mild splenomegaly during FV 
infection alone, suffered from more severe splenomegaly during FV/LDV co-
infection, with a delay in recovery similar to that described above. However, LDV 
coinfection did not alter the distribution of FV infection. Mice deficient in FV-
specific B cells, have a more severe disease in both circumstances, and transfer of FV 
nAb was sufficient to reduce FV infection in both FV-infected mice and FV/LDV-co-
infected mice. A delay in induction of FV nAb in FV/LDV co-infection was observed. 
This relied on the presence of a polyclonal B cell population since the effect was 
simulated by polyclonal activation of B cells (Marques et al., 2008). Thus, it can be 
concluded that polyclonal B cell activation by LDV results in delayed FV nAb 
response and that this, along with a delayed CD8
+
 T cell response, contributes to 
increased severity of FV disease during FV/LDV coinfection.  
 
1.7.5 The effect of FV/LDV co-infection on previous studies 
The above described effects on LDV the pathogenesis of FV disease and the immune 
response to FV were largely overlooked in many previous studies and therefore must 
be taken into consideration when considering studies regarding the immune response 
to FV. 
 
 73 
1.8 The Immune Response to FV 
Ultimate control and clearance of FV infection depends on multiple facets of the 
adaptive immune response, and spontaneous relapse of disease can occur (Hasenkrug 
and Dittmer, 2000; Dittmer et al., 1999; Chesebro et al., 1974). Depletion, adoptive 
transfer and gene knock-out studies have attempted to reveal the individual roles and 
importance of different lymphocyte subsets. The FV-specific immune response has 
been studied using several methods beyond FV infection, including peptide 
immunisation, live attenuated virus vaccine, immunisation with the FBL-3 FV-
induced leukaemia cell line, and retroviral vector vaccines. However, it must be 
considered that these observations may have been affected by LDV contamination of 
FV stocks.  
 
1.8.1 The role of adaptive lymphocytes against FV infection 
Two studies have highlighted the roles of CD8
+
 and CD4
+
 T cells at different stages 
of FV infection. A correlation between CD8
+
 T cell cytotoxic activity and recovery of 
H-2D
b/b
 mice from FV-induced splenomegaly has been observed. Furthermore, 
depletion of CD8
+
 T cells by mAb during acute FV infection prevented recovery of 
splenomegaly. However, mice depleted of CD4
+
 T cells during acute infection began 
to recover but disease was subsequently reactivated, with mice developing 
splenomegaly and erythroleukaemia. It was concluded from this study that CD8
+
 T 
cells were required for recovery from initial disease while CD4
+
 T cells were required 
to maintain control of chronic infection (Robertson et al., 1992). 
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In a complementary experiment, depletion of CD4
+
 T cells by mAb during chronic 
FV infection in immunocompetent and otherwise resistant mice resulted in 
splenomegaly, erythroleukaemia and increased levels of viral replication. Conversely, 
depletion of CD8
+
 T cells during chronic FV infection had no effect on viral load and 
did not lead to reactivation of disease. (Hasenkrug et al., 1998). Together these data 
show a requirement for CD8
+
 T cells in controlling the initial FV infection and CD4
+
 
T cells for control of chronic persistent FV infection.  
 
A constitutive CD8
+
 T cell deficiency did not confer susceptibility to initial FV-
induced disease in Fv2
r
 B6 mice, but did render mice susceptible to onset of late 
splenomegaly, although some of these animals recovered. Furthermore, CD4
+
 T cell 
deficiency did not prevent control of acute infection by Fv2
r
 mice, but these mice 
could not maintain control and eventually succumbed to splenomegaly and 
erythroleukaemia with no recovery, further validating results from CD4
+
 T cell 
depletion described above. This study suggests that both CD4
+
 and CD8
+
 T cells are 
required for prevention of late onset splenomegaly, but are not required to control the 
acute infection. Although B cell-deficient mice also showed increased susceptibility 
to late onset splenomegaly, this was mild compared to CD4
+
 and CD8
+
 T cell 
deficiencies (Hasenkrug, 1999). The findings of these studies are summarised in 
Figure 1.4. 
 
Depletion of T cells in genetically resistant mice has been shown to result in 
susceptibility to FV disease and thus overcomes genetic resistance. Therefore, 
resistance to FV infection is mediated by both genetic and immunological factors. 
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However, processes that compensate for lymphocyte deficiencies exist, resulting in 
abnormal distribution of the remaining lymphocyte subsets, as evidenced by the 
increased percentage of CD8
+
 T cells and a reduced percentage of B cells seen in 
CD4
+
 T cell-deficient mice (Hasenkrug, 1999). 
 
While the experiments described above have lead to the conclusion that CD4
+
 T cells 
are required to control chronic infection while CD8
+
 T cells are necessary for control 
of acute infection, others have suggested that CD4
+
 and CD8
+
 T cells are essential for 
preventing onset of splenomegaly during the chronic phase of infection, but play no 
role in reducing acute infection. These inconsistencies are likely to due to the 
presence of absence of LDV contamination and its effects on the FV-specific immune 
response, and further work to establish the precise roles of T lymphocytes during 
different stages of FV infection using a clean FV stock is therefore required. 
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Figure 1.4 Pathogenesis of Friend virus infection and the effect of lymphocyte 
subset depletion 
Pathogenesis of Friend virus infection in an immunocompetent mouse (uninterrupted 
line), and the effect of constitutive deficiencies or active depletion of CD4
+
 T cells 
(dashed line) or CD8
+
 T cells (dotted line) on viral load during the acute or chronic 
phase of the infection. 
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1.8.2 Cytotoxicity during FV infection 
The ability of CD8
+
 T cells to kill virally infected cells is well-described, and 
depletion of CD8
+
 T cells has been shown to prevent recovery of FV-induced 
splenomegaly in mice (Robertson et al., 1992; Hasenkrug, 1999). With this in mind, 
functional activity of cytotoxic CD8
+
 T cells in the FV model has also been 
investigated. Here, mice deficient in the Fas/FasL pathway were still able to control 
splenomegaly during acute FV infection but could not control persistent infection, 
although knock-out mice did not develop erythroleukaemia. Mice deficient in either 
perforin, granzyme A or granzyme B, or two of the three, were able to control FV 
infection in the presence of functional Fas/FasL, while deficiency of all three 
components rendered mice susceptible to FV-induced erythroleukaemia (Zelinskyy et 
al., 2004). Additionally, CD8
+
 T cells ex vivo from infected mice did not show high 
cytotoxic activity, while previous studies have shown detectable cytotoxic activity of 
CD4
+
 T cells, suggesting that they may be the major killers of infected cells during 
persistent FV infection (Iwashiro et al., 2001b).  
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1.8.3 Cytokine responses 
As in all pathogen-specific immune responses, many cytokines work to control FV 
infection. Interferons are the major anti-viral cytokines, while other cytokines have 
important direct effects or play a role in modulating the activities of both innate and 
adaptive immune cells. 
 
Type I interferons IFN-α and IFN-β were shown to inhibit replication of F-MuLV in 
vitro, with both cytokines induced soon after FV infection. In mice deficient in either 
the type I IFN receptor or IFN-β, viral load in the spleen was increased during both 
acute and chronic infection. IFN-α was shown to have a more profound effect, and 
administration of exogenous IFN-α before challenge was able to reduce FV infection 
in the acute phase by direct inhibition of viral replication and modulation of T cells 
(Gerlach et al., 2006). However, an author’s correction was published stating that FV 
in fact does not induce type I interferons, and that the induction of IFN-α and IFN-β 
was caused by LDV contamination of FV stock . However, mRNA expression of 
IFN-α was detected in splenocytes of FV-infected animals, and the IFN-α subtype 
mediating this suppression was further investigated. Several subtypes of IFN-α were 
shown to be expressed in splenocytes, of which IFN-α1, α4 and α9 subtypes were able 
to reduce FV infection, with IFN-α4 being the most effective. While IFN-α4 and α9 
mediated this effect via activation of NK cells, IFN-α1 also activated CD8+ T cells 
(Gerlach et al., 2009). 
 
IL-4, IL-12 and IFN-γ and their roles in the FV-specific immune response have also 
been investigated. While IFN-γ-deficient mice could not control acute FV infection, 
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IL-4- and IL-12-deficient mice did not have significantly higher viraemia than that 
seen in wild-type mice. Furthermore, some IFN-γ-deficient mice went on to develop 
splenomegaly during later disease, in contrast to IL-4
-/-
, IL-12
-/-
 or control mice. In 
addition, vaccination with the F-MuLV live attenuated virus vaccine was able to 
protect mice deficient in IL-4, IL-12 or IFN-γ. It was also shown that although FV 
nAb were induced in IFN-γ deficient mice, these mice had a compromised ability to 
class switch from IgM to IgG, and so only had IgM nAb. However, this did not affect 
live attenuated virus vaccine-mediated protection against FV (Dittmer et al., 2001). 
 
Use of an env-specific CD4
+
 T cell clone in vitro showed that IFN-γ had a direct 
inhibitory effect on virus production which required T cell activation, but not antigen 
presentation to CD4
+
 T cells. This CD4
+
 T cell clone was also shown to have 
cytotoxic activity which was dependent on antigen presentation, although it did not 
require MHC II expression by target cells, and was enhanced by IFN-γ. While IFN-γ-
deficient B6 mice did not suffer from splenomegaly initially, they could not control 
persistent infection and succumbed to late onset splenomegaly (Iwashiro et al., 
2001b). Further studies of the role of IFN-γ in FV infection found contradicting 
results. IFN-γ deficient mice had reduced levels of infection in the blood and bone 
marrow but not spleen at one week post infection. However, by 2 weeks post infection 
mice deficient in IFN-γ actually had a decreased level of infection in the spleen and 
bone marrow compared to wild-type mice, and were shown to have an increased level 
of nAb. However, later in FV infection IFN-γ-deficient mice had a lower FV nAb titre 
than wild-type mice, and could not prevent splenomegaly (Stromnes et al., 2002). 
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Alternatively, IFN-γ has been shown to inhibit formation of murine erythroid colonies 
and therefore IFN-γ could be also be having a direct effect in reducing FV infection, 
by controlling the proliferation of erythroid precursors induced by gp55 agonism of 
the EpoR during FV infection (Means, Jr. et al., 1994). 
 
Other cytokines have also been studied in the context of FV infection, in particular 
IL-5 which can stimulate B cell growth, IL-6 which can stimulate B cell maturation, 
and the immunosuppressive cytokine IL-10. While IL-5-deficient mice did not have 
higher levels of infection, viral load was increased in the absence of IL-6 or IL-10 
during the acute phase of infection, but control of persistent infection was not altered 
compared to wild-type mice. Additionally, vaccination with a live attenuated virus 
vaccine was still protective even in the absence of each cytokine individually (Strestik 
et al., 2001). 
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1.8.4 Regulation of the immune response to FV 
During chronic FV infection regulatory CD4
+
 T cells act to suppress adaptive immune 
responses, disabling clearance of latent infection but preventing immunopathology. 
Several studies have shown that this effect is mainly mediated by suppression of 
CD8
+
 T cells, and these are described here. 
 
Persistently FV infected mice were shown to have a marked expansion of CD4
+
 T 
cells, while in vitro, CD8
+
 T cell mediated cytotoxicity of murine leukaemia tumour 
cells was shown to be impaired by the presence of CD4
+
 T cells from FV infected 
mice, but not from uninfected mice. This was further confirmed in vivo, and the 
number of CD4
+
 T cells expressing regulatory T cell markers was shown to be 
increased in the expanded CD4
+
 T cell population during chronic infection. The 
suppressive effect of these cells was shown to be mediated by the cytokine TGF-β and 
the cell surface molecule CTLA-4, but not the signature immunosuppressive cytokine 
IL-10 (Iwashiro et al., 2001a). 
 
When TCR transgenic FV-specific CD8
+
 T cells were transferred into persistently 
infected mice, the cells proliferated substantially and became activated compared to 
cells transferred into uninfected mice. Despite activation, these CD8
+
 T cells did not 
produce IFN-γ and were not able to lower viral load. In contrast, TCR transgenic 
CD8
+
 T cells transferred into acutely infected mice were able to lower viral load. 
Furthermore, specific inhibition of Treg-mediated immunosuppression in vivo 
restored IFN-γ-production by these CD8+ T cells and reduced viral load, showing that 
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immunosuppression by Tregs is responsible for compromised CD8
+
 T cell responses 
during chronic FV infection (Dittmer et al., 2004). 
 
As shown above, Treg-mediated suppression reduces IFN-γ-production by CD8+ T 
cells during chronic infection, abrogating this effector function. Further studies have 
examined cytotoxic activity of CD8
+
 T cells during FV infection. In vivo cytotoxicity 
assays showed that cytotoxic CD8
+
 T cells were active against tumour cells during 
acute infection, but not during chronic infection. It was further shown that activated 
FV-specific CD8
+
 T cells express perforin, granzyme A and granzyme B during acute 
FV infection, but not during chronic infection, where there was a deficiency of these 
cytotoxic mediators. This was consistent with high expression of a degranulation 
marker on CD8
+
 T cells isolated from acutely infected mice but a reduced expression 
on those isolated from chronically infected mice (Zelinskyy et al., 2005). Previous 
studies support the conclusion that Tregs are also mediating suppression of CD8
+
 T 
cell cytotoxicity in FV infection, and several further reports have confirmed this 
(Myers et al., 2009; Zelinskyy et al., 2009a; Zelinskyy et al., 2009b) 
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1.8.5 Inducing a protective immune response against FV 
Live attenuated virus vaccination of Fv1
b
 mice with N-tropic F-MuLV alone, which is 
non-pathogenic in mice of this genotype, was shown to be able to protect against 
challenge by B-tropic FV complex. The vaccine was also shown to induce virus-
neutralising Ab, and whole immune spleen cells from these vaccinated mice conferred 
protection when transferred into naive mice, showing that protection occurs via an 
immunological mechanism and not through viral interference (Dittmer et al., 1998). 
 
Increasing the number of whole immune spleen cells transferred has been shown to 
further increase the level of protection against FV infection, leading to an interest in 
the role of individual lymphocyte subsets. Transfer of immune B cells or CD4
+
 T cells 
was not able to reduce viraemia, and all mice became splenomegalic upon infection 
with FV. Transfer of CD8
+
 T cells reduced initial viraemia and aided recovery from 
splenomegaly but was not adequate to prevent initial FV infection or virus 
persistence. When a single lymphocyte subset was absent, mice were not protected 
from initial infection, but did recover from splenomegaly, while transfer of the three 
purified subsets remixed did confer protection. Additionally, transfer of nAb alone 
also reduced virus but did not clear it, and this effect was dependent on the presence 
of non-immune T cells. Thus, all three adaptive lymphocyte subsets appear to be 
necessary for the protection induced by a live attenuated F-MuLV vaccine (Dittmer et 
al., 1999). 
 
Transfer of immune CD8
+
 T cells and passive immunisation with FV neutralising 
mAb permitted CD4
+
 T cell-dependent recovery from splenomegaly in mice. 
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However, transferring increased numbers of each immune lymphocyte subset showed 
that even higher numbers of immune CD4
+
 T cells or immune B cells were not 
sufficient to protect mice against splenomegaly, while adoptive transfer of higher 
numbers of immune CD8
+
 T cells further reduced the incidence of splenomegaly in 
mice compared to that seen after transfer of lower numbers. Increasing virus-
neutralising mAb dose was also able to further reduce splenomegaly. The amount of 
free virus was also reduced by additional immune CD8
+
 T cells or nAb. It was further 
confirmed that all three adaptive lymphocyte subsets were required for protection 
against FV persistence: CD8
+
 T cells for infected cell killing, B cells for production of 
virus-nAb, and CD4
+
 T cells for immunological help to CD8
+
 T cells and B cells 
(Dittmer and Hasenkrug, 2000).
 
 
Transfer of FBL-3 cells from the FBL-3 murine leukaemia-derived cell-line, was not 
able to induce virus-specific nAb, but does induce a strong CD8
+
 T cell response 
which is still protective in the absence of B cells, suggesting that B cell priming of 
CD8
+
 T cells is not required for their function. While live attenuated virus vaccine can 
protect in the presence, but not absence of B cells, administration of nAb restores this 
protection and nAb alone is sufficient to reduce viraemia. The protection seen by a 
live attenuated virus vaccine was reproduced by administration of a CD8
+
 T cell-
inducing FBL-3 vaccination and FV nAb with the protective effect evident in the first 
few days after infection. Non-neutralising Ab had no effect alone but was able to 
increase the effect of virus-nAb in the absence of a CD8
+
 T cell response (Messer et 
al., 2004). This essential role for nAb is also demonstrated during FV/LDV co-
infection as described above, where the delayed induction of nAb production 
contributes towards prevention of recovery from FV disease. (Marques et al., 2008). 
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1.8.6 Inducing FV-specific CD4+ T cells 
Several efforts to assess the effect of increasing FV-specific CD4
+
 T cells on FV 
infection have been inconclusive. Immunisation with an F-MuLV env peptide 
recognised by CD4
+
 T cells, and complete Freund’s adjuvant (CFA) showed varying 
results depending on the epitope used and the H-2 genotype-determined susceptibility 
of the mice. Immunisation with the N-terminal epitope, which is presented in complex 
with the A
b
 class II molecule in H-2
a/b
 mice, was able to protect from late onset 
splenomegaly, while immunisation with the C-terminal epitope, which is presented in 
complex with the E
b/d(k)
 class II molecule, cleared virus and prevented onset of early 
splenomegaly in H-2
a/b
 mice. In contrast, H-2
a/a
 mice were not protected by either 
peptide. Purified F-MuLV virus particles, however, were able to protect against FV 
infection in both H-2
a/b
 and H-2
a/a
 mice. Furthermore, peptide-immunised H-2
a/b
 mice 
showed accelerated development and class-switching from IgM to IgG FV nAb after 
FV-infection. However, reduction of infection was seen in the spleen before induction 
of FV nAb, suggesting that the protective effect demonstrated after peptide induction 
of CD4
+
 T cells occurred via an alternative mechanism, as well as helping production 
of nAb (Miyazawa et al., 1995). 
  
The mechanisms by which this peptide immunisation conferred protection have been 
subsequently analysed. Cytotoxicity assays showed that cells in the spleen exerted 
cytotoxic activity against FV-induced leukaemia cells, and separation of CD4
+
 cells, 
CD8
+
 cells or CD4
-
CD8
-
 cells revealed that all three populations had cytotoxic 
activity after peptide immunisation. Within the CD4
-
CD8
-
 effector population, 
cytotoxic activity was higher than that seen in the CD4
+
 or CD8
+
 populations. 
Furthermore, NK cells were shown to encompass 10-30% of these CD4
-
CD8
-
 cells 
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and depletion of NK cells both reduced the cytotoxic activity of the CD4
-
CD8
-
 
population in an FV-specific manner, and abrogated the protection against 
erythroleukaemia provided by peptide immunisation (Iwanami et al., 2001).  
 
1.8.7 FV-mediated immunosuppression 
FV has been shown to cause immunosuppression in susceptible mice, suppressing 
both cellular and humoral responses (Hasenkrug and Chesebro, 1997). FV infection of 
mice has been reported to suppress antibody development in response to 
immunisation with sheep erythrocytes as well as reducing the number of antibody 
precursors (Ceglowski and Friedman, 1968; Ceglowski and Friedman, 1970). 
Migration of immune cells was also shown to be inhibited in vitro (Friedman and 
Ceglowski, 1971). Other murine leukaemia viruses have also been shown to alter DC 
function, altering antigen presentation during retroviral infection (Gabrilovich et al., 
1994).  
 
However, much of this work was done with FV stocks contaminating with LDV, 
resulting in FV/LDV coinfection. As discussed above, LDV has profound effects on 
the immune response, and potentially the observed immunosuppression during FV 
infection is not mediated by FV, but by LDV. A more recent study has shown that 
direct infection of myeloid DCs with FV inhibits their development and function, and 
results in expansion of Treg cells (Balkow et al., 2007). Although LDV was not 
discussed in the context of this study, the date of publication suggests that this paper 
was published when LDV contamination of FV stocks had been acknowledged by the 
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authors. The potential immunosuppressive activity of FV should therefore be 
reassessed using an uncontaminated FV stock. 
 
1.8.8 Validity of previous studies 
It is clear that the effects of potential LDV contamination of FV stocks were 
overlooked in the studies described above. This may explain why results have been 
varied and ultimately inconclusive. Hence it is likely that conclusions from the above 
studies do not provide an accurate depiction of the immune response to FV. While 
these studies may provide a basis for the study of the immune response to FV, it is 
necessary to re-establish the roles of different lymphocyte subsets and cytokines in the 
immune response against the virus. 
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1.9 Re-assessing the Role of CD4+ T Cells against FV 
While many previous studies have concluded that the role for CD4
+
 T cells is 
predominantly during the chronic phase of FV infection, several others have described 
a role for CD4
+
 T cells in the immune response to acute FV infection. LDV 
contamination of FV stocks and the subsequent effects of LDV co-infection on the 
FV-specific immune response lead us to re-examine the role of CD4
+
 T cells against 
FV infection.  
 
1.9.1 The role of CD4+ T cells in primary FV infection 
In order to ascertain whether CD4
+
 T cells play a role in the control of acute FV 
infection, B6-MHC II
-/-
 mice, which have no endogenous CD4
+
 T cells, were infected 
with FV and the percent of infected erythroid precursor cells in the spleen was 
detected by flow cytometry at the peak of infection. Mice deficient in CD4
+
 T cells 
were shown to have significantly more infected cells in the spleen than WT mice, 
showing that CD4
+
 T cells do indeed contribute towards protection in the primary 
immune response against FV infection (Figure 1.5) (work carried out by Andrew 
Filby). With this in mind, a transgenic mouse was developed in which to further 
examine the role of CD4
+
 T cells against FV infection. 
 
It was shown that the level of infected cells in the spleen at the peak of infection was 
significantly increased in B6-MHC II
-/-
 mice, which are deficient in CD4
+
 T cells, 
compared to immunocompetent mice after infection with a clean LDV-free FV stock. 
This provided evidence that CD4
+
 T cells have a role against FV infection during the 
acute phase, and that infection is augmented in their absence. 
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Figure 1.5 The contribution of endogenous CD4
+
 T cells to protection against 
acute FV infection (work carried out by Andrew Filby) 
MHC class II-deficient (B6-MHC II
-/-
) and control B6 mice were infected with FV, 
and the percentage of FV-infected (glyco-Gag
+
) Ter119
+
 cells in the spleen 7 days 
post infection is shown. Each symbol represents an individual mouse. The dashed line 
indicates the limit of flow cytometric detection. The number denotes the p value as 
compared by the two-tailed Wilcoxon-Mann-Whitney test. 
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1.9.2 The EF4.1 TCRβ-transgenic mouse 
In addition to LDV contamination of FV stocks, another major caveat associated with 
previous studies was the lack of method by which to quantify the FV-specific CD4
+
 T 
cell response, analyse the function or quality of FV-specific CD4
+
 T cells, or even to 
detect whether FV-specific CD4
+
 T cells had been induced at all. 
 
In order to quantify and quantitate the FV-specific CD4
+
 T cell response, and thus 
overcome the above described caveat, a mouse strain expressing a transgenic CD4
+
 T 
cell TCRβ chain was generated in our laboratory. This TCRβ chain was derived from 
a clone (clone SB14-31) that was isolated from an FBL-3-challenged mouse and was 
shown to be reactive to the N-terminal region of the gp70 env protein of FV 
encompassing the amino-acid residues 122-141 (env122-141): 
DEPLTSLTPRCNTAWNRLKL (Iwashiro et al., 1993). These mice are referred to as 
EF4.1 TCRβ-transgenic mice and were created as previously described (Antunes et 
al., 2008).  
 
During CD4
+
 T cell development in EF4.1 mice, the transgenic TCRβ chain pairs 
with endogenous TCRα chains, resulting in a polyclonal CD4+ T cell population. 
Flow cytometric staining of CD69 and CD40L as markers of CD4
+
 T cell activation 
(Figure 1.6A) after in vitro stimulation of EF4.1 TCRβ-transgenic CD4+ T cells with 
F-MuLV env122-141 peptide revealed that 4% of this polyclonal population upregulated 
these markers and hence were specific for F-MuLV env122-141 (Figure 1.6B).  
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A panel of antibodies was tested to identify preferential use of particular Vα TCR 
chains by the FV-specific CD4
+
 T cell population. Vα2 was identified as the TCR 
chain that conferred specificity to FV, with 15% of the Vα2+ population responding to 
env122-141, while only 3% of the Vα2
-
 population responded to in vitro stimulation by 
the peptide. When the response of Vα2+ env-specific CD4+ T cells was compared to 
Vα2- env-specific CD4+ T cells, the Vα2+ population was shown to be more than 30 
times more sensitive to env122-141 (Figure 1.6C) (Antunes et al., 2008). (All work in 
section 1.9.2 was carried out by Inês Antunes.) 
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Figure 1.6 T cell reactivity to env122-141 and TCR Vα2 usage in EF4.1 TCRβ-
transgenic mice (Antunes et al., 2008) (Work carried out by Inês Antunes) 
(A) Flow cytometric example of CD69 and CD40L induction in CD4
+
 EF4.1 TCRβ- 
transgenic T cells 18 hr after stimulation with the env122-141 peptide.  
(B) Mean (± the SEM) percentage of responding cells in total CD4
+
 T cells from 
EF4.1 TCRβ-transgenic or wild-type control mice 18 hr after stimulation.  
(C) Mean (± the SEM) percentage of responding cells, plotted as a fraction of the 
maximal response, in gated TCR Vα2+ or Vα2- CD4+ T cells from EF4.1 TCRβ-
transgenic mice 18 hr after stimulation. 
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1.9.3 Clonal composition of EF4.1 TCRβ-transgenic CD4+ T cells in response to 
FV infection 
High avidity CD8
+
 T cells have been shown to be more protective than those of low 
avidity in several studies (Alexander-Miller et al., 1996; Sedlik et al., 2000). This 
suggests that an FV-specific CD4
+
 T cell response dominated by high avidity cells 
would in theory be more protective than low avidity. The clonal composition of 
responding FV-specific cells was therefore examined. 
 
The response of TCRβ-transgenic CD4+ T cells to FV infection can be followed, and 
the clonal composition of the FV-specific CD4
+
 T cell population studied using flow 
cytometry by transferring CD45.1 EF4.1 TCRβ-transgenic CD4+ T cells into B6 
(CD45.2) mice. By staining for surface markers including CD4 to identify the CD4
+
 T 
cell population, CD45.1 to identify the TCRβ-transgenic donor cell population, CD44 
to identify the antigen-experienced cells, and the Vα2 TCR chain, it was possible to 
study the clonal composition of the responding FV-specific CD4
+
 T cell population. 
FV-specific cells are gated as CD4
+
CD45.1
+
CD44
hi
. 
 
At the peak of FV infection (day 7) approximately 10% of cells in the endogenous 
CD4
+
 T cell population used the Vα2 TCR chain. In the antigen-naïve donor CD4+ T 
cell population, approximately 12% of cells used the Vα2 TCR chain, while in the 
responding donor CD4
+
 T cell population there was an enrichment of high avidity 
Vα2+ CD4+ T cells, expanding to encompass over 60% of all F-MuLV env-specific 
CD4
+
 T cells (Ploquin et al., manuscript submitted) (Figure 1.7). 
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This massive expansion of high avidity Vα2+ CD4+ T cells was followed by their 
dramatic loss, and by day 35 after infection the ratio of Vα2+ cells to Vα2- cells was 
the same as that seen in the antigen naive population (Figure 1.8A). This preferential 
expansion during the peak of infection and increased rate of loss of high avidity Vα2+ 
CD4
+
 T cells was also evident when the number of Vα2+ or Vα2- FV-specific CD4+ T 
cells during the course of infection was plotted, showing that Vα2+ cells are 
selectively lost and that this observation was not merely due to overall loss of overall 
FV-specific CD4
+
 T cells (Ploquin et al., manuscript submitted) (Figure 1.8B).  
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Figure 1.7 Flow cytometric example of expression of Vα2 on CD4+ T cells 
(Ploquin et al., manuscript submitted) (Work carried out by Andrew Filby) 
Flow cytometric example of expression of Vα2 on CD44hi donor TCRβ-transgenic 
CD4
+
 T cells, CD44
lo
 donor EF4.1 CD4
+
 T cells and the endogenous CD4
+
 T cell 
population in mice which received TCRβ-transgenic CD4+ T cells and were FV 
infected 1 day later.  
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Figure 1.8 Clonal composition of FV-specific TCRβ-transgenic CD4+ T cells 
in vivo during FV infection (Ploquin et al., manuscript submitted) (Work carried 
out by Andrew Filby) 
(A) Frequency of env-specific CD4
+
 T cells expressing TCR Vα2 in mice which 
received 1 × 10
6
 EF4.1 TCRβ-transgenic CD4+ T cells and were FV infected. Values 
are the mean ( ± the SEM). The dashed line indicates the percent of Vα2+ cells seen in 
the naïve EF4.1 TCRβ-transgenic CD4+ T cell population.  
(B) Numbers of Vα2+ and Vα2- FV-specific CD4+ T cells recovered from mice after 
FV infection. Values are the mean (± the SEM). 
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1.10 Aims and Objectives 
The aim of the work described in this thesis is to re-evaluate and further establish the 
role of CD4
+
 T cells against retroviral infection, using the FV complex as a mouse 
model of retroviral infection and the established CD4
+
 T cell TCRβ-transgenic 
B6.EF4.1 mouse (Antunes et al., 2008). In contrast to previous studies investigating 
the CD4
+
 T cell response to FV which may have been marred by the presence of 
FV/LDV coinfection, experiments in this thesis used an uncontaminated FV stock.  
 
Additionally, and again in contrast to previous studies, it will be possible to identify, 
quantify and monitor the FV-specific CD4
+
 T cell response due to the availability of 
the EF4.1 TCRβ-transgenic mouse. This will also facilitate examination of the 
functional quality and clonal composition of FV-specific CD4
+
 T cells in the response 
to FV infection and vaccination techniques. Furthermore, the mechanisms underlying 
the loss of high avidity Vα2+ FV-specific CD4+ T cells are examined and ways in 
which to induce and preserve an FV-specific memory CD4
+
 T cell pool dominated by 
high avidity Vα2+ CD4+ T cells are investigated. 
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Chapter Two 
2 Materials and Methods 
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2.1 Mice  
Mouse strains used in the experiments are listed in Table 2.1 and were maintained at 
the National Institute for Medical Research (NIMR) animal facilities. All animal 
experiments were conducted according to the Home Office regulations and local 
guidelines.  
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Common Name Strain Name 
Targeted 
Gene 
Source/Reference 
WT mice 
B6 C57BL/6  
Jackson Laboratory (Bar 
Harbor, Maine, USA) 
Congenic 
B6.CD45.1 
B6.SJL-Ptprc
a
 
Pep3
b
/BoyJ 
 
Jackson Laboratory (Bar 
Harbor, Maine, USA) 
B6.Fv1
n
 B6.C3H-Fv1
n
 Fv1 (Pike et al., 2009) 
B6.Fv2
s
 B6.A-Fv2
s
 Fv2 (Marques et al., 2008) 
Targeted Mutants 
Rag1
-/-
 
B6.129S7-
Rag1
tm1Mom
/J 
Rag 1 (Mombaerts et al., 1992) 
IFNγR1-/- 
B6.129S7-
Ifngr1
tm1Agt
/J 
Ifngr1 (Huang et al., 1993) 
µMT or Igh6
-/-
 
B6.129S7-Igh-
6
tm1Cgn
/J 
Igh6 (Kitamura et al., 1991) 
B6.Fv2
s
 Rag1
-/-
 B6.A-Fv2
s
 Rag1
-/-
 Rag 1, Fv2 (Marques et al., 2008) 
Transgenic 
EF4.1 TCRβ- 
transgenic 
B6 EF4.1 TCRβ TCRβ (Antunes et al., 2008) 
EF4.1 CD45.1 
TCRβ-transgenic 
B6 EF4.1 CD45.1 
TCRβ 
TCRβ (Antunes et al., 2008) 
 
Table 2.1 Name, targeted gene and source (or reference) of mouse strains used. 
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2.2 Flow Cytometry Analysis 
2.2.1 Cell and tissue preparation 
Animals were killed by an approved schedule I method. Spleen and lymph nodes 
(inguinal, axillary, brachial, mesenteric and superficial cervical) were isolated and 
single cell suspensions were prepared by mechanical disruption of organs through a 
70 µm cell strainer (Falcon, Becton Dickinson Labware).  
 
All cell suspensions were prepared and stored in Air-Buffered (AB) Iscove’s 
Modified Dulbecco’s Medium (IMDM) containing 25 mM HEPES buffer and L-
glutamine and supplemented with  
 0.21% NaCl 
 60µg/ml penicillin 
 100µg/ml streptomycin  
(all Invitrogen Life Technologies)  
 
Spleen cells were subjected to erythrocyte lysis by treatment with ammonium–
chloride-potassium (ACK) lysis buffer (pH 7.2-7.4) containing 
 0.15 M NH4Cl  
 1mM KHCO3  
 0.1mM EDTA  
After erythrocyte lysis, cells were washed and resuspended in AB IMDM. 
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Cell numbers were determined using an automated cell counter (Casy1, Schaerfe 
Systems, Reutlinger, Germany) or a Neubauer haemocytometer (Marienfeld). Lymph 
node cellularity was calculated as the sum of the cellular contents of inguinal, 
axillary, brachial, superficial cervical and mesenteric lymph nodes. Total numbers of 
each cell type were calculated from the frequency determined by flow cytometry and 
the total number of cells recovered from each organ. 
 
Blood was taken from mice by making a small incision of the tail vein and 
approximately 50 µl of blood was collected in tubes containing heparin or with 
heparinised capillary tubes. 
 
2.2.2 Cell surface marker staining 
Cell expression of surface antigens was measured by monoclonal antibody (mAb) 
staining of freshly isolated cells, followed by Fluorescence Activated Cell Sorter 
(FACS) analysis. Cell concentrations were adjusted to 1 × 10
8
 cells/ml for analysis. 
Cells were incubated with anti-FcR mAb (2.4G2) to block non-specific binding 
through Fc receptors, and stained with directly-conjugated antibodies to surface 
markers for 30 minutes. All stainings were performed in the dark and cells were 
washed and stained in FACS buffer containing 
 PBS 
 2% FCS 
 0.1% azide 
Antibodies used were obtained from eBiosciences, CALTAG/Invitrogen, BD 
Biosciences or prepared at NIMR and are summarized in Table 2.2. 
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Specificity Clone name Company 
Fcγ III/II R 2.4G2 NIMR 
CD4 (L3T4) RM4-5 eBioscience / Caltag 
CD25 (IL-2 receptor α chain) PC61.5 eBioscience 
CD43 (Ly-48; leukosialin) 1B11 BD Biosciences  
CD44 (Pgp-1; H-CAM; Ly-24) IM7 eBioscience 
CD45.1 (Ly-5.1) A20 eBioscience 
CD45.2 (Ly-5.2) 104 eBioscience 
CD122 5H4 eBioscience 
CD127 (IL-7receptor α chain) A7R34 eBioscience 
Glyco-Gag 34 NIMR 
Ter119/Erythroid cells (Ly-76) TER-119 eBioscience 
TCRVα2 B20.1 eBioscience 
TCRVα2 B20.6 BD Biosciences 
   
2
nd
 layers   
mIgG2b-FITC R12-3 BD Biosciences  
 
Table 2.2 Specificity, clone name and source of anti-mouse antibodies used for 
extracellular staining. Alternative names are shown in parentheses. 
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Up to 4-colour samples were acquired on an analytical flow cytometer (FACSCalibur, 
BD Biosciences) and analyzed with FlowJo v8.7 software (Tree Star Inc). Up to 8-
colour cytometry was performed on a CyAn flow cytometer (Dako, Fort Collins, CO) 
and analyzed with Summit v4.3 analysis software (Dako). 
 
Figure 2.1 shows the gating strategy employed throughout to detect FV-specific 
donor CD4
+
 T cells after adoptive transfer. 
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Figure 2.1 Gating strategy for identification of FV FV-specific donor CD4
+
 T 
cells after adoptive transfer  
Flow cytometric example of the gating applied to define the FV-specific donor 
(CD45.1
+
) CD4
+
 T cell population after adoptive transfer into B6 (CD45.2
+
) 
recipients one day before FV infection. Cells were stained for surface antibodies and 
live cells were gated on size and granularity. CD4
+
 T cells within the live cell 
population were gated and the percentage of cells collected is shown. Donor cells 
(CD45.1
+
) are gated and donor cells within the total CD4
+
 T cell population are 
shown. Responding (CD44
hi
) donor CD4
+
 T cells in FV-infected mice are gated, and 
activated, FV-specific donor CD4
+
 T cells (CD44
hi
 CD45.1
+
) are shown. 
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2.2.3 Intracellular cytokine staining 
For intracellular cytokine staining, cytokine production was induced by stimulating 
cells with phorbol 12,13-dibutyrate (PdBu) and ionomycin (both at 0.5 µg/ml) 
together with surface staining antibodies in tissue culture conditions for 1 hour. After 
this period, an inhibitor of intracellular transport, monensin (at 1µg/ml), was added to 
block secretion of cytokines and cells were incubated for an additional 3 hours in 
tissue culture conditions. Cells were then washed and resuspended in fixation buffer 
(eBioscience) for 20 minutes at room temperature (RT) and then washed and 
incubated in permeabilisation buffer (eBioscience) with antibodies for cytokine 
staining for one hour at RT. Antibodies used for intracellular cytokine staining are 
summarised in Table 2.3. 
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Cytokines Clone Name Company 
IL-2-PE JES6-5H4 eBioscience 
IL-2-PBlue JES6-5H4 Insight Biotech 
IL-17-FITC eBioTC11-18H10.1 eBioscience 
IFN-γ-PE XMG1.2 Insight Biotech 
IFN-γ-FITC XMG1.2 eBioscience 
 
Table 2.3 Specificity, clone, name and source of anti-mouse antibodies used for 
intracellular cytokine staining. 
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2.2.4 CFSE labelling 
For carboxyfluorescein succinimidyl ester (CFSE) labelling, cells were washed in 
Dulbecco’s Phosphate-Buffered Saline solution (D-PBS) (GIBCO) and resuspended 
in PBS with CFSE (Molecular Probes, Invitrogen). For labelling more than 1 × 10
6
 
cells CFSE was used at 2.5 µM, while for lower cell numbers the concentration was 
0.6 µM. Cells were incubated for 10 minutes in tissue culture conditions and then 
washed in culture medium. Dividing cells were identified by CFSE dilution on FACS 
analysis. 
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2.3 Cell Purification and Sorting 
2.3.1 Purification of CD4+ cells 
Target cells were enriched in lymph node and spleen suspensions using 
immunomagnetic positive selection (EasySep beads, StemCell Technologies, 
Vancouver, BC, Canada) according to the manufacturer’s instructions. For CD4+ T 
cell enrichment, single cell suspensions were diluted to a concentration of 1 × 10
8
 
cells/ml. Positive selection was then performed by staining the cells with CD4 PE-
conjugated Ab for 30 minutes at 4
o
C. Cells were washed, PE selection cocktail (25 
µl/ml) was added and cells were incubated at RT for 15 minutes. Magnetic beads (25 
µl/ml) were then added and cells were incubated at RT for a further 10 minutes. The 
tube containing the cells was placed on a magnet (EasySep Magnet, StemCell 
Technologies) for 5 minutes. The magnetic field allowed for retention of labelled 
cells, while the non-labelled cells remained in the supernatant. The supernatant was 
poured off and the tube was removed from the magnet. The walls of the tube, 
containing the selected cells, were washed with AB IMDM. After two additional 
selection steps, positively-selected cells were collected.  
 
2.3.2 Cell sorting 
For cell sorting, enriched cell suspensions were stained with antibodies for surface 
markers and then further purified by MoFlo cell sorters (Dako) by the NIMR Cell 
Sorting facility. Typical cell purity following cell sorting was higher than 98%. For 
example, for sorting of Vα2+ and Vα2- cells for adoptive transfer, CD4+ T cells were 
purified as described above and stained for CD45RB and TCR Vα2. 
CD4
+
/CD45RB
hi/Vα2- or CD4+/CD45RBhi/Vα2+ cells were sorted. 
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2.4 Adoptive Transfer, Infection and Immunisation 
2.4.1 Adoptive transfer of T cells 
CD4
+
 T cells were isolated from spleen and lymph nodes of B6 EF4.1 TCRβ-
transgenic or B6 EF4.1 CD45.1 TCRβ-transgenic donor mice with immunomagnetic 
positive selection (EasySep beads, Stemcell Technologies, Vancouver, BC, Canada) 
according to the manufacturer’s instructions and as described above. In some 
experiments, cells were further isolated using cell sorting. Purified cells were injected 
in recipient mice via the tail vein in 0.1 ml of AB IMDM. 
 
2.4.2 Friend virus infection 
The Friend Virus (FV) used in these studies was a retroviral complex of a replication-
competent B-tropic helper murine leukaemia virus (F-MuLV) and a replication-
defective polycythemia-inducing spleen focus-forming virus (SFFV). The FV stock 
(kindly provided by Dr. Kim Hasenkrug, Laboratory of Persistent Viral Diseases, 
Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT, USA) was free of lactate 
dehydrogenase elevating virus (LDV) and was obtained as previously described 
(Robertson et al., 2008). FV was propagated in vivo and prepared as 10% w/v 
homogenate from the spleen of 12-day-infected BALB/c mice. Mice received an 
inoculum of ~1000 spleen focus-forming units (SFFU) of FV, injected via the tail 
vein in 0.1 ml of PBS. 
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2.4.3 Peptide immunisation 
For peptide immunisation, env124-138 (PLTSLTPRCNTAWNR) was injected with 
MPL adjuvant using the Sigma Adjuvant System (Sigma-Aldrich, Inc., Saint Louis, 
MO, USA). The Sigma adjuvant system is a stable oil-in-water emulsion. Each vial 
contains which contains 0.5 mg Monophosphoryl Lipid A (isolated from Salmonella 
minnesota) and 0.5 mg synthetic trehalose dicorynomycolate (an analogue of 
trehalose dimycolate from the cord factor of the tubercle bacillus) in 44 µl of squalene 
oil, 0.2% TWEEN 80 and water. 
 
15 µM/mouse of peptide in solution was prepared according to the manufacturer’s 
instructions. Briefly, Sigma Adjuvant System vial contents were warmed to 37
o
C, 1 
ml PBS was added and the vial was vortexed to produce an emulsion. Peptide diluted 
in PBS was added to the Sigma adjuvant solution in a 1:1 ratio and this was further 
vortexed to ensure even distribution of peptide within the emulsion. Peptide in 
adjuvant emulsion was kept at 37
o
C and vortexed immediately before injection, and 
was injected intra-peritoneally (i.p.) in 0.15 ml. 
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2.5 Serum Preparation 
Serum was prepared by leaving non-heparinised blood to clot at RT for 2 hours or at 
4
o
C overnight. The clot was then detached from the side of the eppendorf and the 
samples were centrifuged at 3,000 rpm for 5 minutes. Clear sera were transferred to 
new tubes and centrifuged at 12,000 rpm for 5 minutes. Clear sera were then 
transferred to new tubes, heat inactivated at 56
o
C for 10 minutes and then stored at     
-20
o
C. 
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2.6 FV Neutralizing Antibody Titre Assay 
FV-neutralising antibodies in the sera of infected mice were measured using a 
modification of a previously described viral titre assay (Marques et al., 2008). Mus. 
dunni cells (Lander and Chattopadhyay, 1984) were transduced with the XG7 
replication-defective retroviral vector, expressing GFP from a human 
cytomegalovirus (hCMV) promoter and a neomycin-resistance gene under the control 
of the LTR (Bock et al., 2000). (Mus dunni and Mus dunni-XG7 cells were both 
kindly donated by Dr Jonathan Stoye, Division of Virology, NIMR.) M. dunni-XG7 
cells were then infected with F-MuLV-B and supernatant, which contained the 
pseudotyped XG7 vector, was harvested. Serial dilutions of sera from infected mice 
were mixed with ~1,500 infectious units (iu)/ml pseudotyped XG7 vector and allowed 
to incubate for 30 minutes at 37
o
C in IMDM culture medium containing 5% FCS. 
Mixtures were then added to untransduced M. dunni cells and incubated for 3 days. 
The percentage of GFP
+
 M. dunni cells at the end of the incubation period was 
assessed by flow cytometry and the dilution of serum which resulted in 75% 
neutralisation (i.e. 75% reduction in the percentage of GFP
+
 M. dunni cells) was taken 
as the neutralising titre (Bock et al., 2000).  
 
Culture medium which was used for the maintenance of cell lines and in vitro assays 
was IMDM (Sigma) supplemented with  
 5% heat inactivated FCS (BioSera) 
 2 mM L-glutamine (Sigma) 
 100 U/ml penicillin (Sigma) 
 100 µg/ml streptomycin (Sigma) 
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 10-5 m mercaptoethanol (Sigma) 
Tissue culture conditions were  
 95% humidity  
 5% CO2  
 37oC 
 
 115 
2.7 Nucleic Acid Extraction 
2.7.1 DNA extraction 
Spleen cells were incubated for 3 hours with 0.5 ml lysis buffer consisting of 
 100 mM Tris-HCl (pH 8.5) 
 5 mM EDTA 
 200 mM NaCl 
 0.2% SDS 
 200 µg/ml of proteinase K (Roche Diagnostics GmBH) 
 
Samples were vortexed and centrifuged at 12,000g for 10 mins and supernatant was 
transferred to a new tube. An equal amount of isopropanol was added and samples 
were mixed before spinning for 5 mins at 12,000g and washing with 70% ethanol. 
Pelleted DNA was air-dried and resuspended in clean water before being stored at      
-20
o
C. 
 
2.7.2 RNA extraction 
RNA was extracted from cells by adding trizol (0.2 ml per 1 ml samples) followed by 
incubation at room temperature for 5 minutes. Samples were mixed and centrifuged at 
12,000g for 15 minutes at 4
o
C. The aqueous phase was transferred to a fresh tube and 
RNA was precipitated with isopropanol. Samples were centrifuged at 12,000g for 8 
mins at 4
o
C, pellets washed in 75% ethanol and centrifuged for a further 5 min at 
12,000g and 4
o
C. RNA pellets were resuspended in water and stored at -20
o
C. 
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2.7.3 Synthesis of cDNA 
30 µl of RNA resuspended in water was mixed with 30 µl archive kit (Applied 
Biosystems) master mix containing 
 6 µl reverse transcriptase buffer 
 2.4 µl dNTPs 
 6 µl random primers 
 3 µl Multiscribe reverse transcriptase 
 0.75 µl RNasin 
 11.85 µl water 
 
The solution was incubated at 25
o
C for 10 minutes followed by 37
o
C for 2 hours and 
samples then stored at -20
o
C. 
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2.8 Detection of Vα Chains in Vα2- Cells by PCR 
Vα2- cells were sorted from purified CD4+ T cells from naive B6 mice and naive 
B6.EF4.1 mice (CD4
+
, CD44
lo, Vα2-), and CD4+ T cells from B6. EF4.1 mice which 
had been stimulated in vitro with env124-138 for 3 days (CD4
+
, CFSE
lo, Vα2-). RNA 
was extracted and cDNA was synthesised as described above. For detection of Vα 
chains cDNA was subjected to PCR using specific primers for Vα TCR chains 
((Casanova et al., 1991) see Table 2.4). PCR reactions were carried out in a volume of 
20 µl in the suppliers buffer, and contained a final concentration of 
 2 mM MgCl2 (Thermo Scientific) 
 0.2 mM dNTP (G.E. Healthcare) 
 0.4 pmol/µl sense and antisense primer 
 0.1 U Taq DNA polymerase (Thermo Scientific) 
 
PCR amplifications were amplified in an Eppendorf mastercycler thermocycler as 
follows  
 2 min 15 sec denaturation step at 94oC  
 35 cycles of denaturation at 94oC for 15 seconds 
 annealing at 55oC for 15 seconds 
 extension at 72oC for 30 seconds 
 a final extension at 72oC for 2 minutes 
 
PCR products were separated on a 2% agarose gel containing ethidium bromide. 
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Vα Sequence (5’-3’) 
Vα1 GCACTGATGTCCATCTTCTC 
Vα2 AAAGGGAGAAAAAGCTCTCC 
Vα3 AAGTACTATTCCGGAGACCC 
Vα4 CAGTATCCCGGAGAAGGTC 
Vα5 CAAGAAAGACAAACGACTCTC 
Vα6 ATGGCTTTCCTGGCTATTGCC 
Vα7 TCTGTAGTCTTCCAGAAATC 
Vα8 CAACAAGAGGACCGAGCACC 
Vα9 TAGTGACTGTGGTGGATGTC 
Vα10 AACGTCGCAGCTCTTTGCAC 
Vα11 CCCTGCACATCAGGGATGCC 
Vα12 TCTGTTTATCTCTGCTGACC 
Vα13.1 ACCTGGAGAGAATCCTAAGC 
Vα34S-281 TCCTGGTTGACCAAAAAGAC 
VαA10 TGGTTTGAAGGACAGTGGGC 
VαBWB CATTCGCTCAAATGTGAACAG 
VαBMA CAAATGAGAGAGAGAAGCGC 
VαBMB GGAAAATGCAACAGTGGGTC 
Vα5T GACATGACTGGCTTCCTGAAGGCCTTGC 
Cαb ACACAGCAGGTTCTGGGTTC 
 
Table 2.4 Sequences of primers used for detection of Vα TCR chains. 
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2.9 Assessment of Infection 
2.9.1 Spleen index 
The spleen was removed from a euthanised mouse and subsequently spleen and 
mouse were weighed. The following equation was used to calculate the spleen index 
(SI).  SI  = Spleen weight (mg) 
      Mouse weight (g) 
 
2.9.2 Detection of FV infected cells by flow cytometry 
Infected cells were estimated by flow cytometric detection of infected cells using 
surface staining for the glycosylated product of the viral gag gene (glyco-Gag), using 
the mAb 34 (mouse IgG2b) for 30 minutes at RT. Cells were washed with FACS 
buffer and incubated with an anti-mouse IgG2b-FITC secondary reagent (Table 2.2) 
for 20 minutes at RT. Cells were then washed and resuspended in FACS buffer for 
FACS analysis. 
 
2.9.3 Infected cells in the blood 
To reduce numbers of mice used, in some experiments mice were assessed for 
infection by bleeding. Red blood cells were lysed using BD FACS Lysing Solution 
(BD Biosciences). FV-infected cells were detected by flow cytometry as described. 
Figure 2.2 shows the gating strategy employed throughout to detect infected cells in 
the blood or spleen cell suspension. 
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Figure 2.2 Gating strategy for identification of FV infected cells  
Flow cytometric example of the gating applied to define the infected (glyco-Gag
+
) 
erythroid precursors (Ter119
+
) cells in the spleen. Cells were stained for surface 
antibodies and live cells were gated on size and granularity. Ter119
+
 cells within the 
live cell population were gated and the percentage is shown. Glyco-gag
+
 cells 
(infected cells) are gated and infected cells within the total Ter119
+
 cell population 
are shown. 
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2.9.4 Real-Time quantitative PCR 
In order to detect the minimum FV-MuLV copy number detectable by quantitative 
PCR (Q-PCR), the pFMU3A plasmid (10936 bp) was titrated from 100,000 copies 
(1.2pg plasmid DNA) in two-fold dilutions to generate a standard curve (Cycle 
threshold (Ct) value vs F-MuLV env copy number). This showed that the sensitivity 
of the assay was 6 copies of proviral DNA (Ct= 35) (Figure 2.3). 
 
The SYBR green PCR Master Mix (Applied Biosystems, Warrington, UK/ Foster 
City, CA) was used for DNA analysis by real-time Q PCR with a set of primers for 
Friend env: 
 forward 5’-CTGCGCCAGAGACTGCGACGA-3’  
 reverse 5’-GACCCGGGGCAGACATAAAAT-3’ 
Samples for RT-PCR were run on the ABI Prism
®
 7000 Sequence Detection System 
(Applied Biosystems) and expression of F-MuLV-DNA was normalised to that of 
Ifnα/βr. The primers used to amplify Ifnα/βr were as follows:  
 forward 5’-AAGATGTGCTGTTCCCTTCCTCTGCTCTGA-3’  
 reverse 5’-ATTATTAAAAGAAAAGACGAGGCGAAGTGG-3’ 
 
600 ng of DNA (corresponding to 100,000 cells) was used per reaction. Ct values 
were used to calculate number of proviral DNA copies per 100,000 cells from the 
standard curve.  
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Figure 2.3 Titration of pFMU3 plasmid copy number by Q-PCR 
Plasmid pFMU3 was titrated from 100,000 copies to <1 copy. The Ct value for each 
copy number is shown. A dashed line represents the limit of detection of the assay (Ct 
value=35, copy number=6). 
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2.10 Statistical Analysis 
Graphs were created and results analysed for statistical significance with SigmaPlot 
v11.0 (Systat Software Inc., San Jose, CA, USA). Results were analysed with a two-
tailed student’s t-test or, when data was not normally distributed with the non-
parametric two sample independent Wilcoxon signed rank test. p values <0.05 were 
considered to be statistically significant. 
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Results and Discussion
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Chapter Three 
3 Control of FV Infection by CD4+ T cells 
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3.1 Introduction 
Depletion of CD4
+
 T cells in mice has been shown to have only minor effects on 
recovery from acute FV infection, while depletion of CD8
+
 T cells prevented recovery 
from acute FV (Robertson et al., 1992). Conversely, depletion during the chronic 
phase of FV infection resulted in reactivation of viral replication, leading to the 
conclusion that CD4
+
 T cells are required for control of the chronic phase of FV 
infection but are not required for control of acute infection (Hasenkrug et al., 1998; 
Hasenkrug, 1999; Robertson et al., 1992). Furthermore, attempts to induce a 
protective FV-specific CD4
+
 T cell response using peptide immunisation or attenuated 
virus vaccine varied, and were ultimately inconclusive (Dittmer et al., 1999; 
Miyazawa et al., 1995). 
 
It should be emphasised that these studies were carried out using an FV stock which 
was potentially contaminated with LDV, resulting in FV/LDV coinfection. LDV 
infection has profound effects on the immune response to FV, including polyclonal B 
cell activation and delayed CD8
+
 T cell responses (Marques et al., 2008; Robertson et 
al., 2008). These factors may have contributed to inconclusive, or even erroneous 
results in the above mentioned studies. 
 
Importantly, it has recently been shown that immunocompetent mice have lower 
levels of FV infection in the spleen than CD4
+
 T cell-deficient mice after infection 
with a clean, LDV-free FV stock (Pike et al., 2009). This provides evidence for a role 
for CD4
+
 T cells in controlling acute FV infection and suggests that they are required 
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in the primary immune response against FV, in contrast to studies concluding that the 
major role of CD4
+
 T cells in FV infection was during the chronic phase.  
 
This observation, as well as the potential virus contamination of previously used FV 
stocks lead us to reassess the contribution of CD4
+
 T cells against FV infection. The 
EF4.1 TCRβ-transgenic mouse was employed in order to further investigate the role 
of FV-specific CD4
+
 T cells during the acute phase of FV infection. Here, the 
potential protective capacity of FV-specific CD4
+
 T cells was investigated, and the 
mechanisms of action by which the presence of CD4
+
 T cells during acute infection 
can reduce the level of infection in the spleen were elucidated. 
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3.2 The Role of CD4+ T Cells against Acute FV Infection 
3.2.1 Induction of FV-specific CD4+ T cells 
Peptide immunisation with a Th cell epitope was previously found to be sufficient to 
partially protect mice from FV-induced splenomegaly and erythroleukaemia in the 
presence of LDV (Miyazawa et al., 1995). In order to test whether immunisation with 
env124-138 peptide was adequate to induce a FV-specific memory CD4
+
 T cell, 2 × 10
6
 
EF4.1 TCRβ-transgenic CD4+ T cells were transferred into mice one day before 
immunisation with F-MuLV env124-138 peptide and adjuvant. Mice were infected with 
FV 35 days after immunisation, and the percentage of FV infected erythroid precursor 
cells in the spleen day 7 after infection was assessed with flow cytometry to identify 
glyco
-
Gag
+
Ter119
+
 cells in the spleen, as demonstrated in Figure 2.2. A control group 
was FV-infected in parallel. 
 
Compared to controls, mice which had been immunised 35 days before infection 
showed significantly lower levels of infected cells in the spleen (p=0.01) 
demonstrating that immunisation with env124-138 peptide was adequate to induce a 
protective FV-specific memory CD4
+
 T cell response (Figure 3.1). This was 
consistent with previous observations that peptide immunisation to induce a memory 
CD4
+
 T cell response is able to protect against FV infection in the presence of LDV 
coinfection (Miyazawa et al., 1995). 
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Figure 3.1 Control of FV infection 35 days after adoptive transfer and 
immunisation with FV env peptide  
B6 mice received 2 × 10
6
 EF4.1 TCRβ-transgenic CD4+ T cells one day before 
immunisation with env124-138 and adjuvant. Percentage of glyco-Gag
+
Ter119
+
 cells in 
the spleen of FV-infected mice and mice FV-infected 35 days after immunisation are 
shown. Each symbol represents an individual mouse. The dashed line indicates the 
limit of flow cytometric detection. The number within the graph denotes the p value 
as compared using a two-tailed Wilcoxon-Mann-Whitney test.  
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3.2.2 The effect of additional FV-specific CD4+ T cells on FV infection 
As shown above, peptide immunisation to induce an FV-specific CD4
+
 T cell 
response was adequate to reduce the level of FV infection at the peak. However, it is 
possible that peptide-immunisation induced FV-specific CD4
+
 T cells reach a 
different level of differentiation than FV-specific CD4
+
 T cells responding in a 
primary response to FV infection would. Thus, the protective effect of naive FV-
specific CD4
+
 T cells on primary FV infection was examined. 
 
To evaluate the contribution of additional CD4
+
 T cells to protection against FV 
infection, TCRβ-transgenic CD4+ T cells were adoptively transferred into B6 mice 
one day before FV infection and the level of infection measured at different time-
points. A clear population of glyco
-
Gag
+
Ter119
+
 cells (2%) was seen at day 7 after 
infection of B6 mice which had not received TCRβ-transgenic CD4+ T cells (Figure 
3.2A top). However, in mice which had received TCRβ-transgenic CD4+ T cells, this 
population of infected cells was clearly reduced (0.2%) (Figure 3.2A bottom). 
 
In B6 mice, infection peaked at day 7 and was resolved by day 21, when the fraction 
of infected cells in the spleen was below the level of detection by flow cytometry. 
Adoptive transfer of 10
6
 TCRβ-transgenic CD4+ T cells was able to significantly 
reduce the percentage of infected erythroid precursors in the spleen at the peak of 
infection in B6 mice (p=0.034) (Figure 3.2B).  
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In order to investigate whether transfer of TCRβ-transgenic CD4+ T cells was able to 
significantly reduce the level of FV infection in mice with the Fv2 susceptibility 
allele, this experiment was repeated in B6.A-Fv2
s
 mice, which have a higher 
percentage of infected cells at the peak of infection but, like B6 mice, resolve the 
acute phase of infection by day 21. Transfer of TCRβ-transgenic CD4+ T cells one 
day before FV infection of B6.A-Fv2
s
 mice was once more able to protect against FV, 
and significantly decreased the proportion of infected cells in the spleen at the peak of 
infection, in this case by ~10-fold (p<0.00001) (Figure 3.2C). Additionally, this 
protective effect was shown to be dose-dependent, with the anti-retroviral effect 
further improved when mice received increased numbers of TCRβ-transgenic CD4+ T 
cells. This effect was seen in both B6 mice (p=0.001) (Figure 3.3A) and B6.A-Fv2
s
 
mice (p=0.0007) (Figure 3.3B). 
 
These data therefore showed that elevated numbers of FV-specific CD4
+
 T cells were 
sufficient to significantly reduce infection in both B6 wild-type mice, and mice with a 
more severe disease due to the presence of the Fv2 susceptibility allele. Moreover, the 
protective effect seen was proportional to the number of additional FV-specific CD4
+
 
T cells transferred. This demonstrated a previously unappreciated role for CD4
+
 T 
cells in the primary immune response to FV infection, and in controlling the spread of 
FV infection. 
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Figure 3.2 Control of FV infection after adoptive transfer of additional FV-
specific CD4
+
 T cells 
(A) B6 control mice (-) and B6 mice which received 1 × 10
6
 EF4.1 TCRβ-transgenic 
CD4
+
 T cells 1 day before infection (+ T cells), were infected with FV and the 
percentage of FV-infected (glyco-Gag
+
) Ter119
+
 cells in the spleen, 7 days post 
infection, is shown. Numbers within the quadrants denote the percentage of positive 
cells.  
(B-C) Percentage of glyco-Gag
+
Ter119
+
 cells in the spleen of B6 (B) or B6.A-Fv2
s
 
(C) mice after FV infection, with (+ T cells) or without (-) adoptive transfer of 1 × 10
6
 
TCRβ-transgenic CD4+ T cells. Values are the means (± the SEM) of 4-12 mice per 
group per time point. The dashed line indicates the limit of flow cytometric detection. 
Numbers within the graph denote the p values as compared using a two-tailed 
student’s t-test. 
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Figure 3.3 Dose-dependent reduction of FV infection by increased number of 
additional FV-specific CD4
+
 T cells 
(A-B) Percentage of glyco-Gag
+
Ter119
+
 cells in the spleen of B6 (A) or B6.A-Fv2
s
 
mice (B), 7 days after FV infection after adoptive transfer of titrated numbers of 
EF4.1 TCRβ-transgenic CD4+ T cells 1 day before infection. Values are the mean (± 
the SEM) of 3-10 mice per group per CD4
+
 T cell inoculum from 1-3 separate 
experiments (A), or 2-12 mice from 1-4 separate experiments (B). The dashed line 
indicates the limit of flow cytometric detection. Numbers within the graph denote the 
p as compared using a two-tailed student’s t-test. 
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3.3 Mechanisms of Anti-Retroviral CD4+ T Cells in FV Infection 
CD4
+
 T cells are conventionally helpers of the immune system, providing 
immunological help to B cells and CD8
+
 T cells to enhance antibody production and 
cytotoxic killing of virally infected cells, respectively. However, CD4
+
 T cells have 
also been shown to possess direct anti-viral activity. This anti-viral effect can occur 
via production of anti-viral cytokines such as IFN-γ, or direct killing of virally-
infected cells (Jellison et al., 2005). With this in mind, we sought to discover whether 
anti-retroviral CD4
+
 T cells in FV infection were functioning via provision of 
immunological help to other adaptive lymphocytes, or via an independent anti-viral 
mechanism. 
 
3.3.1 Effect of additional FV-specific CD4+ T cells on FV nAb titre 
Induction of virus-nAb is a key effector mechanism by which B cells can protect 
against and control viral infection. To ascertain whether FV-specific CD4
+
 T cells 
were providing immunological help to B cells, FV nAb titre was measured during 
infection of mice which had received EF4.1 TCRβ-transgenic CD4+ T cells one day 
before FV infection. 
 
In both the control group and the group which had received TCRβ-transgenic CD4+ T 
cells, FV nAb was only induced to a level detectable by the assay used at day 14 post 
infection and, while the FV nAb titre continued to increase, by day 21 post infection 
no increased production of FV nAb in mice which had received TCRβ-transgenic 
CD4
+
 T cells was observed compared to control mice (Figure 3.4). 
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While these experiments showed that additional FV-specific CD4
+
 T cells did not 
increase levels of nAb against the virus, FV nAb was not detected until day 14 after 
infection while CD4
+
 T cell-mediated protection against FV infection in B6 mice 
occurred at day 7. This provided further evidence suggesting that control of FV by 
additional FV-specific CD4
+
 T cells was not facilitated via increased FV nAb 
production by B cells.  
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Figure 3.4 Effect of additional FV-specific CD4
+
 T cells on FV nAb titre 
 The FV nAb titre of B6 mice with (+ T cells) or without (-) adoptive transfer of         
1 × 10
6
 TCRβ-transgenic CD4+ T cells one day before FV infection is shown. Values 
are the mean (± the SEM) of 6-9 mice per group per time point from 2 experiments. 
The dashed line indicates the limit of detection of the FV nAb assay. 
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3.3.2 Effect of FV-specific CD4+ T cells on primary FV infection in 
lymphopenic mice 
The above data indicate that additional FV-specific CD4
+
 T cells are not exerting their 
anti-retroviral role via induction of nAb production by B cells. However, they may 
still be helping B cells in other ways, for example inducing opsonising antibody 
production by B cells, resulting in killing of infected cells. Additionally, anti-
retroviral CD4
+
 T cells could exert this effect via helping CD8
+
 T cells to kill virally-
infected cells. In order to discount the possibility that CD4
+
 T cells were exerting the 
observed anti-viral effect via help to other adaptive lymphocytes, the effect of transfer 
of EF4.1 TCRβ-transgenic CD4+ T cells on FV-infection in B6.A-Fv2s Rag1-/- mice 
was investigated. B6.A-Fv2
s
 Rag1
-/-
 mice, in addition to the Fv2
s
 allele, have no 
endogenous B or T lymphocytes and suffer from massive splenomegaly, eventually 
succumbing to disease. Any protection seen in this model after transfer of TCRβ-
transgenic CD4
+
 T cells would show that this protective effect was independent of B 
cells and CD8
+
 T cells, and so was not via provision of help to these cells by CD4
+
 T 
cells. 
 
To assess the effect of EF4.1 TCRβ-transgenic CD4+ T cells on initial FV infection in 
B6.A-Fv2
s
 Rag1
-/-
 mice, the percentage of infected erythroid precursor cells in the 
blood was compared to the percentage of CD4
+
 T cells in the blood at day 7 post 
infection. There was a direct inverse correlation between the two (r2=0.909), where 
mice with a higher percentage of CD4
+
 T cells in the blood had a lower percentage of 
glyco
-
Gag
+
Ter119
+
 cells in the blood, showing that the presence of FV-specific CD4
+
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T cells was adequate to reduce the level of FV infection in the blood during primary 
infection in the absence of CD8
+
 T cells and B cells (Figure 3.5). 
 
To further investigate this B cell- and CD8
+
 T cell-independent role of CD4
+
 T cells 
against FV infection, the effect of titrated numbers of TCRβ-transgenic CD4+ T cells 
on splenomegaly in B6.A-Fv2
s
 Rag1
-/-
 was assessed. Mice which had not received 
TCRβ-transgenic CD4+ T cells began to develop splenomegaly by day 10, and all 
mice in this group had developed large spleens by day 14 post infection. However, 
mice which had received TCRβ-transgenic CD4+ T cells did not develop 
splenomegaly during this time, and at day 14 had significantly smaller spleens than 
control mice (p=0.00001). Furthermore, as few as 10
5
 TCRβ-transgenic CD4+ T cells 
were sufficient to protect mice against splenomegaly until day 21 post infection, while 
transfer of 10
6
 TCRβ-transgenic CD4+ T cells was able to protect mice beyond day 21 
post infection. Although protection against splenomegaly was not maintained beyond 
day 28 after infection, transfer of TCRβ-transgenic CD4+ T cells resulted in a 
significant delay in the onset of splenomegaly in mice (Figure 3.6). 
 
These data demonstrated that FV-specific CD4
+
 T cells were able to protect against 
FV infection in the absence of endogenous adaptive lymphocytes in mice with genetic 
susceptibility to FV disease. Although transfer of EF4.1 TCRβ-transgenic CD4+ T 
cells was unable to prevent eventual onset of splenomegaly during the later stage of 
infection in B6.A-Fv2
s
 Rag1
-/-
 mice, it was sufficient to control the initial infection 
and significantly delay onset of FV-induced disease via a mechanism which did not 
involve provision of immunological help to B cells or CD8
+
 T cells. 
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Figure 3.5 CD8
+
 T cell- and B cell-independent reduction of FV infection by 
FV-specific CD4
+
 T cells 
Correlation between the percentage of FV-infected (glyco-Gag
+
) Ter119
+
 cells and 
the percentage of donor CD4
+
 T cells in the blood, 7 days after FV infection of 
lymphopenic B6.A-Fv2
s
 Rag1
-/-
 mice which received titrated numbers of EF4.1 
TCRβ-transgenic CD4+ T cells. Each symbol represents an individual mouse. The 
dashed line represents the line of correlation (r
2
=0.909). 
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Figure 3.6 CD8
+
 T cell- and B cell-independent protection against FV-induced 
splenomegaly by FV-specific CD4
+
 T cells 
Spleen index after FV infection of B6.A-Fv2
s
 Rag1
-/-
 mice with (+ T cells), or without 
(-) adoptive transfer of indicated numbers of EF4.1 TCRβ-transgenic CD4+ T cells. 
Each symbol represents an individual mouse. The dashed line indicates the spleen 
index of uninfected mice. Numbers within the graph denote the p values as compared 
using a two-tailed Wilcoxon-Mann-Whitney test. 
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3.4 Cytokine Production by FV-specific CD4+ T Cells 
3.4.1 Lineage-specific cytokine production by FV-specific CD4+ T cells 
CD4
+
 T cells can be characterised and divided into Th cell subsets depending on their 
cytokine production. Intra-cellular cytokine staining of FV-specific CD4
+
 T cells at 
day 7 post infection was carried out to identify which T helper cell subset was 
dominating the anti-retroviral protective response against FV infection. This revealed 
that the responding FV-specific CD4
+
 T cell population was comprised of IL-2 single 
producers and IFN-γ single producers, as well as IL-2/IFN-γ double producer CD4+ T 
cells (Figure 3.7A). In contrast, there was negligible production of IL-17A by the FV-
specific CD4
+
 T cell population, either alone or in concert with IFN-γ, discounting the 
possibility of a Th17 cell phenotype (Figure 3.7B). These data indicated that the FV-
specific CD4
+
 T cell population had an inclination towards a Th1 CD4
+
 T cell subset, 
with IL-2 and IFN-γ representing signature Th1 cytokines. 
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Figure 3.7 Cytokine production by FV-specific CD4
+
 T cells 
2 × 10
6
 CD45.1
+
 TCRβ-transgenic CD4+ T cells were transferred into B6 mice 
(CD45.2
+
) 1 day before FV infection. Numbers within the quadrants denote the 
percentages of positive cells. Production of IFN-γ and IL-2 (A) and IFN-γ and IL-17 
(B) by FV-specific donor CD4
+
 T cells is shown. 
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3.4.2 IFN-γ in CD4+ T cell-mediated control of primary FV infection 
CD4
+
 T cells have previously been shown to be able to inhibit viral replication via 
production of the anti-viral cytokine IFN-γ (Christensen et al., 1999; Davis et al., 
2008). In order to determine whether protective CD4
+
 T cells in the FV model were 
acting via production of IFN-γ, the ability of additional FV-specific CD4+ T cells to 
reduce FV infection in B6 mice deficient in the IFN-γ receptor (B6-Ifngr1-/- mice) was 
investigated.  
 
Adoptive transfer and infection experiments were repeated in B6-Ifngr1
-/-
 mice and 
B6 controls. Transfer of EF4.1 TCRβ-transgenic CD4+ T cells was able to reduce 
infection at the peak compared to mice which had not received CD4
+
 T cells, as 
shown above (p=0.0001). Notably, transfer of EF4.1 TCRβ-transgenic CD4+ T cells 
before FV infection of B6-Ifngr1
-/-
 mice was able to reduce the percentage of infected 
erythroid precursor cells in the spleen compared to mice which did not receive CD4
+
 
T cells, despite the inability of endogenous cells to respond to IFN-γ (p=0.004) 
(Figure 3.8). This demonstrates that anti-retroviral FV-specific CD4
+
 T cells in the 
FV model could exert their protective effect independently of IFN-γ. Together, these 
results showed that anti-retroviral FV-specific CD4
+
 T cells were able to control FV 
infection via a CD8
+
 T cell- and B cell-independent mechanism, and that this FV-
specific CD4
+
 T cell-mediated anti-retroviral effect was unlikely to be mediated by 
production of IFN-γ, but was instead operating through an unconventional anti-viral 
mechanism of CD4
+
 T cells. 
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Figure 3.8 Control of FV infection by FV-specific TCRβ-transgenic CD4+ T 
cells in IFN-γR deficient recipients 
Percentage of glyco-Gag
+
Ter119
+
 cells in the spleen of B6 or B6-Ifngr1
-/-
 mice, 7 
days after FV infection, with (+ T cells) or without (-) adoptive transfer of 1 × 10
6
 
EF4.1 TCRβ-transgenic CD4+ T cells 1 day before infection. Each symbol represents 
an individual mouse. The dashed line indicates the limit of flow cytometric detection. 
Numbers within the graph denote the p values as compared using a two-tailed 
Wilcoxon-Mann-Whitney test. 
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3.5 Discussion 
3.5.1 Peptide immunisation and protection against FV 
Mice infected with FV 35 days after cell transfer and immunisation with FV env 
peptide were shown to have a reduced level of infection in the spleen, with protection 
comparable to that observed in mice infected one day after cell transfer. This suggests 
that peptide immunisation is able to induce expansion of FV-specific CD4
+
 T cells to 
a level where they are still present in numbers sufficient to reduce FV infection by 
day 35 after infection. Previous studies revealed a protective effect of peptide 
immunisation which induced a protective FV-specific CD4
+
 T cell response. 
However, one of these peptides (C-terminal) was shown to have an Ab binding 
epitope that, although it did not induce nAb, may have affected the reliability of the 
results obtained (Miyazawa et al., 1995). Although this previous study was carried out 
using a potentially LDV-contaminated FV stock, the current results presented here 
confirm that induction of FV-specific CD4
+
 T cells by peptide immunisation is able to 
induce a protective CD4
+
 T cell response against FV in mice infected with FV alone 
as well as in FV/LDV co-infection. However, the phenotype of the FV-specific CD4
+
 
T cells induced is not defined, and so it is not known whether peptide immunisation is 
inducing a protective response by increasing the number of FV-specific CD4
+
 T cells, 
or by inducing a memory CD4
+
 T cell population which is able to mount a more rapid 
and effective response against FV infection. 
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3.5.2 CD4+ T cell-mediated control of acute FV infection 
The essential role of CD4
+
 T cells in the immune response to pathogens is evident in 
both primary and secondary immunodeficiency in humans and in animal models. 
With regards to FV, CD4
+
 T cells have been shown to make a major contribution to 
controlling the chronic phase of infection in immunocompetent mice (Hasenkrug et 
al., 1998; Robertson et al., 1992). It has also been previously shown that adoptive 
transfer of whole immune spleen cells from mice immunised with an attenuated F-
MuLV is able to reduce FV infection (Dittmer et al., 1998). However, when adaptive 
lymphocytes were divided into the 3 major adaptive lineages, adoptive transfer of 
CD8
+
 T cells was able to reduce FV infection in naive mice, but transfer of CD4
+
 T 
cells from these immune mice was not (Dittmer et al., 1999). This study concluded 
that CD4
+
 T cells alone were not adequate for protection against FV. However, these 
previous studies and others were carried out using an FV stock likely to be 
contaminated with LDV. As discussed, coinfection of LDV with FV has profound 
effects on FV pathogenesis and induction of the FV-specific immune response. 
Infection of CD4
+
 T cell-deficient mice with clean, uncontaminated FV stock has 
demonstrated a clear role for CD4
+
 T cells in controlling the acute phase of FV 
infection (Pike et al., 2009). Here, the effect of adoptive transfer of EF4.1 TCRβ-
transgenic CD4
+
 T cells on FV infection using clean FV stock was assessed. 
 
The results here show that, in contrast to studies using an LDV-contaminated FV 
stock, additional FV-specific CD4
+
 T cells are able to contribute to protection against 
FV infection and in fact, adoptive transfer of these transgenic CD4
+
 T cells 
significantly reduces the percentage of FV-infected cells in the spleen during the acute 
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phase of infection. This significant reduction of infection is observed in both 
immunocompetent Fv2
r
 B6 mice, and mice with susceptibility at the Fv2 locus. These 
data show for the first time that the presence of FV-specific CD4
+
 T cells during acute 
infection contributes to control of FV infection and thus that CD4
+
 T cells have an 
anti-retroviral role during the acute phase of FV infection. 
  
In experiments using LDV-contaminated FV stock, increasing the number of whole 
immune spleen cells in adoptive transfer experiments improved protection against FV 
infection (Dittmer et al., 1998). Furthermore, transfer of immune CD8
+
 T cells was 
able to protect against FV infection, while transfer of immune CD4
+
 T cells was not 
(Dittmer et al., 1999). Increasing the number of immune CD8
+
 T cells transferred also 
resulted in a further improvement in protection, no protection was observed when the 
number of immune CD4
+
 T cells transferred was increased (Dittmer and Hasenkrug, 
2000). Here it is shown that transfer of increased numbers of EF4.1 TCRβ-transgenic 
CD4
+
 T cells in the absence of FV/LDV co-infection results in a significant reduction 
of FV-infected cells in the spleen during the acute phase of infection, demonstrating a 
role for CD4
+
 T cells against FV infection which was previously unrecognised. 
Furthermore, CD4
+
 T cell-mediated protection occurred in a dose-dependent manner, 
with protection improving upon adoptive transfer of increased numbers of EF4.1 
CD4
+
 T cells, showing that protection is proportional to CD4
+
 T cell number, and 
contradicting further experiments. 
 
During FV/LDV-coinfection, the peak of FV infection in the spleen is observed at day 
14, rather than day 7 as seen during FV infection alone, and although additional FV-
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specific CD4
+
 T cells are still able to reduce FV infection at the peak in FV/LDV co-
infected mice, more CD4
+
 T cells are necessary to reduce FV infection when LDV is 
also present (Pike et al., 2009). This may explain the previous observation that 
increasing the number of immune CD4
+
 T cells had no effect on FV infection in 
studies which possibly used an LDV-contaminated stock. It is possible that the 
attenuated virus vaccine used to induce immune mice from which these FV-specific 
CD4
+
 T cells were obtained may have induced adequate numbers to control FV 
infection alone, but not to the magnitude where they were able to control FV/LDV co-
infection due to the increased level of infection. 
 
3.5.3 An independent role for CD4+ T cells against FV infection 
Further to the observation that additional FV-specific CD4
+
 T cells were able to 
reduce FV infection during the acute phase, the mechanism by which this anti-viral 
effect was mediated was elucidated. Experiments were carried out in order to assess 
whether FV-specific CD4
+
 T cells were controlling FV infection via immunological 
help or via a direct effect against FV infected cells. 
 
FV nAb has been shown to play an important role against FV infection, and 
administration of FV nAb in the absence of B cells results in a reduction of FV 
infection (Messer et al., 2004). Furthermore, mice with FV/LDV coinfection suffer a 
more severe infection, partially due to delayed onset of FV nAb production caused by 
LDV (Marques et al., 2008). With this in mind, the effect of additional FV-specific 
CD4
+
 T cells on FV nAb titre during FV infection was studied. It was observed that 
adoptive transfer of TCRβ-transgenic CD4+ T cells before FV infection did not lead to 
 149 
increase in FV nAb titre compared to control mice. Additionally, CD4
+
 T cell-
mediated control of FV infection was observed at day 7 after infection, while FV nAb 
was not induced to a detectable level until day 14 after infection. This showed that 
additional FV-specific CD4
+
 T cells in this model are not reducing FV infection via 
provision of immunological help to B cells to increase the level of production of nAb 
against the virus.  
 
To determine whether CD4
+
 T cells were able to control FV infection in the absence 
of other adaptive lymphocytes, and hence further demonstrating that their anti-
retroviral effect was not via immunological help, adoptive transfer and infection 
experiments were repeated in Fv2 susceptible mice with no endogenous T cells or B 
cells. Adoptive transfer of FV-specific CD4
+
 T cells was able to reduce levels of 
infection in the blood at day 7 after infection, with an inverse correlation observed 
between the percentage of CD4
+
 T cells in the blood and the percentage of infected 
erythroid precursors in the blood. Additionally, while control mice developed 
splenomegaly by day 10 after infection, mice which had received EF4.1 TCRβ-
transgenic CD4
+
 T cells maintained significantly smaller spleens after day 10. 
Notably, although protection was not maintained past day 28 after infection, there was 
a significant delay in the onset of splenomegaly in these mice, providing evidence that 
FV-specific CD4
+
 T cells were able to control FV infection and the spread of FV in 
the absence of both B cells and CD8
+
 T cells. These data showed that the observed 
role of CD4
+
 T cells against FV infection is both B cell- and CD8
+
 T cell-independent 
and that these cells were not exerting their anti-retroviral effect via immunological 
help to other adaptive immune cells, and instead may be exerting a direct anti-
retroviral activity against FV infection. 
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3.5.4 Cytokine production in the control of FV infection 
An alternative mechanism to providing help to other adaptive lymphocytes, by which 
FV-specific CD4
+
 T cells may have been controlling FV infection, is production of 
anti-viral cytokines such as interferons, which are able to exert direct anti-viral 
activity. CD4
+
 T cell responses to intracellular infections, including viral infections, 
are typically mediated by the IFN-γ-producing Th1 CD4+ T cell subset (Zhu et al., 
2010). Intracellular cytokine staining of the responding EF4.1 TCRβ-transgenic CD4+ 
T cell population demonstrated that the FV-specific CD4
+
 T cell population contained 
both IFN-γ and IL-2 single producers, as well as IFN-γ/IL-2 double producers, and 
hence exhibited characteristics of a Th1 phenotype, as predicted. However, very few 
cells in the FV-specific CD4
+
 T cell population produced IL-17, and hence this 
population did not contain cells of the Th17 subset, which correlates with the 
observation that Th17 cells are associated mainly with parasite infections and 
autoimmunity. 
 
CD4
+
 T cells have previously been shown to have direct anti-viral effects via 
production of IFN-γ hepatitis C virus (HCV) infection and γ-herpesvirus infection 
(Christensen et al., 1999; Davis et al., 2008). However, efforts to establish the role of 
CD4
+
 T cell-derived IFN-γ in the control of FV infection have so far been 
inconclusive. Previously in FV, while one study has shown a direct inhibition of viral 
replication by IFN-γ (Iwashiro et al., 2001b), another suggested a contrasting 
function, with the absence of IFN-γ resulting in decreased infection and an increased 
nAb titre (Stromnes et al., 2002). A further study suggested that IFN-γ may be 
detrimental during certain stages of FV infection, but beneficial during others 
(Stromnes et al., 2002).  
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With the observation of IFN-γ production by FV-specific CD4+ T cells in mind, the 
potential role of CD4
+
 T cell-derived IFN-γ in control of acute FV infection was 
investigated by infection of mice deficient in the IFN-γ receptor. It was observed that 
adoptive transfer of additional FV-specific CD4
+
 T cells in these mice was still able to 
reduce FV infection in spite of the inability of endogenous cells to respond to IFN-γ. 
This showed that the protective effect of FV-specific CD4
+
 T cells was not mediated 
via a direct effect of IFN-γ on infected cells, or by activation of endogenous innate 
immune cells by IFN-γ. These observations suggest that IFN-γ does not have a role in 
CD4
+
 T cell-mediated control of acute FV infection. However, it is possible that it 
may be important during the control of chronic infection, and this cannot be ruled out 
by these experiments. 
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3.5.5 Potential mechanisms of CD4+ T cell control of FV infection  
The data presented here demonstrate a B cell-, CD8
+
 T cell-, and IFN-γ-independent 
role for CD4
+
 T cells against FV infection, indicating that the anti-retroviral effect of 
FV-specific CD4
+
 T cells occurs via an alternative mechanism. The observation that 
FV-specific CD4
+
 T cells have a direct role in controlling acute FV infection supports 
previous results showing that CD4
+
 T cells can have direct cytotoxic effects against 
FV, as well as during other viral infections.  
 
Direct killing of infected cells by CD4
+
 T cells has been observed previously in FV 
infection, and although erythroid precursor cells, the major target of FV infection, do 
not express MHC class II and so cannot be recognised by CD4
+
 T cells directly, T cell 
activation was sufficient to induce CD4
+
 T cell-mediated cytolysis in this previous 
study (Iwashiro et al., 2001b). Mice deficient in the Fas/FasL pathway were able to 
control acute, but not chronic infection (Zelinskyy et al., 2004). This is therefore 
unlikely to be the mechanism by which CD4
+
 T cells reduce acute infection, but could 
be the means by which they contribute to the control of persistent FV infection.  
 
The observation that mice deficient in perforin and/or granzymes are less protected 
against FV infection has been attributed to compromised CD8
+
 T cell cytotoxicity 
(Zelinskyy et al., 2004). As CD8
+
 T cells have been shown to be deficient in these 
cytolytic molecules during chronic FV infection (Zelinskyy et al., 2005) this may 
explain why depletion of CD8
+
 T cells during chronic infection did not affect viral 
load, and did not result in reactivation of disease. Potentially, cytotoxic CD4
+
 T cells 
are taking over the role of CD8
+
 T cell-mediated killing of FV-infected cells during 
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chronic FV infection. Hence, elevated levels of FV infection in perforin/granzyme-
deficient mice may have been due to compromised cytotoxic activity of CD4
+
 T cells 
rather than CD8
+
 T cells. By using gene microarrays, upregulation of perforin and 
granzyme B transcription has been observed in FV-specific CD4
+
 T cells. In contrast, 
no upregulation of FasL was observed, suggesting that a direct cytotoxic action of 
FV-specific CD4
+
 T cells is more likely to be mediated by perforin and granzymes 
than the Fas/FasL pathway (Ploquin M., personal communication). 
 
IFN-γ has also been shown to enhance CD4+ T cell killing (Iwashiro et al., 2001b), 
and this may contribute towards control of acute infection as despite IFN-γR deficient 
mice still being protected against FV infection to the same extent as those who can 
respond to IFN-γ, TCRβ-transgenic CD4+ T cells still have a functional IFN-γ 
receptor and hence endogenously produced IFN-γ, or FV-specific CD4+ T cell derived 
IFN-γ in an autocrine manner, may increase potential cytotoxic ability of FV-specific 
CD4
+
 T cells and hence contribute towards control of acute infection. 
 
CD4
+
 T cells may alternatively be reducing FV infection via an indirect mechanism, 
for example, production of cytokines to induce innate immune cells to phagocytose 
infected cells, or increase activity of NK cells. Importantly, NK cells have been 
demonstrated to be a major cytotoxic cell type mediating protection against FV 
infection after peptide immunisation with a CD4
+
 T cell epitope (Iwanami et al., 
2001). As protection against acute infection and delayed splenomegaly by FV-specific 
CD4
+
 T cells is observed in mice which have no endogenous adaptive immune 
response, this suggests that the innate immune system may contribute towards this. In 
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conclusion, the potential mechanisms by which FV-specific CD4
+
 T cells are exerting 
this novel anti-retroviral effect are diverse, and may involve complex networks 
involving cytokines and innate immune cells.  
 
These data have demonstrated a clear role for CD4
+
 T cells in the control of acute 
retroviral infection. This anti-retroviral viral effect is mediated via an unconventional 
CD4
+
 T cell mechanism, and may provide further evidence for the importance of 
cytotoxic CD4
+
 T cells in control of retroviral infections. These data are also in 
agreement with studies showing the importance of CD4
+
 T cells during HIV infection 
(Rosenberg et al., 1997). Furthermore, the absence of conventional CD4
+
 T cell 
mechanisms supports the role of cytotoxic CD4
+
 T cells during HIV infection (Norris 
et al., 2001; Norris et al., 2004). These results therefore suggest that vaccine 
approaches targeting induction of HIV-specific CD4
+
 T cells provide candidates for 
further HIV vaccine design. The cause and effect relationship between CD4
+
 T cell 
count and HIV viraemia is not defined (Jansen et al., 2006; Lichterfeld et al., 2005), 
although LTNP’s have been shown to have highly functional memory CD4+ T cells 
(Jansen et al., 2006; Potter et al., 2007). The importance of inducing and maintaining 
a strong CD4
+
 T cell response in order to protect against infection by HIV must 
therefore be further examined. 
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Chapter Four 
4 FV-specific CD4+ T cell Kinetics 
 
 156 
4.1 Introduction  
CD4
+
 T cells from EF4.1 TCRβ-transgenic mice have been shown to have an elevated 
frequency of FV-specific cells compared to those from wild-type mouse strains, with 
4% of cells in polyclonal EF4.1 CD4
+
 T cell population responding to env122-141 in 
vitro (Antunes et al., 2008).  
 
Furthermore, it is shown here that additional FV-specific CD4
+
 T cells are able to 
reduce the level of FV infection during the acute phase of infection in 
immunocompetent mice, and delay splenomegaly by a B cell-, CD8
+
 T cell- or IFN-γ-
independent mechanism. To further assess the FV-specific CD4
+
 T cell response to 
FV infection, donor CD4
+
 T cells were identified. The kinetics of FV-specific CD4
+
 T 
cells in response to in vivo FV infection were studied using an adoptive transfer 
model. The effect of EF4.1 CD4
+
 T cell precursor number and antigen dose on 
expansion and contraction of FV-specific CD4
+
 T cells was examined. 
 
In response to stimulation, CD4
+
 T cells proliferate in an antigen-specific manner, and 
subsequently contract, with ~10% remaining and entering the memory cell pool. In 
previous studies, it was not possible to identify and quantify the FV-specific CD4
+
 T 
cell response, and hence was not possible to study the expansion and contraction of 
FV-specific CD4
+
 T cells in response to either FV infection or vaccination techniques. 
In order to overcome this problem, the B6.EF4.1 TCRβ-transgenic mouse has been 
developed, and is used in adoptive transfer experiments to elucidate the kinetics of the 
CD4
+
 T cell.  
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4.2 Expansion of EF4.1 TCRβ-transgenic CD4+ T Cells in Response to in vivo 
FV Infection of Immunocompetent Mice 
4.2.1 Effect of precursor number on kinetics of FV-specific CD4+ T cells  
In order to establish the kinetics of FV-specific CD4
+
 T cells in response to FV 
infection, titrated numbers of EF4.1 TCRβ-transgenic CD4+ T cells (105, 106 or 107 
cells) were transferred into B6 mice one day before FV infection. Mice were killed at 
day 1 or 7 post infection and the number of FV-specific donor CD4
+
 T cells engrafted 
in the spleen at these time points was quantified with flow cytometry as described 
(Figure 2.1). 
 
In mice that received TCRβ-transgenic CD4+ T cells, but were not infected with FV, 
there was a negligible percentage of cells expressing CD44 in the donor CD4
+
 T cell 
population. However, in mice that had received TCRβ-transgenic CD4+ T cells and 
were FV-infected, there was a marked expansion of CD44
hi
 donor cells, to comprise 
~3% of the entire CD4
+
 T cell population. This demonstrated that donor TCRβ-
transgenic CD4
+
 T cells expanded and proliferated in response to FV infection 
(Figure 4.1A). 
 
The number of FV-specific donor CD4
+
 T cells recovered at day 1 after infection was 
directly proportional to cell expansion of FV-specific donor CD4
+
 T cells at day 7 
post infection (Figure 4.1B). The number of FV-specific cells in mice which had 
received TCRβ-transgenic CD4+ T cells but had not been FV-infected is also shown, 
and, in the absence of FV infection, no expansion of FV-specific donor CD4
+
 T cells 
was observed. Furthermore, the level of expansion of FV-specific CD4
+
 T cells did 
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not begin to plateau even when 10
7
 TCRβ-transgenic CD4+ T cells were transferred 
into mice, indicating that the maximum response had not been reached and that upon 
transfer of larger numbers of TCRβ-transgenic CD4+ T cells, further expansion and 
hence a stronger FV-specific CD4
+
 T cell response could potentially be achieved.  
 
Adoptive transfer studies of transgenic CD4
+
 T cells in the LCMV mouse model have 
shown that when mice received higher numbers of transgenic CD4
+
 T cells, virus-
specific cells were lost at a more rapid rate (Whitmire et al., 2008). In order to study 
the effect of precursor number in the continued FV-specific CD4
+
 T cell response, 
kinetics of FV-specific CD4
+
 T cells were followed for 35 days after FV-infection and 
transfer of 10
6
 or 10
7
 EF4.1 TCRβ-transgenic CD4+ T cells. At the peak of FV-
specific CD4
+
 T cell expansion, day 7 after infection, the number of FV-specific 
CD4
+
 T cell numbers had increased 100-fold compared to the number of cells 
engrafted in the spleen at day 1 post infection. FV-specific donor CD4
+
 T cell 
numbers subsequently declined between days 7 and 14 post infection and had reached 
a plateau by day 35 after infection. This precursor-determined elevated level of 
expansion was maintained throughout the course of infection, and the rate of FV-
specific CD4
+
 T cell contraction between day 7 and day 35 post infection was 
comparable whether mice had received 10
6
 or 10
7
 EF4.1 TCRβ-transgenic CD4+ T 
cells (Figure 4.1C). 
 
These data demonstrated that precursor number did not have a limiting effect on the 
ongoing FV-specific CD4
+
 T cell response, and FV-specific CD4
+
 T cells were not 
lost at a higher rate when precursor number was increased. 
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Figure 4.1 Priming of adoptively transferred TCRβ-transgenic FV-specific 
CD4
+
 T cells during FV infection 
(A) 1 × 10
6
 CD45.1
+
 TCRβ-transgenic CD4+ T cells were transferred into B6 
(CD45.2
+
) recipients, which remained uninfected (-FV) or were infected with FV 1 
day later (+FV). The percentage of activated donor (CD44
+
 CD45.1
+
) CD4
+
 T cells in 
gated total splenic CD4
+
 T cells 7 days post infection is shown.  
(B) Correlation between numbers of grafted FV-specific CD4
+
 T cells in the spleen 1 
day after transfer and numbers of the same cells 7 days post infection with FV (+FV). 
Numbers of FV-specific cells recovered from uninfected mice (-FV) are also shown 
for comparison. Values are the mean (± the SEM) of 3-8 mice per group per CD4
+
 T 
cell inoculum from 1-3 separate experiments.  
(C) 10
6
 or 10
7
 CD45.1
+
 TCRβ-transgenic CD4+ T cells were transferred into B6 
recipients one day before FV infection. Numbers of FV-specific CD4
+
 T cells 
recovered from mice are shown. Values are the mean (± the SEM) of 3-8 mice per 
CD4
+
 T cell inoculum from 2-3 separate experiments. 
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4.2.2 Effect of antigen dose on kinetics of FV-specific CD4+ T cells 
Upon interaction with antigen presented in complex with MHC class II molecules on 
APCs, CD4
+
 T cells proliferate and acquire effector function. In order to investigate 
the relationship between antigen dose and expansion and contraction of FV-specific 
CD4
+
 T cells, three systems were used; infection of B6 mice with F-MuLV-N (Figure 
4.2A), infection of B6 mice with FV (Figure 4.2B) and infection of B6.A-Fv2
s
 mice 
with FV (Figure 4.2C). Mice received 2 × 10
6
 TCRβ-transgenic CD4+ T cells one day 
before infection. These systems provided conditions where antigen level was low, 
intermediate or high, respectively.  
 
After infection with F-MuLV-N, an N-tropic strain of F-MuLV which is attenuated in 
B6 mice due to the Fv1
b
 allele, there was a very low percentage of infected erythroid 
precursor cells in the spleen at the peak of infection. This low level of initial infection 
was resolved rapidly, with the fraction of infected cells below the level of detection 
by flow cytometry by day 14 after infection. At day 7 post infection FV-specific 
CD4
+
 T cells had expanded ~60-fold compared to the number of FV-specific CD4
+
 T 
cells engrafted at day 1 post infection. FV-specific CD4
+
 T cell numbers subsequently 
contracted, with an elevated rate of contraction between days 21 and 35 post infection 
(Figure 4.2A). Thus, the low level of antigen present after infection with F-MuLV-N 
was not adequate to induce a prolonged FV-specific CD4
+
 T cell response to FV in 
B6 mice. 
 
In contrast to infection with F-MuLV-N, B6 mice are permissive to infection by B-
tropic F-MuLV. However, due to resistance at the Fv2 locus (Fv2
r
), B6 mice are not 
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susceptible to FV-induced splenomegaly and erythroleukaemia. FV infection resulted 
in around 1% infected cells at the peak (day 7 post infection) and infection was 
subsequently resolved, decreasing below the level of detection by flow cytometry by 
day 35 post infection as shown above. The number of FV-specific CD4
+
 T cells 
increased ~70-fold at the peak of infection and, although they subsequently began to 
contract as observed after F-MuLV-N infection, it was at a reduced rate with cell 
numbers reaching a plateau between days 21 and 35 post infection (Figure 4.2B). 
From these data it was clear that at a higher level of antigen, a proportionally 
increased and longer-lived FV-specific CD4
+
 T cell response could be induced. 
 
Finally, B6.A-Fv2
s
 mice are permissive to infection by B-tropic F-MuLV but are also 
susceptible to FV-induced splenomegaly and erythroleukaemia due to the Fv2 allele 
(Fv2
s
). Infection is more severe than that observed in B6 mice, with 10-fold more 
infected cells seen at the peak of infection. In addition to this elevated level of 
antigen, a >200-fold expansion of FV-specific CD4
+
 T cells was seen compared to the 
number of TCRβ-transgenic CD4+ T cells recovered at day 1 post infection. FV-
specific CD4
+
 T cells subsequently contracted and, with kinetics similar to those seen 
in B6 mice, reached a plateau by day 35 post infection (Figure 4.2C). These results 
showed that increased antigen was able to induce an increased peak expansion of FV-
specific CD4
+
 T cells, but was not able to maintain these cells at levels higher than 
that seen in FV infection of B6 mice, despite an increased initial level of antigen. A 
direct correlation between the mean percentage of infected cells in the spleen at the 
peak of infection, and the mean number of FV-specific donor CD4
+
 T cells recovered 
at the peak of expansion was also apparent in each of the three systems described 
above (Figure 4.3). 
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In conclusion, expansion of FV-specific donor CD4
+
 T cells appeared to be directly 
proportional to the amount of antigen in the system. Hence, the magnitude of the FV-
specific CD4
+
 T cell response was antigen dose-dependent. While low level antigen 
was unable to maintain an FV-specific CD4
+
 T cell response, higher levels of antigen 
could maintain higher numbers of these cells throughout FV infection. However, FV-
specific CD4
+
 T cell loss was not alleviated by the increased amount of antigen 
present during the initial FV infection of B6.A-Fv2
s
 mice. Together, these data 
demonstrated that the magnitude of the anti-retroviral FV-specific CD4
+
 T cell 
response was determined both by precursor CD4
+
 T cell number and the amount of 
initial antigen stimulation that donor CD4
+
 T cells had experienced. 
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Figure 4.2 Relationship between antigen dose and FV-specific CD4
+
 T cell 
expansion and contraction 
(A) 2 × 10
6
 CD45.1
+
 TCRβ-transgenic CD4+ T cells were transferred into B6 
(CD45.2
+
) recipients, which were infected with F-MuLV-N 1 day later. Numbers of 
FV-specific CD4
+
 T cells recovered from mice and the percentage of glyco-
Gag
+
Ter119
+
 cells in the spleen are shown. Values are the mean (± the SEM) of 6-10 
mice from 2-3 separate experiments.  
(B) 2 × 10
6
 CD45.1
+
 TCRβ-transgenic CD4+ T cells were transferred into B6 
(CD45.2
+
) recipients, which were infected with FV 1 day later. Numbers of FV-
specific CD4
+
 T cells recovered from mice and the percentage of glyco-Gag
+
Ter119
+
 
cells in the spleen are shown. Values are the mean (± the SEM) of 10-16 mice from 3-
5 separate experiments.  
(C) 2 × 10
6
 CD45.1
+
 TCRβ-transgenic CD4+ T cells were transferred into B6.A-Fv2s 
(CD45.2
+
) recipients, which were infected with FV 1 day later. Numbers of FV-
specific CD4
+
 T cells recovered from mice and the percentage of glyco-Gag
+
Ter119
+
 
cells in the spleen are shown. Values are the mean (± the SEM) of 5-9 mice from 2-5 
separate experiments. 
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Figure 4.3 Relationship between peak expansion of FV-specific CD4
+
 T cells 
and peak level of infection  
Correlation between the peak percentage of FV-infected (glyco-Gag
+
) Ter119
+
 cells 7 
days after infection of the indicated host and virus and the numbers of FV-specific 
CD4
+
 T cells recovered at the same time point. Values are the mean (± the SEM) of 5-
10 mice from 2-4 separate experiments per virus/host combination. 
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4.3 Detecting FV During the Chronic Phase of Infection 
Flow cytometric detection of infected erythroid precursor cells (glyco
-
Gag
+
Ter119
+
 
cells) in the spleen is sufficient to differentiate between levels of infection during the 
acute phase in the three systems described above. However, by day 35 after infection 
the percentage of infected erythroid precursor cells is below detection by flow 
cytometry, even in B6.A-Fv2
s
 mice despite more severe infection and high antigen 
level. FV is known to establish a persistent, chronic infection (Chesebro et al., 1979). 
With this in mind, a Q-PCR assay that could measure the number of proviral copies of 
F-MuLV env gene per 100,000 nucleated spleen cells was developed in order to 
provide a more sensitive technique with which to detect FV infection during the 
chronic phase. 
 
Using this assay, the number of copies of F-MuLV env per 100,000 cells in the spleen 
of acutely infected B6 mice (day 7 post infection) was compared to that during 
chronic infection (day 35 post infection) in the three systems described above. B6 
mice infected with F-MuLV-N, which had also received EF4.1 TCRβ-transgenic 
CD4
+
 T cells, had undetectable levels of F-MuLV env, even with the more sensitive 
assay. This is in agreement with the reported inability of F-MuLV-N to persist in B6 
mice (Dittmer et al., 1998). In contrast, in B6 and B6.A-Fv2
s
 mice which had received 
EF4.1 TCRβ-transgenic CD4+ T cells one day before FV infection, F-MuLV env was 
still detectable by day 35 after infection (Figure 4.4). However, the difference 
between the number of F-MuLV env copies per 100,000 nucleated spleen cells during 
chronic infection in B6 and B6.A-Fv2
s
 mice was not significant.  
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These data showed that B6 and B6.A-Fv2
s
 mice, despite a significant reduction in 
infected cells during the acute phase, still had detectable levels of F-MuLV env during 
chronic infection, suggesting that although additional FV-specific CD4
+
 T cells were 
able to reduce the peak level of infection, they were not sufficient to clear FV 
infection completely and a persistent chronic infection was still established. 
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Figure 4.4 Detection of F-MuLV env in the spleen by Q-PCR  
2 × 10
6
 TCRβ-transgenic CD4+ T cells were transferred into the indicated host and 
were infected with the indicated virus 1 day later. DNA was extracted from spleens of 
mice 35 days after FV infection and Q-PCR to detect F-MuLV env was carried out. 
For acute infection, DNA was extracted from the spleen of B6 mice 7 days after FV 
infection. The F-MuLV env copy number per 100,000 nucleated spleen cells is 
plotted. Each symbol represents an individual mouse. Solid lines represent the means 
of each group. The dashed line indicates the numbers of copies of F-MuLV env per 
100,000 spleen cells in uninfected mice as detected by Q-PCR.  
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4.4 Discussion 
4.4.1 Expansion of virus-specific CD4+ T cells in the FV mouse model 
In previous studies investigating CD4
+
 T cell responses to viral infection, increasing 
the number of transgenic virus-specific CD4
+
 T cell precursors resulted in a 
compromised survival of these cells, with cells being lost more rapidly when higher 
numbers were transferred into mice than when lower numbers were transferred. An 
example of this is the elevated rate of T cell loss observed when 10
5
 LCMV-specific 
CD4
+
 T cells were transferred compared to when only 10
3
 cells were transferred. This 
increased loss was attributed to competition for IFN-γ signals by CD4+ T cells, as this 
difference in loss was not observed when the transgenic CD4
+
 T cells did not express 
the IFN-γR (Whitmire et al., 2008). This phenomenon was also seen in VSV 
infection, although in this model T cell loss was attributed to competition by CD4
+
 T 
cells for antigen (Blair and Lefrancois, 2007).  
 
The effect of increased precursor number on expansion and contraction of virus-
specific CD4
+
 T cells was assessed here using EF4.1 TCRβ-transgenic CD4+ T cells 
in the FV model. In contrast to the above described studies, increasing the number of 
transgenic CD4
+
 T cells adoptively transferred did not result in accelerated loss of 
FV-specific CD4
+
 T cells. Instead, the rate of cell loss was comparable regardless of 
the number of cells initially transferred. In addition, the level of peak expansion 
continued to increase even when 10
7
 EF4.1 TCRβ-transgenic CD4+ T cells were 
transferred. Thus, it can be concluded that intial expansion of FV-specific CD4
+
 T 
cells in the model used in this thesis is not limited by either antigen or IFN-γ, and that 
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these CD4
+
 T cells are still receiving adequate stimulation for survival and memory 
cell generation even when the precursor number is higher.  
 
The difference in the results shown here using the FV model compared to LCMV and 
VSV studies may also reflect a difference in the virus-specific CD4
+
 T cell response 
in retroviral infection compared to non-retrovirus viral infection. However, it is 
necessary to draw attention to the monoclonal character of the transgenic CD4
+
 T 
cells used in the two previous studies described above. The EF4.1 TCRβ-transgenic 
mouse used in the studies here have a polyclonal CD4
+
 T cell population, and hence 
adoptive transfer experiments to study the virus-specific CD4
+
 T cell response carried 
out here are of a more physiological nature than models where transgenic CD4
+
 T 
cells were monoclonal. This indicates that the results presented here are likely to be 
more reliable than those from previous studies, and the use of the FV retroviral 
complex suggests that these results can be more reliably extrapolated to CD4
+
 T cell 
responses in human retroviral infections. 
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4.4.2 Antigen-dependent virus-specific CD4+ T cell expansion 
Further to the results presented here regarding the non-limiting effect of antigen on 
precursor number compared to previous studies, the role of antigen dose on the 
expansion and contraction of FV-specific CD4
+
 T cells was examined by studying the 
CD4
+
 T cell response in three conditions where antigen level was low, intermediate or 
high. While, low levels of antigen were not adequate to induce and maintain a strong 
FV-specific CD4
+
 T cell response, high levels of antigen induced a strong FV-specific 
CD4
+
 T cell response which did not decline as rapidly as when the antigen level was 
lower.  
 
These data demonstrated that the expansion of FV-specific CD4
+
 T cells is antigen 
dose-dependent, and thus that antigen is a limiting factor for the expansion of FV-
specific CD4
+
 T cells. It further showed that during conditions where the level of 
antigen is high, for example in B6 mice, cells are not rapidly deleted due to 
overactivation by antigen during a persistent viral infection. This is in contrast to 
studies which observed CD8
+
 T cell loss during chronic persistent infection by LCMV 
(Fuller et al., 2004; Moskophidis et al., 1993). 
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4.4.3 Infection with an attenuated F-MuLV is unable to induce a strong or 
long-lived FV-specific CD4
+
 T cell response 
Previous studies concluded that CD4
+
 T cells had no role in protecting against FV 
infection after absence of protection in mice which received CD4
+
 T cells from 
immune mice which had been immunised with attenuated F-MuLV (Dittmer and 
Hasenkrug, 2000). Here, availability of the EF4.1 TCRβ-transgenic mouse has 
allowed detection and quantification of the FV-specific CD4
+
 T cell response after 
both infection and immunisation. Employing this model, it is shown here that 
although FV-specific CD4
+
 T cells initially expanded in response to attenuated F-
MuLV vaccination, there was a more rapid contraction of virus-specific CD4
+
 T cells 
than that observed after WT FV infection. This shows that the inability to confer 
protection by transfer of CD4
+
 T cells from immune mice in a previous study likely 
occurred because vaccination with attenuated F-MuLV only induced a weak FV-
specific CD4
+
 T cell response, and this FV-specific CD4
+
 T cell response was long-
lasting FV-specific memory CD4
+
 T cells. Therefore, the results and conclusions 
regarding the lack of requirement for CD4
+
 T cells in FV infection may be dismissed.  
 
In contrast to the findings here, studies which used SIV as a model for HIV showed 
that infection with attenuated SIV was able to induce a functional SIV-specific 
effector-memory CD4
+
 T cell response (Gauduin et al., 2006). The different results 
seen in this previous study compared to the experiment described here may lie in the 
different degree of attenuation if the viruses used. As the attenuated F-MuLV did not 
induce an FV-specific CD4
+
 T cell response as strong as the wild-type virus, it is 
possible that it is too attenuated, and that a virus with a lower degree or different 
mechanism of attenuation would be able to induce an improved CD4
+
 T cell response. 
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4.4.4  An alternative assay for detection of low level FV infection 
Flow cytometry to detect infected erythroid precursor cells in the spleen of B6 mice is 
a method of adequate sensitivity to measure levels of FV in acute infection and to 
assess the effect of transfer of EF4.1 TCRβ-transgenic CD4+ T cells on protection 
during the acute phase. However by day 14 after infection, the percentage of infected 
erythroid precursors in the spleen is below the level of detection by flow cytometry. A 
Q-PCR assay with which to measure the number of proviral copies of F-MuLV env in 
all spleen cells provides a more sensitive method by which to quantify FV infection 
when the level of infection is low, for example during the chronic phase of infection 
when acute infection has been resolved but the virus has not been completely cleared. 
This further allowed assessment of the effect of elevated numbers of FV-specific 
CD4
+
 T cells during FV infection, as demonstrated in chapter 6. 
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Chapter Five 
5 Mechanisms of High Avidity FV-specific CD4+ T 
cell Loss
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5.1 Introduction 
It has been demonstrated in vitro that the FV-specific CD4
+
 T cell population in 
TCRβ-transgenic B6.EF4.1 mice contains virus-specific CD4+ T cells of different 
avidities, with high avidity CD4
+
 T cells defined by their use of the Vα2 TCR chain 
(Vα2+) (Antunes et al., 2008). During in vivo FV infection in immunocompetent mice, 
there is a preferential expansion of these high avidity Vα2+ FV-specific CD4+ T cells 
to constitute >60% of responding CD4
+
 T cells at the peak of infection. However, this 
expansion is followed by a rapid loss of high avidity cells, faster than that of low 
avidity cells. By day 35 after infection, clonal composition of the virus-specific CD4
+
 
T cell pool is the comparable to that seen in virus-naive EF4.1 TCRβ-transgenic CD4+ 
T cells (Ploquin et al., manuscript submitted.).  
 
To survive as memory cells, CD4
+
 T cells require continued stimulation from antigen 
and cytokines, and insufficient stimulation and signalling can compromise their 
survival within the memory cell pool (Lanzavecchia and Sallusto, 2005). 
Furthermore, a number of factors can actively contribute to and promote loss of virus-
specific T cells, including chronic antigen stimulation leading to deletion, or direct 
infection of virus-specific cells. Here, the potential mechanisms underlying the loss of 
high avidity virus-specific CD4
+
 T cell in the FV mouse model were elucidated, and 
ways in which to maintain an FV-specific response with an elevated level of high 
avidity virus-specific CD4
+
 T cells were investigated. 
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5.2 Infection of FV-specific CD4+ T Cells by FV 
HIV, which infects and kills CD4
+
 T cells, has been shown to preferentially infect 
HIV-specific CD4
+
 T cells, contributing to loss of the HIV-specific immune response 
(Douek et al., 2002; Mattapallil et al., 2005). FV has been shown to infect cells via the 
cationic amino-acid transporter (CAT-1), which is expressed on most or all murine 
cells (Wang et al., 1991). T cells are therefore potential targets for FV infection, and 
similar to observed HIV tropism, FV-specific T cells may be infected preferentially. 
Here the effect of direct infection of FV-specific CD4
+
 T cells and its potential 
contribution to loss of high avidity Vα2+ FV-specific CD4+ T cells is investigated. 
 
To determine whether direct infection of FV-specific CD4
+
 T cells by FV was causing 
selective loss of the high avidity Vα2+ FV-specific CD4+ T cell population, the role of 
the Fv1 gene in conferring permissiveness to infection was exploited by transferring 
TCRβ-transgenic CD4+ T cells with different susceptibility to FV infection. Mice 
received Fv1
b
 TCRβ-transgenic CD4+ T cells, which are permissive to infection by B-
tropic FV, or Fv1
n
 TCRβ-transgenic CD4+ T cells, which are not permissive to 
infection by B-tropic FV, in a 1:1 ratio. (NB: TCRβ-transgenic CD4+ T cells used in 
all other experiments are Fv1
b
). In order to identify the separate populations, Fv1
b
 
cells were CD45.1
+
, while Fv1
n
 cells were CD45.1/2
+
. Cells were transferred into 
CD45.2
+
 B6 hosts. When analysed by flow cytometry, endogenous host CD4
+
 T cells 
(CD45.2
+
), donor Fv1
b
 FV-specific CD4
+
 T cells (CD45.1
+
) and donor Fv1
n
 FV-
specific CD4
+
 T cells (CD45.1/CD45.2
+
) could be identified, and the clonal 
composition of each population could be analysed (Figure 5.1A). Donor CD4
+
 T cell 
kinetics were followed to determine whether there was a preferential loss of FV-
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infection permissive Fv1
b
 FV-specific CD4
+
 T cells, particularly, the high avidity 
population. 
 
Expansion and contraction of both Fv1
b
 and Fv1
n
 FV-specific donor CD4
+
 T cells 
after FV infection were comparable, and there was no preferential loss of cells which 
had susceptibility to FV infection (Figure 5.1B). Furthermore, when the kinetics of 
high avidity Vα2+ cells were examined in Fv1n FV-specific donor CD4+ T cells and 
Fv1
b
 FV-specific donor CD4
+
 T cells, no difference was observed in the rate of 
expansion or contraction of Vα2+ cells (Figure 5.1C). Therefore, FV-specific CD4+ T 
cells that were not able to be infected by FV do not have a survival advantage over 
those which potentially can be FV-infected. This demonstrated that loss of FV-
specific CD4
+
 T cells, and in particular selective loss of high avidity FV-specific 
CD4
+
 T cells, was not due to direct cytopathic infection of virus-specific CD4
+
 T cells 
in the FV model. 
 
 
 
 
 
 
 
 
 177 
 
Figure 5.1 Kinetics and clonal composition of FV-specific TCRβ-transgenic 
CD4
+
 T cells that are permissive or not to infection by FV 
2 × 10
6
 CD45.1
+
 Fv1
b
 TCRβ-transgenic CD4+ T cells and 2 × 106 CD45.1/2+ Fv1n 
TCRβ-transgenic CD4+ T cells were transferred into B6 mice (CD45.2+) 1 day before 
FV infection.  
(A) Host CD4
+
 T cells, CD45.1
+
 Fv1
b
 donor CD4
+
 T cells, and CD45.1/2
+
 Fv1
n
 donor 
CD4
+
 T cells are gated. 
(B) Numbers of CD45.1
+
 Fv1
b
 or CD45.1/2
+
 Fv1
n
 FV-specific CD4
+
 T cells 
recovered after infection are shown. The dashed line indicates maximum donor cell 
expansion in the absence of infection. 
(C) Percentages of CD45.1
+
 Fv1
b
 or CD45.1/2
+
 Fv1
n
 FV-specific CD4
+
 T cells 
expressing TCR Vα2 are shown. The dashed line indicates the percentage of Vα2+ 
cells seen in the donor cell population. 
Values are the mean (± the SEM) of 5 mice per group per time point from 2 separate 
experiments.
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5.3 Activation of High and Low Avidity FV-specific CD4+ T Cells 
FV-specific CD4
+
 T cells were defined by expression of CD44, a permanent marker 
of cell activation. CD44 continues to be expressed on the cell surface even when a cell 
is no longer activated and is a marker of memory CD4
+
 T cells. In contrast, CD43 is 
transiently expressed when a cell is activated, and downregulated when cells cease to 
be activated. Expression of CD43 on CD44
+
 donor CD4
+
 T cells in response to FV 
infection was assessed. 
 
At the peak of infection and FV-specific CD4
+
 T cell expansion, day 7 post infection, 
CD43 expression correlated with CD44 expression, and the percentage of Vα2+ or 
Vα2- FV-specific CD4+ T cells expressing CD43 was comparable, verifying the use of 
CD44 as a marker to identify activated virus-specific CD4
+
 T cells at the peak of 
expansion. (Figure 5.2). However, fewer CD44
hi
 cells were expressing CD43 at day 
14 after infection, indicating that cells were mainly activated at the peak of FV 
infection and suggesting that CD43 would provide a more reliable marker to assess 
activation of FV-specific CD4
+
 T cells during the later stage of FV infection. Notably, 
at day 14 after infection, the Vα2+ FV-specific CD4+ T cell population contained 
significantly more CD43 expressing cells than the Vα2- population (p=0.008). This 
indicates that the Vα2+ FV-specific CD4+ T cell population did not express more 
CD43 than the Vα2- population at the peak of infection, but retained CD43 expression 
after this and hence was fully activated for longer. 
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Figure 5.2 Expression of CD43 on high and low avidity FV-specific CD4
+
 T 
cells during FV infection 
2 × 10
6
 CD45.1
+
 EF4.1 TCRβ-transgenic CD4+ T cells were transferred into B6 mice 
(CD45.2
+) 1 day before FV infection. Percentage of Vα2- FV-specific donor CD4+ T 
cells and Vα2+ FV-specific donor CD4+ T cells expressing CD43 during FV infection. 
Values are (± the SEM) of 2-5 mice per group per time point from 2 separate 
experiments. The number within the graph denotes the p value as compared using a 
two-tailed student’s t-test. 
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5.4 Cytokine Profiles of High and Low Avidity FV-specific CD4+ T Cells 
Lanzavecchia and Sallusto described a model of progressive differentiation whereby 
cells express a different range of cytokines relative to the amount of antigen 
stimulation received (Lanzavecchia and Sallusto, 2005). It is shown here in section 
3.4.1 that FV-specific CD4
+
 T cells had a predominantly Th1 phenotype, producing 
IFN-γ and IL-2, but negligible IL-17. With this in mind, the percentage of IL-2 single 
producers, IFN-γ single producers, and IL-2/IFN-γ double producers in the Vα2- and 
Vα2+ FV-specific CD4+ T cell populations were compared in order to assess whether 
the high avidity population was more differentiated than the low avidity population. 
 
The percentage of Vα2+ FV-specific CD4+ T cells producing IL-2 alone was 
equivalent to that seen in the Vα2- population (Figure 5.3A). There was a trend 
towards an increased proportion of IFN-γ single producers in the Vα2+ population but 
this difference was not statistically significant (Figure 5.3C). Notably, there were 
significantly more FV-specific CD4
+
 T cells producing both IL-2 and IFN-γ in the 
Vα2+ population compared to the Vα2- population (p=0.04) (Figure 5.3B). These data 
showed that a higher proportion of high avidity FV-specific CD4
+
 T cells were 
producing cytokines compared to the low avidity FV-specific CD4
+
 T cell population. 
However, although the high avidity population contained more double cytokine-
producers than the low avidity, the overall phenotype of high avidity cells did not 
indicate a high level of differentiation. Therefore, high avidity FV-specific CD4
+
 T 
cells were not likely to be lost preferentially over low avidity cells due to terminal 
differentiation. 
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Figure 5.3 Cytokine production by high and low avidity FV-specific CD4
+
 T 
cells after FV infection 
2 × 10
6
 CD45.1
+
 TCRβ-transgenic CD4+ T cells were transferred into B6 mice 
(CD45.2
+
) 1 day before FV infection. 
(A) Percentage of IL-2-producing Vα2- and Vα2+ FV-specific donor CD4+ T cells 7 
days after FV infection.  
(B) Percentage IFN-γ and IL-2 double-producing FV-specific donor CD4+ T cells 7 
days after FV infection.  
(C) Percentage of IFN-γ-producing Vα2- and Vα2+ FV-specific donor CD4+ T cells 7 
days after FV infection.  
Values are the mean (+ the SEM) of 6 mice per group from 2 separate experiments. 
The number within the graph denotes the p value as compared using a two-tailed 
student’s t-test. 
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5.5 Homeostatic Cytokine Receptor Expression on high and low avidity FV-
specific CD4
+
 T Cells 
In order to survive and thrive in the memory pool, CD4
+
 T cells require signals from 
homeostatic cytokines including IL-7, IL-15 and IL-2 (Lanzavecchia and Sallusto, 
2005). To receive survival signals from these cytokines it is necessary to express the 
appropriate cell surface receptor and a deficiency in homeostatic cytokine receptors 
may result in a compromised ability of the memory T cell to survive. Expression of 
the IL-2 receptor α chain (IL-2Rα), the IL-2 receptor β chain/IL-15 receptor α chain 
(IL-2Rβ/IL-15Rα) and the IL-7 receptor α chain (IL-7Rα) were studied and the 
proportion of high and low avidity FV-specific CD4
+
 T cells expressing these 
receptors was compared. 
 
The proportion of cells expressing IL-2Rα followed expected kinetics during the 
course of infection, with ~3% of cells expressing it at day 1 post infection, then an 
increase to ~10% as cells entered effector stage. While the proportion of Vα2- FV-
specific CD4
+
 T cells expressing IL-2α had declined by day 14, the proportion of 
Vα2+ FV-specific CD4+ T cells continued to rise, and at day 14 after infection the 
population contained significantly more IL-2Rα expressing cells than the Vα2- 
population (p=0.008) (Figure 5.4A). This suggested that potentially high avidity 
Vα2+ cells had an enhanced ability to receive signals from IL-2, and so their loss 
could not be attributed to an inability to receive survival signals from IL-2. However, 
this difference was still minimal and so this observation may not be of biological 
significance. 
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The proportion of cells expressing IL-2Rβ/IL-15Rα also followed expected kinetics, 
where ~5% of cells express it initially, expression subsequently increasing in the late 
effector cell population, and then remaining stable as cells entered the memory CD4
+
 
T cell pool. However, there was no difference in the percentage of cells (~20% in 
each case) expressing IL-2Rβ/IL-15Rα when Vα2- FV-specific CD4+ T cells were 
compared with Vα2+ FV-specific CD4+ T cells (Figure 5.4B). 
 
Finally, the proportion of cells expressing IL-7Rα again followed expected kinetics, 
with ~38% of cells expressing the receptor initially. This had declined by day 7 post 
infection where only 12% of cells expressed IL-7Rα. At day 14 after infection, when 
cells had entered the memory pool, approximately 25-30% of cells were expressing 
IL-7Rα, and although there was a trend towards fewer Vα2+ FV-specific CD4+ T cells 
expressing the IL-7Rα compared to Vα2- cells, this difference was not significant 
(Figure 5.4C). 
 
These data demonstrated that expression of receptors for IL-2, IL-7 and IL-15 was 
standard in both high and low avidity virus-specific CD4
+
 T cell populations, and so 
both can effectively receive survival signals from these cytokines. Also, compared to 
low avidity Vα2- FV-specific CD4+ T cells, high avidity Vα2+ FV-specific CD4+ T 
cells did not have a markedly lower expression of any of the homeostatic cytokine 
receptors, and were not lost due to a compromised ability to receive survival signals. 
In contrast, high avidity FV-specific CD4
+
 T cells may actually be able to receive 
increased signals from IL-2. 
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Figure 5.4 Homeostatic cytokine receptor expression on high and low avidity 
FV-specific CD4
+
 T cells 
2 × 10
6
 CD45.1
+
 TCRβ-transgenic CD4+ T cells were transferred into B6 mice 
(CD45.2
+
) 1 day before FV infection. 
(A) Percentage of Vα2- FV-specific donor CD4+ T cells or Vα2+ FV-specific donor 
CD4
+
 T cells expressing IL-2Rα (CD25) after FV infection.  
(B) Percentage of Vα2- FV-specific donor CD4+ T cells or Vα2+ FV-specific donor 
CD4
+
 T cells expressing IL-2Rβ/IL-15Rα (CD122) after FV infection.  
(C) Percentage of Vα2- FV-specific donor CD4+ T cells or Vα2+ FV-specific donor 
CD4
+
 T cells expressing IL-7Rα (CD127) after FV infection. 
Values are (± the SEM) of 5-8 mice per group per time point from 2-3 separate 
experiments. The number within the graph denotes the p value as compared using a 
two-tailed student’s t-test. 
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5.5.1 The effect antigen persistence on the loss of high avidity FV-specific CD4+ 
T cells 
 
The rapid decline of high avidity virus-specific CD4
+
 T cells seen in FV infection is 
reminiscent of T cell loss during chronic viral infection (Moskophidis et al., 1993). 
Non-persisting sources of antigen which have previously been shown to induce an 
FV-specific T cell response, were used to examine the potential contribution of 
chronic and persistent antigen stimulation to the loss of high avidity Vα2+ CD4+ T 
cells.  
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5.5.2 The effect of peptide immunisation on loss of high avidity FV-specific 
CD4
+
 T cells 
Immunisation of mice with an env124-138 peptide and Sigma adjuvant system provides 
a source of antigen which induces a memory FV-specific CD4
+
 T cell pool adequate 
to reduce FV infection to a comparable level of that after transfer of naive EF4.1 
TCRβ-transgenic CD4+ T cells one day before FV infection, as shown above (Figure 
3.1). 
 
Mice received TCRβ-transgenic CD4+ T cells one day before immunisation. Peptide 
immunisation induced a strong FV-specific CD4
+
 T cell response, comparable to that 
induced by a wild-type FV infection, with FV-specific CD4
+
 T cell expansion at the 
peak of infection and a subsequent decline at a steady rate (Figure 5.5A). High 
avidity Vα2+ FV-specific CD4+ T cells preferentially expanded within this population 
but, despite the absence of persisting antigen, returned to levels seen in virus naive 
cells by 35 days after infection (Figure 5.5B). Thus it appeared that peptide 
immunisation was able to induce an FV-specific CD4
+
 T cell response initially 
dominated by high avidity cells, but that these cells were subsequently lost with 
kinetics similar to those observed in a WT infection. 
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Figure 5.5 Kinetics and clonal composition of FV-specific CD4
+
 T cells after 
immunisation with an F-MuLV env peptide  
2 × 10
6
 CD45.1
+
 TCRβ-transgenic CD4+ T cells were transferred into B6 mice 
(CD45.2
+
) 1 day before either FV infection or immunisation with env124-138 and 
adjuvant. 
(A) Numbers of FV-specific donor CD4
+
 T cells recovered after infection or 
immunisation are. The dashed line indicates maximum donor cell expansion in the 
absence of infection. 
(B) Percentage of FV-specific donor CD4
+
 T cells expressing TCR Vα2. Values are 
the mean (± the SEM) of 6 mice per group per time point from 3 separate 
experiments. The dashed line indicates the percent of Vα2+ cells seen in the naive 
donor cell population. 
0 7 14 21 28 35
0
20
40
60
80
0 7 14 21 28 35
103
104
105
106
107
Days post transfer/
immunisation
e
n
v
-s
p
e
c
if
ic
 d
o
n
o
r 
T
 c
e
lls
B6 + env124-138
FV
T
C
R
 V
α
2
, 
%
A B
Days post transfer/
immunisation
e
n
v
-s
p
e
c
if
ic
 d
o
n
o
r 
T
 c
e
lls
T
C
R
 V
α
2
, 
%
 188 
5.5.3 Effect of FBL-3 cell transfer on high avidity CD4+ T cell loss 
To further confirm that high avidity virus-specific CD4
+
 T cells were not being lost 
due to chronic antigen stimulation by persisting antigen, the FBL-3 cell line which is 
derived from an F-MuLV-induced leukaemia, was used to immunise mice. FBL-3 
cells express FV antigens, and transfer into mice has been shown to induce a 
protective immune response against FV infection (Klarnet et al., 1989). FBL-3 cells 
are cleared within a week by gag-specific CD8
+
 cytotoxic T cells (Chen et al., 1996).  
 
Mice received equal numbers of TCRβ-transgenic CD4+ T cells and FBL-3 cells. An 
FV-specific CD4
+
 T cell response equivalent to that of the wild-type infection was 
induced, with expansion at day 7 post infection followed by contraction (Figure 
5.6A). Once more, this response was dominated by high avidity Vα2+ CD4+ T cells at 
the peak of expansion, but these cells were subsequently lost at a higher rate than low 
avidity cells, returning to proportions seen in antigen naive CD4
+
 T cells by day 35 
after transfer (Figure 5.6B).  
 
Together these data demonstrated that an FV-specific CD4
+
 T cell response 
dominated by high avidity clones could not be maintained even in the absence of 
persisting antigen. Hence, chronic and persistent antigen stimulation is not responsible 
for the selective loss of Vα2+ FV-specific CD4+ T cells. 
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Figure 5.6 Kinetics and clonal composition of FV-specific CD4
+
 T cells after 
transfer of FBL-3 cells 
2 × 10
6
 CD45.1
+
 TCRβ-transgenic CD4+ T cells were transferred into B6 mice 
(CD45.2
+
) 1 day before FV infection or transfer of 2-3 × 10
6
 cells from the FBL-3 F-
MuLV-induced tumour cell-line. 
(A) Numbers of FV-specific donor CD4
+
 T cells recovered after infection or FBL-3 
transfer are. The dashed line indicates maximum donor cell expansion in the absence 
of infection. 
(B) Percentages of FV-specific donor CD4
+
 T cells expressing TCR Vα2 are shown. 
The dashed line indicates the percentage of Vα2+ cells seen in the donor cell 
population. 
Values are the mean (± the SEM) of 2-4 mice per group per time point from 1-2 
separate experiments. 
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5.6 Effect of Antigen Dose on High Avidity FV-specific CD4+ T Cell Kinetics 
As described in section 4.2.2, there are three systems in which it is possible to study 
the effect of antigen dose on the CD4
+
 T cell response; infection of B6 mice with an 
attenuated virus (F-MuLV-N), infection of B6 mice with FV, and infection of B6.A-
Fv2
s
 mice with FV. These models were employed to further assess the effect of 
different amounts of antigen and antigen persistence on the kinetics of high avidity 
FV-specific CD4
+
 T cells. 
 
In B6 mice infected with F-MuLV-N, where antigen is at its lowest level, Vα2+ cells 
only expanded to comprise approximately 55% of all FV-specific CD4
+
 T cells, and 
thus did not expand to the levels seen in a wild-type infection, where high avidity 
Vα2+ cells expand to comprise >60% of the total FV-specific CD4+ T cell population 
at the peak of infection (Figure 5.7A). Notably, Vα2+ cells returned to levels seen in 
naive TCRβ-transgenic CD4+ T cells by day 14, sooner than after a WT infection. 
This showed that there was not sufficient antigen to either expand the FV-specific 
CD4
+
 T cell population initially or to maintain the high avidity FV-specific CD4
+
 T 
cell population beyond the peak of infection.  
 
In the wild-type infection where B6 mice are infected with FV, Vα2+ clones 
preferentially expanded to comprise >60% of all FV-specific CD4
+
 T cells but were 
subsequently lost until they reached levels seen in the naive TCRβ-transgenic CD4+ T 
cells by day 35 post infection (Figure 5.7B). In contrast, when Vα2+ cell kinetics 
were studied after infection of B6.A-Fv2
s
 mice where antigen level was higher than in 
infection of B6 mice, the FV-specific donor CD4
+
 T cell population contained a 
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higher proportion of Vα2+ cells than in the wild-type infection (mean=75%). Vα2+ 
cells were subsequently lost at a similar rate to that observed in wild-type infection. 
However, between day 21 and day 35 post infection they nonetheless gained a 
survival advantage over Vα2- cells (Figure 5.7C). Thus, low levels of antigen did not 
appear to be adequate to induce and maintain an FV-specific CD4
+
 T cell response of 
high avidity. In contrast, a higher level of antigen was beneficial for initial induction 
of the CD4
+
 T cell response and notably, high avidity FV-specific CD4
+
 T cells could 
be maintained in the presence of persistent antigen and were not lost due to excessive 
antigen stimulation. 
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Figure 5.7 Effect of antigen dose on the loss of high avidity FV-specific 
TCRβ-transgenic CD4+ T cells 
(A) 2 × 10
6
 CD45.1
+
 TCRβ-transgenic CD4+ T cells were transferred into B6 
(CD45.2
+
) recipients, which were infected with F-MuLV-N 1 day later. Percentages 
of FV-specific donor CD4
+
 T cells expressing TCR Vα2 are shown. Values are the 
mean (± the SEM) of 6-10 mice from 2-3 separate experiments. 
(B) 2 × 10
6
 CD45.1
+
 TCRβ-transgenic CD4+ T cells were transferred into B6 
(CD45.2
+
) recipients, which were infected with FV 1 day later. Percentages of FV-
specific donor CD4
+
 T cells expressing TCR Vα2 are shown. Values are the mean (± 
the SEM) of 10-16 mice from 3-5 separate experiments. 
(C) 2 × 10
6
 CD45.1
+
 TCRβ-transgenic CD4+ T cells were transferred into B6.A-Fv2s 
(CD45.2
+
) recipients, which were infected with FV 1 day later. Percentages of FV-
specific donor CD4
+
 T cells expressing TCR Vα2 are shown. Values are the mean (± 
the SEM) of 5-9 mice from 2-5 separate experiments. 
The dashed line indicates the percentage of Vα2+ cells in the naive donor cell 
population. 
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5.7 Secondary CD4+ T Cell Responses in FV Infection 
The data presented in sections 3.2.1 and 5.5.2 have demonstrated that immunisation 
with Th epitope F-MuLV env peptide was adequate to protect against FV infection, 
and was able to induce an FV-specific CD4
+
 T cell response comparable in both 
magnitude and clonal composition to that of a WT infection in immunocompetent 
mice. To investigate the secondary response of virus-specific CD4
+
 T cells to FV, 
mice were re-immunised or FV-infected 35 days after initial peptide immunisation. 
 
Secondary peptide immunisation of mice induced a robust FV-specific CD4
+
 T cell 
response which was long-lived, and did not undergo the rapid contraction phase seen 
after primary peptide immunisation (Figure 5.8A). In contrast, FV infection 35 days 
after primary peptide immunisation did not induce a response as strong as that 
induced either by secondary peptide immunisation or primary FV infection. These 
FV-specific CD4
+
 T cells were not lost at the same rapid rate seen after primary FV 
infection. Instead, by day 21 the number of FV-specific CD4
+
 T cells had reached 
levels seen at day 35 after initial immunisation or FV infection due to a reduced initial 
expansion (Figure 5.8A).  
 
At the peak of expansion after secondary immunisation, the clonal composition of 
FV-specific CD4
+
 T cells was similar to that seen after primary peptide immunisation, 
but did not contain as many Vα2+ cells as after primary FV infection. Secondary FV 
infection induced an FV-specific CD4
+
 T cell response of a similar clonal 
composition. However, although Vα2+ cells in the CD4+ T cell population gained a 
survival advantage in the response to secondary immunisation, those responding to 
 194 
secondary FV infection were rapidly lost. Thus, by day 35 after infection, re-
immunised mice had a higher level of Vα2+ FV-specific CD4+ T cells than mice 
which had been infected after primary immunisation (Figure 5.8B). 
 
Together, these experiments demonstrated that a secondary env124-138 peptide 
immunisation was adequate to induce a long-lasting FV-specific CD4
+
 T cell response 
comprised predominantly of high avidity cells. Notably, induction of a secondary 
response using virus rather than F-MuLV env peptide did not induce a long-lasting 
FV-specific CD4
+
 T cell response, and the remaining population contained a low 
proportion of high avidity clones. 
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Figure 5.8 Kinetics and clonal composition of secondary FV-specific CD4
+
 T 
cell responses after secondary FV infection or env peptide immunisation 
2 × 10
6
 CD45.1
+
 TCRβ-transgenic CD4+ T cells were transferred into B6 mice 
(CD45.2
+
) 1 day before FV infection or immunisation with env124-138 and adjuvant. 35 
days after immunisation mice were FV infected or re-immunised. 
(A) Numbers of FV-specific donor CD4
+
 T cells recovered after secondary infection 
or immunisation are shown. The dashed line indicates maximum donor cell expansion 
in the absence of infection. 
(B) Percentage of FV-specific donor CD4
+
 T cells expressing TCR Vα2 after 
secondary infection or immunisation is shown. The dashed line indicates the 
percentage of Vα2+ cells seen in the naive donor cell population.  
Values are the mean (± the SEM) of 3-8 mice per group per time point from 2-4 
separate experiments. 
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5.8 Kinetics of High Avidity Vα2+ FV-Specific CD4+ T cells in the Absence of B 
cells 
During FV infection, antigen can be presented by several types of specialised APCs 
resident in the spleen (the major site of FV infection), including dendritic cells, 
macrophages and B cells. It has been shown that after FV infection of B6-Igh6
-/-
 mice 
which do not have any B cells, high avidity cells in the FV-specific CD4
+
 T cell 
population were maintained (Ploquin et al., manuscript submitted). However, due to 
the absence of B cells, in this situation the spleen has an altered cell composition and 
architecture which results in an altered immune response and a more severe FV 
infection. To investigate the FV-specific CD4
+
 T cell response in the absence of B 
cells without live viral infection, B6-Igh6
-/-
 were immunised with env124-138 peptide 
which, as shown in section 5.5.2, is able to induce an FV-specific CD4
+
 T cell 
response. 
 
Immunisation of mice in the absence of B cells induced an FV-specific CD4
+
 T cell 
response comparable to that seen after immunisation of complete B6 mice with a 
similar peak expansion and steady rate of contraction of FV-specific CD4
+
 T cell 
numbers (Figure 5.9A). However, in accordance with results seen after FV-infection 
in the absence of B cells, high avidity FV-specific CD4
+
 T cells were not lost as 
rapidly after expansion as in immunocompetent mice and by day 35 the FV-specific 
CD4
+
 T cell population was comprised of a significantly higher proportion of high 
avidity cells (p=<0.0001) (Figure 5.9B).  
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These data further verified the observation that high avidity cells were maintained 
after infection of B6-Igh6
-/-
 mice with FV, confirming that in the absence of B cells, 
high avidity FV-specific CD4
+
 T cells can be maintained. This suggested that deletion 
of high avidity clones in the FV-specific CD4
+
 T cell population was occurring as the 
result of interaction with B cells. This interaction was perhaps in place as a 
mechanism to regulate and therefore in the case of FV infection, limit virus-specific 
CD4
+
 T cell expansion. 
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Figure 5.9 Kinetics and clonal composition of FV-specific TCRβ-transgenic 
CD4
+
 T cells in B6-Igh6
-/-
 mice after immunisation with env peptide 
2 × 10
6
 CD45.1
+
 TCRβ-transgenic CD4+ T cells were transferred into B6 or B6-Igh6-/- 
mice (CD45.2
+
) 1 day before immunisation with env124-138 and adjuvant. 
(A) Numbers of FV-specific donor CD4
+
 T cells recovered after immunisation are 
shown. The dashed line indicates maximum donor cell expansion in the absence of 
infection. 
(B) Percentage of FV-specific donor CD4
+
 T cells expressing TCR Vα2 is shown. 
The dashed line indicates the percentage of Vα2+ cells seen in the naive donor cell 
population. The number within the graph denotes the p value as compared using a 
two-tailed student’s t-test. 
Values are the mean (± the SEM) of 6-9 mice per group per time point from 2 
separate experiments.  
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5.9 Discussion 
5.9.1 Infection of CD4+ T cells by FV does not contribute to their loss 
HIV preferentially infects HIV-specific CD4
+
 T cells, which are gradually deleted 
during HIV infection via mechanisms which are not currently understood (Douek et 
al., 2002). Although the major targets of FV infection are erythroid precursors and B 
cells, FV can infect any cell which expresses the ecotropic MuLV receptor CAT-1 
and so CD4
+
 T cells can theoretically be infected, and FV-specific T cells may be 
particularly susceptible. The initial question regarding the problem of high avidity 
FV-specific CD4
+
 T cell loss was whether infection of CD4
+
 T cells by FV was 
causing selective loss of high avidity FV-specific CD4
+
 T cells in the FV model. With 
this in mind the Fv1 allele was exploited, and loss of high avidity cells within a 
population which was genetically susceptible to infection was compared to that within 
cells that were not genetically susceptible to infection. There was no preservation of 
high avidity FV-specific CD4
+
 T cells which were genetically not susceptible to FV 
infection was observed compared to those which were susceptible to FV infection. 
Whether FV-specific CD4
+
 T cells are infected is not shown by these results, but it 
can be concluded that direct infection of virus-specific CD4
+
 T cells does not 
contribute to the selective loss of high avidity FV-specific CD4
+
 T cells in the FV 
model.  
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5.9.2 Differentiation level of high avidity FV-specific CD4+ T cells 
The model of progressive differentiation describes that different levels of antigen 
stimulation lead to different T cell cytokine profiles, and cells which receive very high 
levels of antigen stimulation are differentiated to a level whereby they undergo 
activation-induced cell deletion (Lanzavecchia and Sallusto, 2005). Intra-cellular 
cytokine staining demonstrated that high and low avidity FV-specific CD4
+
 T cells 
contained IL-2 single producer, IL-2/IFN-γ double producer and IFN-γ single 
producer populations. Although there was no difference in the percentage of either IL-
2 of IFN-γ single producers within the two populations, there were significantly more 
double producers in the high avidity FV-specific CD4
+
 T cell population. This 
demonstrated that the high avidity FV-specific CD4
+
 T cell population was not 
differentiated to a higher level than the low avidity FV-specific CD4
+
 T cell 
population. However, it did show that more CD4
+
 T cells in the high avidity FV-
specific population were differentiated in general than in the low avidity population.  
 
CD43 was also expressed at a significantly higher level on high avidity cells 
compared to low avidity cells at day 14 after FV infection, confirming that these high 
avidity cells were more activated than their low avidity counterparts. Parallel studies 
have demonstrated further differences in activation and differentiation between high 
and low avidity cells. These studies showed that compared to low avidity FV-specific 
CD4
+
 T cells, high avidity FV-specific CD4
+
 T cells demonstrated further 
characteristics of elevated activation, including reduced expression of the T cell 
inhibitory molecule programmed death 1 (PD-1), and increased expression of the T 
cell stimulatory molecule inducible costimulator (ICOS) and the signalling 
lymphocyte activation molecule (SLAM) Ly108 (Ploquin et al., manuscript 
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submitted). Together, these data showed that high avidity FV-specific CD4
+
 T cells 
are activated more than their low avidity counterparts and for longer. This high level 
of prolonged activation of FV-specific CD4
+
 T cells suggests that they are likely to be 
predisposed to AICD. 
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5.9.3 Homeostatic cytokine expression 
Signals from homeostatic cytokines such as IL-2, IL-7 and IL-15 are required for the 
development and maintenance of memory T cells (Lanzavecchia and Sallusto, 2005). 
The hypothesis that high avidity FV-specific CD4
+
 T cells may be unable to survive 
due to a compromised ability to receive signals from these homeostatic cytokines was 
investigated. When expression of receptors for these cytokines was compared on high 
and low avidity FV-specific CD4
+
 T cells, no significant difference was seen in the 
proportion of cells expressing receptors for IL-7 and IL-15. However, the receptor for 
IL-2 was expressed on significantly more cells in the high avidity population at day 
14 after infection than in the low avidity population.  
 
These data suggest that the ability to receive more signals from IL-2 endows high 
avidity FV-specific CD4
+
 T cells with a survival advantage over low avidity cells. 
However, IL-2 has been shown to have a negative effect on division of memory CD8
+
 
T cells, and this may also apply to CD4
+
 T cells (Ku et al., 2000). The increased 
expression of IL-2R on high avidity FV-specific CD4
+
 T cells may therefore 
potentially be detrimental to these cells, and could in fact contribute to their loss 
rather than enhancing their survival. It must also be considered that although 
statistical significance has been observed, because the difference in expression of IL-
2R between high and low avidity cells is very low it is possible that it is not 
biologically significant, and hence does not affect survival of high avidity FV-specific 
CD4
+
 T cells. 
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5.9.4 Persistent antigen and its contribution to the loss of high avidity FV-
specific CD4
+
 T cells 
The observation that high avidity FV-specific CD4
+
 T cells were lost during FV 
infection in immunocompetent mice is comparable to the CD8
+
 T cell loss observed 
during chronic persistent viral infection (Moskophidis et al., 1993; Fuller et al., 2004). 
High avidity FV-specific CD4
+
 T cells have been shown to be activated for longer and 
to contain a higher proportion of differentiated cells than the low avidity cell 
population, and FV infection has been shown to be persistent (Chesebro et al., 1979). 
In line with previous observations of T cell loss during chronic infection, the loss of 
high avidity CD4
+
 T cells due to chronic antigenic stimulation during persistent FV 
infection was investigated. In order to test this hypothesis, experiments were carried 
out using non-persisting sources of antigen to induce an FV-specific immune 
response, specifically F-MuLV env peptide immunisation and immunisation with an 
F-MuLV-induced tumour cell-line, and the FV-specific CD4
+
 T cell response was 
examined. The results presented showed that the overall FV-specific CD4
+
 T cell 
population was lost at the same rate after induction with a non-persisting antigen 
source as when antigen was persisting. High avidity FV-specific CD4
+
 T cells were 
preferentially induced but despite the absence of persisting antigen they were still 
preferentially deleted. Thus, it appears that persistent antigen stimulation of FV-
specific CD4
+
 T cells is not causing the loss of high avidity cells and therefore that 
non-persisting vaccination techniques may be unable to induce a virus-specific 
response dominated by high avidity CD4
+
 T cells in some pathogens. 
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5.9.5 High levels of antigen do not cause high avidity CD4+ T cell loss 
In other experiments described here, low levels of antigen were unable to induce a 
long-lived FV-specific CD4
+
 T cell response, while an increased level of antigen was 
able to induce a stronger overall FV-specific CD4
+
 T cell response. Despite not 
causing loss of whole FV-specific CD4
+
 T cells, a high level of antigen may have 
altered the clonal composition of the responding CD4
+
 T cell population, and cause an 
exacerbated loss of high avidity Vα2+ CD4+ T cells, and a CD4+ T cell response 
dominated by low avidity cells. 
 
The relationship of antigen dose to clonal composition of virus-specific CD4
+
 T cells 
was studied by employing the three variable antigen conditions described before. 
After infection with attenuated F-MuLV, where antigen level is low and the whole 
FV-specific CD4
+
 T cell response has contracted by day 35 after infection, high 
avidity cells were lost even more rapidly, and had returned to the level seen in the 
naive CD4
+
 T cell population sooner after infection than when antigen level was 
higher. Attenuated F-MuLV does not persist, and this further confirms the conclusion 
that high avidity FV-specific CD4
+
 T cells are not exhausted and deleted due to 
persistent antigen stimulation.  
 
At intermediate levels of antigen, using WT FV infection of B6 mice, high avidity 
cells are preferentially induced and subsequently lost, as described (Ploquin et al., 
manuscript submitted). In the condition where antigen level was at its highest, high 
avidity cells within the FV-specific CD4
+
 T cell population were induced to higher 
levels. Notably, although they subsequently began to decline they did not reach the 
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levels seen in the naive CD4
+
 T cell population or in those conditions where antigen 
was lower. Instead, high avidity cells began to recover and had gained a survival 
advantage over low avidity cells between days 21 and 35 after infection, suggesting 
that high antigen level is in fact beneficial to survival of high avidity FV-specific 
CD4
+
 T cells, and that a high level of persistent antigen is not the cause of high 
avidity FV-specific CD4
+
 T cell loss. These data further confirm that results observed 
regarding T cell loss during chronic persistent viral infections in previous studies, for 
example in LCMV, do not reflect the kinetics and the effect of high antigen level on 
the CD4
+
 T cell response to FV. Potentially, the high avidity Vα2+ cells present in the 
FV-specific CD4
+
 T cell at day 35 after infection are of a different phenotype to those 
which expand at the peak of infection, and thus may be able to control chronic FV 
infection via different mechanisms compared to those employed by high avidity FV-
specific CD4
+
 T cells which control acute FV infection. This may explain the 
different roles of CD4
+
 T cells observed at different stages of infection in this and 
previous studies which lead to the conclusion that CD4
+
 T cells had a more important 
role during chronic infection than acute infection. 
 
It has been shown that HAART-mediated prolonged suppression of HIV viraemia 
during HIV infection can lead to the loss of HIV-specific CD4
+
 T cells (Pitcher et al., 
1999). This supports the observation that lower antigen levels during a chronic and 
persistent retroviral infection are not sufficient to maintain a virus-specific memory 
CD4
+
 T cell pool. Although FV infection is chronic and persistent, the level of antigen 
presented during a wild-type infection is apparently inadequate for maintenance of an 
FV-specific CD4
+
 T cell response dominated by high avidity CD4
+
 T cells. 
 206 
5.9.6 Secondary immune responses to FV 
The work shown here in section 3.2.1 demonstrates that immunisation of mice after 
transfer of EF4.1 TCRβ-transgenic CD4+ T cells results in a memory FV-specific 
CD4
+
 T cell response which is sufficient to reduce levels of FV infection in 
immunocompetent mice, to levels comparable to those seen when mice receive 
transgenic CD4
+
 T cells in parallel with FV infection. The kinetics of the FV-specific 
CD4
+
 T cell secondary response, particularly those of high avidity after FV infection 
or peptide immunisation were investigated. Secondary immunisation was able to 
induce a strong FV-specific CD4
+
 T cell response and notably, high avidity cells 
within this CD4
+
 T cell population were maintained at higher levels than that seen 
after primary peptide immunisation, or after wild-type infection. This suggests that 
secondary env peptide immunisation was able to boost the FV-specific CD4
+
 T cell 
response, resulting in an FV-specific memory CD4
+
 T cell pool that was dominated 
by high avidity cells. 
 
In contrast, infection with FV 35 days after immunisation did not induce a strong 
overall FV-specific CD4
+
 T cell secondary response. As mice have a reduced level of 
FV-infected cells in the spleen after peptide immunisation, the poor FV-specific CD4
+
 
T cell response observed during FV infection after peptide immunisation is likely to 
be due to the low level of antigen present. As seen in mice infected with attenuated 
FV, low levels of antigen are inadequate to induce a strong and long-lived FV-specific 
CD4
+
 T cell response, explaining why control of FV infection after peptide 
immunisation results in a low level FV-specific CD4
+
 T cell response. 
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5.9.7 Preservation of elevated levels of high avidity FV-specific CD4+ T cells in 
the absence of B cells 
Studies carried out in parallel to the work in this thesis have demonstrated that high 
avidity FV-specific CD4
+
 T cells can be maintained after FV infection of mice 
deficient in B cells (Ploquin et al., manuscript submitted). However, due to lack of 
FV-specific antibodies in these mice infection is more severe. Disrupted splenic 
architecture and exacerbated FV infection in B-cell deficient mice may have altered 
the FV-specific CD4
+
 T cell response, and the observation that high avidity FV-
specific CD4
+
 T cells can be maintained during infection of these mice may be a 
consequence of these factors. In order to overcome this limitation, mice deficient in B 
cells were immunised with peptide, which has been shown here to induce an FV-
specific CD4
+
 T cell response comparable to that of a WT FV infection. Although 
mice deficient in B cells still have altered splenic architecture, the absence of active 
virus infection allowed the clonal composition of the FV-specific CD4
+
 T cell 
response to be more reliably assessed. 
 
After peptide immunisation of B-cell deficient mice, the overall FV-specific CD4
+
 T 
cell response declined at the same rate as that observed in a wild-type infection. 
Importantly, and in agreement with the parallel study, although high avidity FV-
specific CD4
+
 T cells within this population began to be deleted preferentially, they 
recovered and gained a survival advantage over low avidity cells, and by day 35 after 
infection the FV-specific CD4
+
 T cell population was comprised of significantly more 
high avidity cells than control mice, with similar kinetics to those observed in FV 
infection of B6.A-Fv2
s
 mice where antigen is at a high level. 
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It is important to mention that despite an increased proportion of high avidity cells in 
the FV-specific CD4
+
 T cell population at day 35 after FV infection where antigen is 
high, or peptide immunisation in B cell-deficient mice, an initial decline in high 
avidity cells was observed, Again, the resulting high avidity cells could potentially be 
of a different phenotype to those expanding during the peak of infection. The CD4
+
 T 
cell kinetics observed after infection of B6.A-Fv2
s
 mice, including an increased level 
of high avidity FV-specific cells at day 35 after infection compared to day 35 after 
wild-type infection, are comparable to those seen after env peptide immunisation of 
B-cell-deficient mice, suggesting that an increased level of antigen is able to override 
the effect of B cell antigen presentation on the loss of high avidity CD4
+
 T cells. 
 
The data presented here and those from studies carried out in parallel suggest that an 
interaction between B cells and FV-specific CD4
+
 T cells is contributing to the loss of 
high avidity cells with the overall population. The parallel studies also show that an 
FV-specific CD4
+
 T cell population dominated by high avidity cells is evident when 
B-cell deficient mice were reconstituted with MHC class II-deficient B cells (Ploquin 
et al., manuscript submitted). This further suggests that an interaction taking place 
during presentation of antigen to high avidity FV-specific CD4
+
 T cells by B cells 
leads to the preferential deletion of high avidity FV-specific CD4
+
 T cell clones, in a 
potentially immunoregulatory manner. 
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Chapter Six 
6 Effect of CD4+ T cell Avidity on Protection Against 
FV Infection 
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6.1 Introduction 
High avidity CD8
+
 T cells have been shown to be more effective in clearing viral 
infections than those of a low avidity, and high avidity CD4
+
 T cells are associated 
with resistance to Leishmaniasis (Malherbe et al., 2004; Sedlik et al., 2000). 
Furthermore, it is shown here that high avidity FV-specific CD4
+
 T cells were 
activated for longer than their low avidity counterparts, and that there was a 
significantly higher proportion of double cytokine producers in the high avidity 
population. This suggested that the level of anti-viral activity demonstrated in section 
3.2.2 mediated by high avidity FV-specific CD4
+
 T cells would be more potent than 
that mediated by low avidity FV-specific CD4
+
 T cells. As well as TCRα chain usage 
by low avidity FV-specific CD4
+
 T cells, the anti-retroviral role of high avidity FV-
specific CD4
+
 T cells compared to low avidity FV-specific CD4
+
 T cells was 
therefore examined. 
 
In order to determine whether high avidity FV-specific CD4
+
 T cell clones using the 
Vα2 TCR chain were more effective at reducing acute FV infection than those low 
avidity cells using alternative TCRα chains, CD4+ T cells from B6.EF4.1 TCRβ-
transgenic mice were purified and naive Vα2+ and Vα2+ cells were sorted and 
transferred separately into mice one day before FV infection. Vα2+ and Vα2+ cells 
were transferred in the ratio in which they were present ex vivo from B6.EF4.1 mice. 
For example, if 10% of the sorted whole CD4
+
 T cell population were Vα2+, mice 
would receive either 0.1 × 10
6
 Vα2+ cells or 0.9 × 106 Vα2- cells (ratio of 1:9). 
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6.2 TCR Vα Chain Usage by Low Avidity FV-specific CD4+ T Cells 
High avidity FV-specific CD4
+
 T cells make a homogeneous Vα2+ population, while 
Vα TCR chain usage by the low avidity virus-specific CD4+ T cell population is not 
yet defined. To further characterise this population, PCR was employed to identify 
TCR Vα chain usage by low avidity Vα2- FV-specific donor CD4+ T cells. Vα2- cells 
were sorted from three conditions  
 (i) B6 control mice  
 (ii) EF4.1 TCRβ-transgenic B6 mice 
 (iii) EF4.1 TCRβ-transgenic CD4+ T cells stimulated with F-MuLV env 
 peptide for 3 days in vitro  
RNA was extracted from these sorted Vα2- cells, and synthesised cDNA was 
subjected to semi-quantitative PCR to identify Vα chain usage. 
 
Results showed that Vα3 was expressed in unstimulated Vα2- TCRβ-transgenic CD4+ 
T cells and at even higher levels in stimulated Vα2- TCRβ-transgenic CD4+ T cells 
but not in B6 control Vα2- CD4+ T cells. Vα8 was expressed weakly in in vitro 
peptide-stimulated Vα2- TCRβ-transgenic CD4+ T cells but not in naive Vα2- TCRβ-
transgenic CD4
+
 T cells or B6 control cells. Vα4 was also expressed in both 
stimulated and unstimulated Vα2- TCRβ-transgenic CD4+ T cells but has previously 
been identified as a non-productive transgene in B6.EF4.1 mice and thus is not 
indicative of Vα4 chain usage by low avidity Vα2- virus-specific CD4+ T cells. 
Expression of other Vα TCR genes by cells from B6.EF4.1 mice was consistent with 
B6 control mice (Figure 6.1). 
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These data demonstrate that, corresponding with the high avidity FV-specific CD4
+
 T 
cell population, the low avidity Vα2- virus-specific CD4+ T cell population is also 
relatively homogeneous, with the transgenic FV-specific TCRβ chain preferentially 
pairing with the Vα3 and Vα8 endogenous TCRα chains. This provides a marker for 
further analysis of the low avidity FV-specific CD4
+
 T cell population. 
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Figure 6.1 TCR Vα chain usage by Vα2- FV-specific CD4+ T cells 
Vα2- cells were sorted from naive B6 CD4+ T cells, naive B6.EF4.1 CD4+ T cells, and 
B6.EF4.1 TCRβ-transgenic CD4+ T cells which had been stimulated in vitro with 
env124-138 peptide for 72 hours. RNA was extracted and cDNA was synthesised and 
subjected to PCR using specific primers for Vα TCR chains. 
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6.3 Protection Against FV-induced Splenomegaly by High or Low Avidity 
CD4
+
 T Cells in the Absence of CD8
+
 T cells and B cells 
As previously shown, FV-infected B6.A-Fv2
s
 Rag1
-/-
 mice which received no CD4
+
 T 
cells succumbed to splenomegaly by day 14 post infection. In contrast, mice which 
had received either Vα2+ or Vα2- TCRβ-transgenic CD4+ T cells maintained spleen 
indices typical of uninfected animals by day 14 (Figure 6.2). Other than one animal 
from the group which had received Vα2+ TCRβ-transgenic CD4+ T cells and which 
developed severe splenomegaly by day 21 post infection, all other mice were 
protected up to this point. However, we did observe symptoms of previously 
described immunopathology in mice which had received Vα2- TCRβ-transgenic CD4+ 
T cells (Antunes et al., 2008). 
 
These data show that adoptive transfer of either Vα2- or Vα2+ TCRβ-transgenic CD4+ 
T cells alone was sufficient to delay FV-induced splenomegaly in lymphopenic mice 
but that there was no protective advantage of high avidity CD4
+
 T cells in the absence 
of other endogenous lymphocytes. 
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Figure 6.2 Protection against FV-induced splenomegaly in B6.A-Fv2
s
 Rag1
-/-
 
mice by high or low avidity EF4.1 TCRβ-transgenic CD4+ T cells 
Spleen index after FV infection of B6.A-Fv2
s
 Rag1
-/-
 mice without (-) or with (+ T 
cells) adoptive transfer of Vα2- TCRβ-transgenic CD4+ T cells or Vα2+ TCRβ-
transgenic CD4
+
 T cells is shown. Each symbol represents an individual mouse. The 
dashed line indicates the spleen index of uninfected mice. 
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6.4 Reduction of Acute FV Infection in Immunocompetent Mice by High or 
Low Avidity TCRβ-transgenic CD4+ T Cells 
Mice which had received whole TCRβ-transgenic CD4+ T cells had significantly 
fewer infected cells than those which had received no CD4
+
 T cells (p=0.0004), as 
shown in section 3.2.2. Transfer of either Vα2+, or Vα2- TCRβ-transgenic CD4+ T 
cells alone was sufficient to reduce the percentage of infected cells in the spleen 
(p=0.01 and p=0.02 respectively), and this level of protection was not significantly 
different compared to mice which had received whole EF4.1 TCRβ-transgenic CD4+ 
T cells. However, there was no significant difference in the levels of infected cells in 
the spleen when mice which received either Vα2+ or Vα2- TCRβ-transgenic CD4+ T 
cells were compared (Figure 6.3). These results showed that transfer of high avidity 
Vα2+ or low avidity Vα2- clones individually were able to protect mice to a level 
comparable to that seen by transfer of whole TCRβ-transgenic CD4+ T cells. 
However, there was no difference in the level of protection exerted by high avidity 
FV-specific CD4
+
 T cells compared to low avidity FV-specific CD4
+
 T cells at this 
early time point. 
 
Further to this, Q-PCR was used to determine whether the level of F-MuLV in each of 
the groups was different during acute FV infection. DNA was extracted from spleen 
cells and Q-PCR was used to measure F-MuLV env DNA copies per 100,000 cells. 
No significant difference was seen between any of the groups when the two 
independent sample Wilcoxon Rank sum test was used to measure significance 
(Figure 6.4).  
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Figure 6.3 Protection against acute FV infection in B6 mice by additional 
high or low avidity EF4.1 TCRβ-transgenic CD4+ T cells 
Percentage of glyco-Gag
+
Ter119
+
 cells in the spleen of B6 mice, 7 days after FV 
infection, without (-) or with (+ T cells) adoptive transfer of whole TCRβ-transgenic 
CD4
+
 T cells, Vα2- TCRβ-transgenic CD4+ T cells or Vα2+ TCRβ-transgenic CD4+ T 
cells, 1 day before infection. Each symbol represents an individual mouse. The dashed 
line indicates the limit of flow cytometric detection. Numbers within the graph denote 
the p values as compared using two-tailed Wilcoxon-Mann-Whitney tests. 
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Figure 6.4 F-MuLV DNA during acute infection of B6 mice after adoptive 
transfer of high or low avidity EF4.1 TCRβ-transgenic CD4+ T cells 
Total TCRβ-transgenic CD4+ T cells, Vα2- TCRβ-transgenic CD4+ T cells or Vα2+ 
TCRβ-transgenic CD4+ T cells were transferred into B6 mice which were FV infected 
1 day later. DNA was extracted from spleens of mice 7 days after FV infection and Q-
PCR was used to detect F-MuLV env. The copy number per 100,000 nucleated spleen 
cells is plotted. Each symbol represents an individual mouse. Solid lines represent the 
mean of each group. The dashed line indicates the numbers of copies of F-MuLV env 
per 100,000 cells in uninfected mice as detected by Q-PCR. 
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6.5 Control of Chronic FV infection in Immunocompetent Mice by High or 
Low Avidity EF4.1 TCRβ-transgenic CD4+ T Cells 
Q-PCR was also used to establish whether there was a difference in the level of FV 
infection after transfer of high or low avidity cells during the chronic phase of 
infection.  
 
It was observed that in the group of animals which had received whole TCRβ-
transgenic CD4
+
 T cells, there was a trend towards fewer F-MuLV env DNA copies 
than in those which had received no cells but this was not statistically significant. In 
addition, mice which had received Vα2+ TCRβ-transgenic CD4+ T cells trended 
towards a lower amount of F-MuLV env DNA in the spleen than those which had 
received Vα2- TCRβ-transgenic CD4+ T cells during the chronic phase, but once 
again this was not statistically significant (Figure 6.5). 
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Figure 6.5 F-MuLV DNA during chronic infection of B6 mice after adoptive 
transfer of high or low avidity EF4.1 TCRβ-transgenic CD4+ T cells 
Total TCRβ-transgenic CD4+ T cells, Vα2- TCRβ-transgenic CD4+ T cells or Vα2+ 
TCRβ-transgenic CD4+ T cells were transferred into B6 mice which were FV infected 
1 day later. DNA was extracted from spleens of mice 35 days after FV infection and 
Q-PCR was used to detect F-MuLV env. The copy number per 100,000 nucleated 
spleen cells is plotted. Each symbol represents an individual mouse. Solid lines 
represent the mean of each group. The dashed line indicates the numbers of copies of 
F-MuLV env per 100,000 cells in uninfected mice as detected by Q-PCR. 
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6.6 Discussion 
6.6.1 Heterogeneity of low avidity FV-specific CD4+ T cells 
In order to establish TCR Vα chain use in the low avidity Vα2- FV-specific CD4+ T 
cell population, PCR amplification of TCR Vα chains was used. Vα3 was identified 
as the preferred TCR Vα chain of the low avidity FV-specific CD4+ T cell population. 
T cell hybridomas support this data and thus indicate that, similar to the high avidity 
population, the low avidity FV-specific CD4
+
 T cell population is relatively 
homogeneous. The identification of the use of the Vα3 TCR chain by low avidity cells 
also provides a marker which may be used to identify and further investigate low 
avidity FV-specific CD4
+
 T cells. 
 
6.6.2 Effect of CD4+ T cell avidity on protection 
Previously, high avidity virus-specific CD8
+
 T cells have been shown to be more 
protective than those of low avidity (Alexander-Miller et al., 1996; Sedlik et al., 
2000). Furthermore, a CD4
+
 T cell response dominated by high avidity cells 
correlated with resistance of mice against Leishmania infection (Malherbe et al., 
2000). A high avidity clone using the Vα2 TCR chain has been identified within the 
EF4.1 FV-specific CD4
+
 T cell population (Antunes et al., 2008). Further to this, the 
effect of CD4
+
 T cell avidity on protection against FV infection was investigated here.  
 
While transfer of high or low avidity EF4.1 TCRβ-transgenic CD4+ T cells was able 
to reduce levels of FV infection comparable to that seen after transfer of whole EF4.1 
TCRβ-transgenic CD4+ T cells, transfer of high avidity Vα2+ TCRβ-transgenic CD4+ 
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T cells did not result in increased protection compared to transfer of low avidity Vα2- 
TCRβ-transgenic CD4+ T cells in immunocompetent mice. This experiment was 
repeated in mice with no endogenous adaptive immune cells and susceptibility at the 
Fv2 allele. Transfer of either high or low avidity EF4.1 TCRβ-transgenic CD4+ T 
cells was able to delay the onset of splenomegaly compared to mice which had 
received no CD4
+
 T cells. However, mice which had received high avidity EF4.1 
TCRβ-transgenic CD4+ T cells began to develop large spleens at day 21 after 
infection, while those mice which had received low avidity cells did not.  
 
Notably, mice which had received low avidity EF4.1 TCRβ-transgenic CD4+ T cells 
began to show symptoms of disease which were not consistent with those observed in 
FV-induced disease, and upon further investigation no splenomegaly was observed in 
these animals. It has been previously demonstrated that an uncontrolled FV-specific 
CD4
+
 T cell response can result in immunopathology manifested as anaemia (Antunes 
et al., 2008). Although no measure of red blood cell count was carried out in the 
current study, symptoms and spleen appearance were in line with those seen in CD4
+
 
T cell-induced anaemia in the previous study.  
 
High or low avidity cells were transferred in the ratio in which they were extracted 
from mice, as described. Hence, the suspected and likely immunopathology is 
potentially due to an increased number of low avidity FV-specific CD4
+
 T cells, 
rather than a difference in avidity. Together the results shown here, and in previous 
work by Antunes et al. suggest that a subtle balance of CD4
+
 T cell avidity and cell 
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number must be achieved in order to induce adequate CD4
+
 T cells to protect against 
FV infection while avoiding immunopathology.  
 
Importantly, these results demonstrated that cells of both low and high avidities were 
induced during acute FV infection to a level at which they could contribute to control 
of FV, showing that there is sufficient antigen to stimulate FV-specific CD4
+
 T cells 
regardless of avidity. Alternatively, low avidity cells may be required for protection 
during acute FV infection, while high avidity cells may play a role in the chronic 
phase of infection where the antigen level is low and potentially unable to be seen by 
CD4
+
 T cells of low avidity. However it is possible that CD4
+
 T cell avidity in fact 
does not determine the extent of anti-viral ability of FV-specific CD4
+
 T cells, and 
further work is required in order to determine the exact effect of CD4
+
 T cell avidity 
on protection against FV infection. 
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Chapter Seven 
7 Future Work and Concluding Remarks
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7.1 Future Work 
In order to continue the study of CD4
+
 T cells in retroviral infection, it is important to 
establish the mechanism by which CD4
+
 T cells are exerting their anti-retroviral 
effect. CD4
+
 T cell derived IFN-γ has been shown not to be required for control of 
acute FV infection. However, endogenous IFN-γ may act on adoptively transferred 
CD4
+
 T cells to enhance their potential cytotoxic activity. Generation of EF4.1 TCRβ-
transgenic mice which are deficient in the receptor for IFN-γ would further determine 
whether IFN-γ was acting on adoptively transferred CD4+ T cells in order to enhance 
infected cell killing. 
 
An additional potential and previously described mechanism of cytotoxicity mediated 
by CD4
+
 T cells against FV is induction of the Fas/FasL pathway. Further 
investigation may reveal that CD4
+
 T cells have multiple direct mechanisms which 
work in synergy to exert the maximum possible anti-retroviral effect. 
 
It is shown here that peptide immunisation with a Th epitope is able to induce an FV-
specific CD4
+
 T cell response comparable to that of the wild-type infection, and that 
peptide immunisation in B cell-deficient mice is able to induce an FV-specific 
response dominated by high avidity CD4
+
 T cells. Peptide immunisation using 
adjuvants which specifically agonise TLRs on APCs other than B cells, for example 
TLR-3 which is selectively expressed on DCs. Polyinosinic-polycytidylic acid (Poly 
I:C), is a TLR-3 agonist which could be used as an alternative to the Sigma adjuvant 
system during peptide immunisation with an F-MuLV env peptide, in order to 
promote antigen presentation by dendritic cells. 
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Identification of Vα3 chain usage by the low avidity Vα2- FV-specific CD4+ T cell 
population provides a marker with which cells from the low avidity FV-specific CD4
+
 
T cell population can be identified and further examined for functionality, and for 
protective capacity compared to high avidity FV-specific CD4
+
 T cell. Additionally, 
this low avidity population could be enriched in order to further examine the effect of 
T cell avidity on protection against FV infection. 
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7.2 Concluding Remarks 
7.2.1 A novel role for CD4+ T cells in control of acute FV infection 
Previous studies investigating the role of CD4
+
 T cells in immune responses against 
FV infection have been inconclusive, and from the data shown here it is clear that 
these previous results cannot be relied upon to give an accurate representation of the 
immune response to FV due to the caveats discussed above. As well as the likelihood 
of LDV contamination of FV stocks, it has not previously been possible to quantify 
the CD4
+
 T cell response to FV. The use of clean FV stock and the EF4.1 TCRβ-
transgenic mouse, which enables detection of the FV specific CD4
+
 T cell response, 
has allowed a reassessment of the role of CD4
+
 T cells against FV. Here, a previously 
unappreciated anti-retroviral role for CD4
+
 T cells against FV infection has been 
demonstrated. The results here show that CD4
+
 T cells play an important role in the 
control of acute FV infection, in contrast to results from previous studies which were 
unable to identify a role for CD4
+
 T cells during the acute phase of FV infection. 
Findings from previous studies may have been due to LDV contamination of FV 
stock, or an inability to detect FV-specific CD4
+
 T cells in response to infection, both 
of which are overcome in this study by the use of a clean FV stock and the EF4.1 
TCRβ-transgenic mouse. Furthermore, these anti-retroviral CD4+ T cells were shown 
to control FV infection independently of other adaptive immune cells, and their anti-
retroviral effect was not mediated by IFN-γ, suggesting a direct anti-retroviral 
mechanism of CD4
+
 T cells which has not been widely described in FV infection 
since the issue of LDV contamination was acknowledged. Further work potentially 
identifying direct CD4
+
 T cell killing and the major mediators of this would be in 
agreement with observed ex vivo CD4
+
 T cell cytotoxicity in HIV, further 
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consolidating the FV model as a viable model for the study of CD4
+
 T cells in 
retroviral infection. 
 
It is also shown here that virus-specific CD4
+
 T cell expansion and contraction in the 
FV mouse model is different to that observed in other mouse models of viral infection 
using non retroviruses. This suggests that studying the CD4
+
 T cell response to FV 
infection will provide more accurate information regarding the CD4
+
 T cell response 
to retroviral infection, and hence is a potentially valuable mouse model for the study 
of immune responses to retroviral infections.  
 
The results showing that CD4
+
 T cells do play a role in controlling acute retroviral 
infection suggest that vaccination strategies targeted towards inducing retrovirus-
specific CD4
+
 T cells are valid potential candidates for a successful vaccine to protect 
against retroviral infection.  
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7.2.2 High avidity FV-specific CD4+ T cells are lost due to previously 
undescribed mechanisms 
Many factors which have previously been shown to contribute to the loss of T cells 
during viral infection and their effect on the loss of high avidity FV specific CD4
+
 T 
cells have been investigated and discussed here. In summary, high avidity FV-specific 
CD4
+
 T cells were not lost due to direct infection by the virus and did not have a 
reduced ability to receive signals from homeostatic cytokines. In spite of high avidity 
FV-specific CD4
+
 T cells being activated for longer and having a higher proportion of 
double Th1 type cytokine producers than their low avidity counterparts, they were not 
lost due to exhaustion or terminal activation-induced deletion and were maintained in 
the absence of persistent antigen or chronic antigen stimulation. In contrast, a high 
level of persistent antigen favours their survival, and results in an FV-specific CD4
+
 T 
cell response dominated by high avidity clones.  
 
 
Notably, in accordance with previous data demonstrating the preservation of high 
avidity cells within the FV-specific CD4
+
 T cell population during FV infection of B-
cell deficient mice, high avidity cells were maintained after immunisation with an F-
MuLV env peptide of the same mice, and continued to dominate the FV-specific 
CD4
+
 T cell population despite no increase in the overall response. Prior work from 
the lab has shown that loss of high avidity CD4
+
 T cells does not occur when B cells 
do not express MHC class II, showing that an interaction between B and T cells 
during antigen presentation by B cells to CD4
+
 T cells is causing the preferential loss 
of high avidity FV-specific CD4
+
 T cells. Furthermore, this loss of high-avidity cells 
did not occur during FV infection of mice deficient in the pro-apoptotic molecule 
SLAM-associated protein (SAP), which is required for SLAM signalling, correlating 
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with the observed increased expression of the SLAM Ly108 on high avidity FV-
specific CD4
+
 T cells compared to those of low avidity (Ploquin et al., manuscript 
submitted). This shows a previously unrecognised effect of B cells on shaping the 
clonal composition of a virus-specific T cell response. Although B cells have been 
shown to be required for efficient T cell development (Lund and Randall, 2010), their 
role in formation of a clonal response was not previously known. 
 
The above described findings suggests that vaccine approaches which target APCs 
other than B cells for antigen presentation would be able to induce a retrovirus-
specific CD4
+
 T cell response dominated by high avidity CD4
+
 T cells. There are 
several approaches by which this may be carried out. The first of these approaches is 
the use of TLR-specific peptide immunisation adjuvants, which selectively agonise 
TLRs expressed on DCs only and not B cells, which as described above can easily be 
tested in the FV mouse model. A recently trialled technique is that of targeting DC-
SIGN (dendritic cell-specific intracellular adhesion molecule). 
 
Vaccination studies have shown that targeting specific receptors on DCs results in 
induction of a broad adaptive virus-specific immune response, for example in EBV 
(Gurer et al., 2008). In HIV, a therapeutic vaccination technique where HIV-infected 
patients received autologous DCs loaded with HIV antigen demonstrated a reduction 
in viral load which correlated with virus-specific T cell responses. Together, these 
studies and the data shown here suggest that DC-targeted vaccination techniques 
provide an alternative vaccine candidate for induction of protection against retroviral 
infection. 
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